Ribonucleic acid respiratory syncytial virus (RSV) vaccine compositions and methods

Modified RSV vaccines with specific amino acid mutations and optimized constructs enhance immune response efficacy by stabilizing the F protein conformation, effectively neutralizing the virus in vulnerable populations.

JP2024542478AInactive Publication Date: 2024-11-15RNAIMMUNE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529573
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-19
Filing Date
2022-11-21
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current vaccines for respiratory syncytial virus (RSV) are ineffective in inducing robust immune responses and do not account for the conformational changes in the F protein, which are crucial for neutralization by antibodies.

Method used

Development of RNA encoding RSV fusion glycoproteins with specific non-naturally occurring amino acid mutations, such as S155C, S190F, V207L, and S290C, to enhance immunogenicity and stability, combined with optimized vaccine constructs like F4, F3, and F6, which include heptad repeats and signal peptides, and delivery using lipid nanoparticles.

Benefits of technology

The modified RSV vaccines induce strong humoral and cellular immune responses, effectively neutralizing the virus and reducing viral load, particularly in vulnerable populations like infants and the elderly.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542478000001_ABST
    Figure 2024542478000001_ABST
Patent Text Reader

Abstract

Provided herein is a ribonucleic acid (RNA) encoding a fusion glycoprotein (F) protein or an immunogenic fragment thereof of respiratory syncytial virus (RSV), comprising at least one non-naturally occurring amino acid mutation. Related polynucleotides, vectors, cells, compositions, kits, methods of production, and methods of use are also provided. The F protein or immunogenic fragment thereof encoded by the RSV RNA, or each of these equivalents, comprises, essentially consists of, or even further consists of at least one non-naturally occurring amino acid mutation, for example, compared to the amino acid sequence shown in SEQ ID NO:53 or 87.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119(e) and the Paris Convention to U.S. Provisional Application No. 63 / 281,578, filed November 19, 2021, the entire contents of which are incorporated by reference herein.

[0002] Field of Disclosure Prophylactic and therapeutic agents for vaccination, prevention, and treatment of respiratory syncytial virus (RSV) infection are provided. Summary of the Invention

[0003] Disclosure Summary Provided herein is a ribonucleic acid (RNA) encoding a fusion glycoprotein or immunogenic fragment thereof of respiratory syncytial virus (RSV), or a fusion glycoprotein (F) protein or immunogenic fragment thereof of respiratory syncytial virus (RSV), or an equivalent of each of these. The F protein or immunogenic fragment thereof encoded by the RSV RNA, or an equivalent of each of these, comprises, consists essentially of, or even further consists of at least one non-naturally occurring amino acid mutation, for example, as compared to the amino acid sequence set forth in SEQ ID NO: 53 or 87.

[0004] In some embodiments, the RSV RNA encodes at least one non-naturally occurring amino acid mutation in the glycoprotein, a fragment or equivalent thereof comprising, consisting essentially of, or even consisting of one or more of cysteine ​​(C) (S155C) as the amino acid corresponding to S155 in SEQ ID NO: 87 or 53, phenylalanine (F) (S190F) as the amino acid corresponding to S190 in SEQ ID NO: 87 or 53, leucine (L) (V207L) as the amino acid corresponding to V207 in SEQ ID NO: 87 or 53, C (S290C) as the amino acid corresponding to S290 in SEQ ID NO: 87 or 53, or equivalents thereof that retain these amino acid mutations. In one aspect, the RSV RNA encodes a glycoprotein, fragment or equivalent thereof that comprises all four mutations, non-limiting examples of which are optimized vaccine F4 or vaccine A2-4 without a transmembrane domain and optimized vaccine F3 or vaccine A2-3 with a transmembrane domain. Further provided are polynucleotides, DNA or RNA, that encode the fusion glycoprotein, immunogenic fragment, or equivalent thereof. Exemplary DNA sequences encoding F proteins are provided in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 54, 57, 63, 66, or 69.

[0005] In some embodiments, the RSV RNA immunogenic fragment encodes a fusion peptide, a heptad repeat A (HRA), an F protein, and a heptad repeat B (HRB), and optionally an N-terminal signal peptide, an N-terminal heptad repeat C (HRC) peptide, wherein the immunogenic fragment further comprises an N-terminal p27 peptide, wherein the immunogenic fragment optionally further comprises a C-terminal transmembrane domain and a cytoplasmic domain, wherein the immunogenic fragment optionally further comprises a C-terminal trimerization domain.

[0006] The RSV RNA disclosed herein can further include RNA encoding a p27 peptide (eg, the p27 peptide can include SEQ ID NO:77, or can include amino acids 110-137 of SEQ ID NO:53).

[0007] In certain embodiments, the RSV RNA can further comprise RNA encoding an HRC (e.g., the HRC optionally comprises SEQ ID NO: 74, or optionally comprises amino acids 27-109 of SEQ ID NO: 53).

[0008] In another embodiment, the RSV RNA can further include RNA encoding a signal peptide (eg, the signal peptide of SEQ ID NO: 71 or the signal peptide of amino acids 1-26 of SEQ ID NO: 53).

[0009] In yet further embodiments, the at least one non-naturally occurring amino acid mutation encoded in the fusion glycoprotein, fragment thereof, or equivalent thereof comprises, consists essentially of, or even further consists of one or more of histidine (H) as the amino acid corresponding to D486 in SEQ ID NO: 87 or 53 (D486H), glutamine (Q) as the amino acid corresponding to E487 in SEQ ID NO: 87 or 53 (E487Q), tryptophan (W) as the amino acid corresponding to F484 in SEQ ID NO: 87 or 53 (F484W), or H as the amino acid corresponding to D489 in SEQ ID NO: 87 or 53 (D489H), or equivalents thereof that retain these amino acid mutations. Further provided are RNA-encoded polypeptides, or polynucleotides that are DNA or RNA that code for the fusion glycoprotein, immunogenic fragment, or equivalent thereof. Exemplary DNA sequences of F proteins are provided in SEQ ID NO: 2, 4, 6, 8, 10, 12, 54, 57, 63, 66, or 69.

[0010] In some embodiments, the at least one non-naturally occurring amino acid mutation in the encoded glycoprotein, fragment thereof, or equivalent thereof is a cysteine ​​(C) at the amino acid corresponding to S155 in SEQ ID NO: 87 or 53 (S155C), a phenylalanine (F) at the amino acid corresponding to S190 in SEQ ID NO: 87 or 53 (S190F), a leucine (L) at the amino acid corresponding to V207 in SEQ ID NO: 87 or 53 (V207L), a leucine (L) at the amino acid corresponding to S290 in SEQ ID NO: 87 or 53 (V207L), a cysteine ​​(C) at the amino acid corresponding to S155 in SEQ ID NO: 87 or 53 (S155C), a phenylalanine (F) at the amino acid corresponding to S190 in SEQ ID NO: 87 or 53 (S190F ...90 in SEQ ID NO: 87 or 53 (S190F), a cysteine ​​(C) at the amino acid corresponding to S190 in SEQ ID NO: 87 or 53 (S190F), a cysteine ​​(C) at the amino acid corresponding to S190 in SEQ ID NO: 87 or 53 (S190F), a cysteine ​​(C) at the amino acid corresponding to S190 in SEQ ID NO: 87 or 53 (S190F), a cysteine ​​(C) at the amino acid corresponding to S190 in SEQ ID NO The glycoprotein may comprise, or essentially consist of, or even further consist of, one or more of: C (S290C) as the amino acid corresponding to SEQ ID NO: 87 or 53, D486 (D486H) as the amino acid corresponding to E487 in SEQ ID NO: 87 or 53, glutamine (Q) (E487Q) as the amino acid corresponding to E487 in SEQ ID NO: 87 or 53, tryptophan (W) (F484W) as the amino acid corresponding to F484 in SEQ ID NO: 87 or 53, or H (D489H) as the amino acid corresponding to D489 in SEQ ID NO: 87 or 53. In another embodiment, the encoded glycoprotein, fragment thereof, or equivalent thereof comprises all eight mutations, examples of which are identified as Optimized Vaccine F6 or Vaccine A2-6 without a transmembrane domain and Optimized Vaccine F5 or Vaccine A2-5 with a transmembrane domain. Further provided are polynucleotides, DNA or RNA, that encode the RNA-encoded polypeptide or the fusion glycoprotein, immunogenic fragment, or equivalent thereof.

[0011] In some embodiments, the amino acid sequence of the protein or immunogenic fragment or equivalent does not comprise SEQ ID NO:53 or a fragment of SEQ ID NO:53, and the polynucleotide does not encode SEQ ID NO:53 or a fragment of SEQ ID NO:53.

[0012] In some embodiments, the polynucleotide is RNA, optionally messenger RNA (mRNA).

[0013] In some embodiments, the fusion glycoprotein, its respective fragment, or its respective equivalent further comprises a RSV transmembrane domain, and DNA, RNA (e.g., mRNA) encoding the fusion glycoprotein, its fragment, or its equivalent, and the aforementioned transmembrane domain. In one aspect, the polynucleotide is an RNA that comprises, consists essentially of, or even further consists of a polynucleotide (such as SEQ ID NO: 97 or 61), or its equivalent. In some embodiments, the RNA further comprises a three prime untranslated region (3'UTR), a polyadenylation (polyA) tail, and a five prime untranslated region (5'UTR).

[0014] In another embodiment of the disclosure, the immunogenic fragment of the RSV RNA further comprises a polynucleotide encoding an N-terminal signal peptide, an N-terminal HRC peptide, and an N-terminal p27 peptide, or the immunogenic fragment further comprises a C-terminal transmembrane domain and a cytoplasmic domain, or a C-terminal trimerization domain, or the immunogenic fragment further comprises an N-terminal signal peptide, an N-terminal HRC peptide, and an N-terminal p27 peptide, and a C-terminal transmembrane domain and a cytoplasmic domain, or a C-terminal trimerization domain.

[0015] In further embodiments, the RSV RNA disclosed above and herein encodes at least one non-naturally occurring amino acid mutation, including D486H, E487Q, F484W, and D489H, and / or S155C, S190F, V207L, and S290C of SEQ ID NO: 87 or 53, or equivalents thereof that retain the above mutations.

[0016] In a further embodiment, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, and trimerization domain of an optimized F4 vaccine (SEQ ID NO: 7) or an equivalent thereof, wherein said equivalent of SEQ ID NO: 7 comprises the mutations S155C, S190F, V207L, and S290C, or said F protein comprises the fusion peptide, HRA, F protein, and trimerization domain of an A2-4 vaccine (amino acids 138-556 of SEQ ID NO: 62) or an equivalent thereof, wherein said equivalent of SEQ ID NO: 62 comprises the mutations S155C, S190F, V207L, and S290C. Further provided are polynucleotides, DNA or RNA, that encode the RNA-encoded polypeptide, or the fusion glycoprotein, immunogenic fragment, or equivalent thereof.

[0017] In some embodiments, the amino acid sequence of the protein or immunogenic fragment or equivalent does not comprise SEQ ID NO:53 or a fragment of SEQ ID NO:53, and the polynucleotide does not encode SEQ ID NO:53 or a fragment of SEQ ID NO:53.

[0018] In another embodiment, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, and trimerization domain of an optimized F vaccine (SEQ ID NO: 11) or an equivalent thereof, wherein said equivalent of SEQ ID NO: 11 comprises the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H; or said F protein comprises the fusion peptide, HRA, F protein, and trimerization domain of an A2-6 vaccine (amino acids 138-556 of SEQ ID NO: 68) or an equivalent thereof, wherein said equivalent of SEQ ID NO: 68 comprises the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H. Further provided are polynucleotides, DNA or RNA, that encode the RNA-encoded polypeptide, or the fusion glycoprotein, immunogenic fragment, or equivalent thereof.

[0019] In some embodiments, the amino acid sequence of the protein or immunogenic fragment or equivalent does not comprise SEQ ID NO:53 or a fragment of SEQ ID NO:53, and the polynucleotide does not encode SEQ ID NO:53 or a fragment of SEQ ID NO:53.

[0020] In another embodiment, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, transmembrane domain, and cytoplasmic domain of an optimized F vaccine (SEQ ID NO:5) or an equivalent thereof, wherein said equivalent of SEQ ID NO:5 comprises the mutations S155C, S190F, V207L, and S290C, or said F protein comprises the fusion peptide, HRA, F protein, and transmembrane domain and cytoplasmic domain of an A2-3 vaccine (amino acids 138-574 of SEQ ID NO:59) or an equivalent thereof, wherein said equivalent of SEQ ID NO:59 comprises the mutations S155C, S190F, V207L, and S290C. Further provided are polynucleotides, DNA or RNA, that encode a polypeptide encoded by the RNA, or a fusion glycoprotein, immunogenic fragment, or equivalent thereof.

[0021] In some embodiments, the amino acid sequence of the protein or immunogenic fragment or equivalent does not comprise SEQ ID NO:53 or a fragment of SEQ ID NO:53, and the polynucleotide does not encode SEQ ID NO:53 or a fragment of SEQ ID NO:53.

[0022] In a further aspect, provided herein is an RSV RNA encoding an F protein comprising a fusion peptide, HRA, F protein, transmembrane domain, and cytoplasmic domain of an optimized F vaccine (SEQ ID NO: 9) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 9 comprises the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H; or the F protein comprises the fusion peptide, HRA, F protein, and transmembrane domain and cytoplasmic domain of an A2-5 vaccine (amino acids 138-574 of SEQ ID NO: 65) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 65 comprises the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H. Further provided are polynucleotides, either DNA or RNA, that encode an RNA-encoded polypeptide, or a fusion glycoprotein, immunogenic fragment, or equivalent thereof.

[0023] In some embodiments, the amino acid sequence of the protein or immunogenic fragment or equivalent does not comprise SEQ ID NO:53 or a fragment of SEQ ID NO:53, and the polynucleotide does not encode SEQ ID NO:53 or a fragment of SEQ ID NO:53.

[0024] In one aspect, a polynucleotide such as DNA encoding the RNA disclosed herein is provided. In a further aspect, a vector comprising the polynucleotide disclosed herein is provided. In one embodiment, the vector is a plasmid that optionally comprises, or essentially consists of, or even further consists of SEQ ID NO: 29 or an equivalent thereof. In yet a further aspect, a cell is provided that comprises one or more of the fusion glycoprotein disclosed herein, a fragment thereof, or an equivalent thereof, the RNA disclosed herein, the polynucleotide disclosed herein, or the vector disclosed herein. The cell can be a prokaryotic or eukaryotic cell. In one aspect, a composition is provided that comprises, or essentially consists of, or even further consists of a carrier, optionally a pharma- ceutically acceptable carrier, and one or more of the fusion glycoprotein, a fragment thereof, or an equivalent thereof, the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, or the cell disclosed herein.

[0025] Further provided are methods for producing the DNA, RNA, or fusion glycoprotein, fragments, or equivalents, or vectors disclosed herein. In some embodiments, the methods comprise, or consist essentially of, or even further comprise, culturing the cells disclosed herein under conditions suitable for expression or replication of the DNA, RNA, or fusion glycoprotein, fragments, or equivalents, or vectors disclosed herein. In other aspects, the DNA or RNA is replicated using chemical in vitro methods. In one embodiment, the methods comprise, or consist essentially of, or even further comprise, contacting the polynucleotide or vector disclosed herein with RNA polymerase, adenosine triphosphate (ATP), cytidine triphosphate (CTP), guanosine-5'-triphosphate (GTP), and uridine triphosphate (UTP) or chemically modified UTP (such as the cryopreservative agent N1-methylpseudouridine trisphosphate) under conditions suitable for expression or replication of the RNA. In a further embodiment, the methods disclosed herein further comprise the step of isolating the RNA, DNA, or fusion glycoprotein, fragment thereof, or equivalent thereof.

[0026] In one aspect, a composition is provided that comprises, or consists essentially of, or even further comprises the RNA disclosed herein and a carrier (such as a pharma- ceutically acceptable carrier). In some embodiments, the pharma-ceutically acceptable carrier comprises, or consists essentially of, or even further comprises a polymeric nanoparticle. In further embodiments, the polymeric nanoparticle comprises, or consists essentially of, or even further comprises a histidine-lysine copolymer (HKP). In some embodiments, the pharma-ceutically acceptable carrier further comprises a lipid, optionally one or more of a cationic lipid (e.g., Dlin-MC3-DMA, i.e., MC3), a helper lipid, cholesterol, or a PEGylated lipid. In some embodiments, the pharma-ceutically acceptable carrier comprises, or consists essentially of, or even further comprises a lipid nanoparticle (LNP). In some embodiments, the LNPs comprise one or more of 9-heptadecanyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate (SM-102), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), or equivalents of each of these. In further embodiments, the LNPs further comprise one or more of a helper lipid, cholesterol, or a PEGylated lipid. Additional pharma- ceutically acceptable carriers (e.g., phosphate buffered saline, and preservatives such as cryopreservatives, etc.) can be added to the nanoparticle composition.

[0027] In further embodiments, the pharma- ceutically acceptable carrier further comprises a diluent, adjuvant, binder, stabilizer, buffer, salt, lipophilic solvent, or preservative. In some embodiments, the nanoparticle is a self-assembled nanoparticle. In a further aspect, a composition is provided that comprises, or consists essentially of, or even further consists of the self-assembled nanoparticles comprising RNA disclosed herein. In some embodiments, the nanoparticle encapsulates the RNA. In other embodiments, the nanoparticle is conveniently bound or non-covalently bound to the RNA.

[0028] In further embodiments, the method of producing composition is provided.In some embodiments, the method comprises, or essentially consists of, or even further comprises the step of contacting RNA disclosed herein with HKP, whereby RNA and HKP are self-assembled into nanoparticles.In addition or alternatively, the method comprises, or essentially consists of, or even further comprises the step of contacting RNA disclosed herein with lipid, whereby RNA and lipid are self-assembled into nanoparticles.In further embodiments, the contacting step is carried out in a microfluidic mixer.

[0029] In another embodiment, one or more of the following methods are provided: (a) a method for preventing a subject from symptomatic RSV infection; (b) a method for inducing an immune response against RSV in a subject in need of induction of an immune response against RSV; (c) a method for reducing the binding of RSV or its F protein in a subject in need of reducing the binding of RSV or its F protein; (d) a method for treating a subject infected with RSV; or (e) a method for reducing the RSV viral load in a subject in need of reducing the RSV viral load. The method comprises, or consists essentially of, or even further consists of administering to the subject one or more of the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, or the composition disclosed herein. These methods can also be performed in vitro in a cell system. Such in vitro methods are useful for assaying for efficacy and possible combination therapy. In one embodiment, the subject is a human patient selected from an infant, a pediatric patient, or a pregnant woman, or an adult aged 60 or over.

[0030] In one embodiment, an inhalation system is provided comprising, consisting essentially of, or even further consisting of an RNA disclosed herein, a polynucleotide disclosed herein, a vector disclosed herein, or a composition disclosed herein, and a nebulizer.

[0031] Also provided are kits for use in the methods described herein. In some embodiments, the kits comprise, or consist essentially of, or further consist of instructions for use, and one or more of the DNA disclosed herein, the fusion glycoprotein disclosed herein, fragments thereof, or equivalents thereof, the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, the cell disclosed herein, the composition disclosed herein, and optionally, the inhalation system disclosed herein. [Brief description of the drawings]

[0032] [Figure 1A-B] Figure 1A and Figure 1B show the complete sequence of the RSV virus. RSV has a negative-sense single-stranded RNA genome (Figure 1A). The genome is linear and approximately 15,000 nucleotides long. Figure 1B shows the resulting protein assembly.

[0033] [Diagram 2] Figure 2 shows the alignment of F1 (SEQ ID NO:53) (top) from backbone 2A with the optimized backbone (SEQ ID NO:87) (bottom). Amino acid changes are indicated.

[0034] [Figure 3A-B] Figure 3A is an illustration of the structure of respiratory syncytial virus, including the location of the membrane-associated F protein of the RSV virus, and Figure 3B shows the protein coding regions of 11 proteins of the RSV viral genome.

[0035] [Figure 4A] Figures 4A and 4B show the pre-fusion and post-fusion structures of the RSV F protein. Figure 4A shows an X-ray crystallography diagram of the trimeric pre-fusion structure of the RSV F protein undergoing conformational rearrangement. The figure is reproduced from: Bermingham, Imogen M et al. "The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion." Journal of virology vol.92,4 e01323-17.30 Jan.2018,doi:10.1128 / JVI.01323-17.

[0036] [Figure 4B]Figure 4B shows an X-ray crystallography diagram of the post-fusion form of the F protein of RSV. The figure is reproduced from: Bermingham, Imogen M et al. "The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion." Journal of Virology vol.92,4 e01323-17.30 Jan.2018,doi:10.1128 / JVI.01323-17. The F protein exists in multiple conformational forms. In the pre-fusion state (PreF), the protein exists in a trimer form and contains the major antigenic site O. O serves as the primary target of neutralizing antibodies in the subject.

[0037] [Diagram 5] FIG. 5 shows protein mapping diagrams for mRNA-optimized vaccine candidates of respiratory syncytial virus (RSV) F protein. Optimized F1 is the RSV F protein backbone lacking any mutations (SEQ ID NO: 87). F2-F6 show different RSV-optimized vaccine constructs. The column "TM / Secreted" indicates that the vaccine is transmembrane or secreted. The conformation column indicates whether the three-dimensional conformation of the vaccine is a pre-fusion or post-fusion conformation of the RSV F protein. F1 to F6 are the same protein mapping diagrams for "A" or "A2" RSV vaccines (A2-1 to A2-6, respectively) that differ only in their backbone structure (see FIG. 2 for sequence comparison).

[0038] [Figure 6A]Figures 6A and 6B show the results of a sandwich ELISA for secreted RSVF constructs. Sandwich ELISA was used to measure the in vitro expression of the secreted forms of A2 and optimized vaccine candidates. Cell supernatants were diluted 1:5, 1:25, and 1:125 dilutions in ELISA blocking buffer. The results show that the secreted pre-fusion F protein has similar expression levels in both optimized and A2 sequence backgrounds. Data for RSV-optimized candidates and A2 strain backgrounds are shown in bar graphs (Figure 6A) and line graphs (Figure 6B). [Figure 6B] Figures 6A and 6B show the results of a sandwich ELISA for secreted RSVF constructs. Sandwich ELISA was used to measure the in vitro expression of the secreted forms of A2 and optimized vaccine candidates. Cell supernatants were diluted 1:5, 1:25, and 1:125 dilutions in ELISA blocking buffer. The results show that the secreted pre-fusion F protein has similar expression levels in both optimized and A2 sequence backgrounds. Data for RSV-optimized candidates and A2 strain backgrounds are shown in bar graphs (Figure 6A) and line graphs (Figure 6B).

[0039] [Figure 7] Figure 7 shows the FACS analysis of RSVF binding to pre-fusion specific antibodies. A2 and optimized vaccines and controls were bound to D25 and AM14 antibodies. FACS analysis demonstrated that transmembrane pre-fusion F protein can bind to pre-fusion F specific antibodies D25 and AM14 in both optimized and A2 sequence backgrounds. RNAi optimized vaccine F3 has the highest activity among all these vaccine candidates.

[0040] [Figure 8] Figure 8 shows the expression levels of His-tagged constructs of optimized vaccine F3 and optimized vaccine F6. Anti-His antibody was used to detect expression. Proteins were measured under reducing (R) and non-reducing (NR) conditions.

[0041] [Figure 9] FIG. 9 shows an exemplary challenge study.

[0042] [Figure 10A] Figures 10A and 10B show the immunogenicity and neutralizing activity of A2 and optimized vaccine candidates. IgG titers at 35 DPI for the RSV A2 F protein (Figure 10A) and Pre-F protein (Figure 10B) are shown. [Figure 10B] Figures 10A and 10B show the immunogenicity and neutralizing activity of A2 and optimized vaccine candidates. IgG titers at 35 DPI for the RSV A2 F protein (Figure 10A) and Pre-F protein (Figure 10B) are shown.

[0043] [Figure 11] Figure 11 shows the immunogenicity and neutralizing activity of A2 and optimized vaccine candidates. Figure 11 shows mouse serum titers against RSV A2 at 35 DPI PRNT50.

[0044] [Figure 12] FIG. 12 shows another exemplary challenge study.

[0045] [Figure 13A] Figures 13A and 13B show the results of the immunoassay ELISA for the optimized vaccine F3 (Figure 13A) and optimized vaccine F6 (Figure 13B) candidates. [Figure 13B] Figures 13A and 13B show the results of the immunoassay ELISA for the optimized vaccine F3 (Figure 13A) and optimized vaccine F6 (Figure 13B) candidates.

[0046] [Figure 14A]Figures 14A and 14B show the immunogenicity of RNAi-optimized vaccine-F3 and RNAi-optimized vaccine-F6 after the second immunization. ELISA data was collected 35 days after using PreF protein as an antigen (Figure 14A) and 35 days after using RSV A2 F protein as an antigen (Figure 14B). [Figure 14B] Figures 14A and 14B show the immunogenicity of RNAi-optimized vaccine-F3 and RNAi-optimized vaccine-F6 after the second immunization. ELISA data was collected 35 days after using PreF protein as an antigen (Figure 14A) and 35 days after using RSV A2 F protein as an antigen (Figure 14B).

[0047] [Figure 15] FIG. 15 shows that the IgG titers induced by RNAi-optimized vaccine-F3 and RNAi-optimized vaccine-F6 after the second immunization were measured using RSVB F protein as the antigen.

[0048] [Figure 16A-B] Figures 16A and 16B show the endpoint titer results for optimized vaccines F3 and F6 against the Pre-F protein (Figure 16A) and the A2 F protein (Figure 16B).

[0049] [Figure 17A-B] Figures 17A and 17B show the endpoint titer results comparing the optimized vaccine F3 and the optimized vaccine F6 for the A2 F protein and PreF protein (Figure 17A) and the RSV A2 F protein and the RSVB F protein for the optimized vaccine F3 and the optimized vaccine F6 (Figure 17B).

[0050] [Figure 18A-B]Figures 18A and 18B show the efficiency of optimized vaccine-F3 and optimized vaccine-F6 in 14 DPI mouse serum. PRNT50 14 DPI (Figure 18A) and PRNT90 14 DPI (Figure 18B) were examined.

[0051] [Figure 19A-B] Figures 19A and 19B show the efficacy of optimized vaccine-F3 and optimized vaccine-F6 in mice serum 35 DPI. PRNT50 35 DPI (Figure 18A) and PRNT90 35 DPI (Figure 18B) were examined.

[0052] [Figure 20] Figure 20 shows a comparison of the neutralization efficiency of optimized vaccine-F3 and optimized vaccine-F6. The neutralization titer of the test serum sample was defined as the reciprocal of the highest serum dilution that reduced viral infectivity by 90% and above.

[0053] [Figure 21] FIG. 21 shows the results of ELISpot analysis of RSV optimized vaccines F3 and F6.

[0054] [Figure 22] FIG. 22 shows the analysis of IFN-γ secreting cells obtained by ELISpot assay.

[0055] [Figure 23A-B] Figures 23A-D show T cell responses to optimized vaccines F3 and F6 as determined by intracellular staining. [Fig. 23C-D] Figures 23A-D show T cell responses to optimized vaccines F3 and F6 as determined by intracellular staining.

[0056] [Fig. 24A-B]Figures 24A-I show the gating strategies for flow cytometry analysis of intracellular staining experiments. Total population (Figure 24A), single cells (Figure 24B), and live / dead cells (Figures 24C-I) were included in the aforementioned strategies. [Fig. 24C-D] Figures 24A-I show the gating strategies for flow cytometry analysis of intracellular staining experiments. Total population (Figure 24A), single cells (Figure 24B), and live / dead cells (Figures 24C-I) were included in the aforementioned strategies. [Figure 24E] Figures 24A-I show the gating strategies for flow cytometry analysis of intracellular staining experiments. Total population (Figure 24A), single cells (Figure 24B), and live / dead cells (Figures 24C-I) were included in the aforementioned strategies. [Fig. 24F-G] Figures 24A-I show the gating strategies for flow cytometry analysis of intracellular staining experiments. Total population (Figure 24A), single cells (Figure 24B), and live / dead cells (Figures 24C-I) were included in the aforementioned strategies. [Fig. 24H-I] Figures 24A-I show the gating strategies for flow cytometry analysis of intracellular staining experiments. Total population (Figure 24A), single cells (Figure 24B), and live / dead cells (Figures 24C-I) were included in the aforementioned strategies. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0057] Detailed Description definition It should be understood that the section or subsection headings used herein are for organizational purposes only and are not to be construed as limiting and / or isolating the subject matter of the described invention.

[0058] It is to be understood that the invention is not limited to the particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting of the invention, since the scope of the invention will be limited only by the appended claims.

[0059] Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which this disclosure belongs.Although any method and material similar or equivalent to the method and material described herein can be used in the practice or testing of this disclosure, the preferred method, device, and material are described herein.All technical publications and patent publications cited herein are incorporated herein by reference in their entirety.Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such disclosure by virtue of prior disclosure.

[0060] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of tissue culture, immunology, molecular biology, microbiology, cell biology, and recombinant DNA, within the skill of the art. For example, Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubel et al. eds. (2007) Current Protocols in Molecular Biology; the series Methods in Enzymology (Academic Press, Inc., NY); MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Techique, 5th edition; Gait ed. (1984) Oligonucleotide Synthesis; US Patent No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds.(1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Herzenberg et al. eds (1996) Weir's Handbook of Experimental Immunology; Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition (Cold Spring Harbor Laboratory Press (2002)); Sohail (ed.) (2004) Gene Silencing by RNA Interference: Technology and Application (CRC Press); and Plotkin et al., Plotkin; Human Vaccines, 7. th See the latest edition (Elsevier).

[0061] As used herein and in the claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. For example, the term "a cell" includes a plurality of cells (including mixtures thereof).

[0062] As used herein, the term "comprising" is intended to mean that the compounds, compositions, and methods include the recited elements, but do not exclude others. "Consisting essentially of," when used to define compounds, compositions, and methods, is intended to mean excluding any other elements of essential importance to the combination. Thus, a composition consisting essentially of elements as defined herein would not exclude, for example, trace amounts of contaminants from isolation and purification methods, as well as pharma- ceutically acceptable carriers, preservatives, and the like. "Consisting of" is intended to mean excluding more than trace amounts of other components. Embodiments defined by each of these transition terms are within the scope of this technology.

[0063] All numerical designations including ranges (e.g., pH, temperature, time, concentration, and molecular weight) are approximate and vary in the (+) or (-) direction by increments of 1, 5, or 10%. It should be understood, although not always explicitly stated, that all numerical designations are preceded by the term "about." It should also be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents thereof are known in the art.

[0064] As used herein, the term "about" when referring to measurable values ​​such as amounts and concentrations is meant to include variations of 20%, 10%, 5%, 1%, 0.5%, and even 0.1% of the stated amount.

[0065] As used herein, the comparative terms used herein (such as high, low, increase, decrease, decrease, or any grammatical variation thereof) can refer to a certain variation from the baseline. In some embodiments, such variation can refer to about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 1-fold, or about 2-fold, or about 3-fold, or about 4-fold, or about 5-fold, or about 6-fold, or about 7-fold, or about 8-fold, or about 9-fold, or about 10-fold, or about 20-fold, or about 30-fold, or about 40-fold, or about 50-fold, or about 60-fold, or about 70-fold, or about 80-fold, or about 90-fold, or about 100-fold, or more. In some embodiments, such variation can refer to about 1%, or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 0%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 75%, or about 80%, or about 85%, or about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% of the standard.

[0066] As would be understood by one of ordinary skill in the art, for any and all purposes, all ranges disclosed herein include any and all possible subranges and combinations of subranges thereof. Further, as would be understood by one of ordinary skill in the art, a range includes its individual members.

[0067] "Optionally" or "as needed" means that the subsequently described circumstances may or may not occur, such that the description includes instances in which the circumstances occur and instances in which they do not occur.

[0068] As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated items in a list, and also refers to and includes no combinations ("or") when interpreted as alternatives.

[0069] "Substantially" or "essentially" means nearly all or nearly completely (e.g., 95% or more of some given amount). In some embodiments, "substantially" or "essentially" means 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%.

[0070] The terms "acceptable," "effective," or "sufficient," when used to describe the selection of any components, ranges, dosage forms, etc. disclosed herein, are intended to mean that said components, ranges, dosage forms, etc. are suitable for the purposes of the disclosure.

[0071] In some embodiments, the terms "first," "second," "third," "fourth," or similar terms in a component name are used to distinguish and identify more than one component that shares a certain identity in its name. For example, "first RNA" and "second RNA" are used to distinguish two RNAs.

[0072] Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) or human orthopneumovirus, is a common infectious virus that causes respiratory tract infections. Syncytium refers to giant cells known as syncytia that form when infected cells fuse together. RSV is an enveloped virus with a size of approximately 150 nanometers. The genome resides within a helical nucleocapsid and is surrounded by an envelope that contains matrix proteins and all the viral glycoproteins. After fusion of the virus and host cell membranes, the viral nucleocapsid (containing the viral genome) and the associated viral polymerase are delivered to the cytoplasm of the host cell. Both transcription and translation occur in the cytoplasm. The RNA-dependent RNA polymerase transcribes the genome into 10-segment messenger RNA (mRNA), which is translated into structural proteins by the host cell machinery. The RNA-dependent RNA polymerase synthesizes a positive-sense complement called the antigenome. This complementary strand is used as a template to construct a genomic negative-sense RNA, which is packaged into a nucleocapsid and transported to the plasma membrane for assembly and particle budding.

[0073] RSV is a negative-sense single-stranded RNA virus. The genome is linear and approximately 15,000 nucleotides long. RSV is non-segmented, which means that RSV cannot participate in gene reassortment and antigenic shift. RSV contains 10 genes that code for 11 proteins. The gene sequence is NS1-NPM-SH-GF-M2-L. NS1 and NS2 function as non-structural promoter genes. See, for example, Figures 1A and 1B.

[0074] The F protein from RSV is a type I transmembrane surface protein, and the protein has an N-terminal cleavage signal peptide and a membrane anchor near the C-terminus. It is synthesized as an inactive 67-kD precursor, designated F0. The F0 protein is activated at two sites by a furin-like protease to yield two disulfide-linked polypeptides, F2 and F1, from the N- and C-termini, respectively. The released 27-amino acid peptide is designated "pep27". The F2 subunit consists of heptad repeat C (HRC), while F1 contains the fusion peptide (FP), heptad repeat A (HRA), heptad repeat B (HRB), transmembrane domain (TM), and cytoplasmic domain (CP).

[0075] The F protein construct carrying the transmembrane domain has the following regions: aa1 to aa26 is the "signal peptide"; aa27 to aa109 is the "heptad repeat C" also known as the "F2 protein"; aa110 to aa137 is the "27 amino acid fragment released when F0 is cleaved into F1 and F2" or "p27"; and aa138...574 is the "F1 protein". The F1 protein in turn has the following subregions: aa138 to aa155 is the "fusion peptide"; aa156 to 214 is the "heptad repeat A"; aa475 to aa524 is the "heptad repeat B"; aa525 to aa550 is the "transmembrane region"; and aa551 to aa574 is the "cytoplasmic domain".

[0076] The F protein construct, which does not possess a transmembrane domain, has the following regions: aa1 to aa26 is the "signal peptide"; aa27 to aa109 is the "heptad repeat C" also known as the "F2 protein"; aa110 to aa137 is the "27 amino acid fragment released when F0 is cleaved into F1 and F2" or "p27"; and aa138...556 is the "F1 protein". The F1 protein, in turn, has the following subregions: aa138 to aa155 is the "fusion peptide"; aa156 to 214 is the "heptad repeat A"; aa475 to aa524 is the "heptad repeat B"; and aa525 to 556 is the "trimerization domain".

[0077] The terms "protein", "peptide" and "polypeptide" are used interchangeably and in their broadest sense refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits (also referred to as residues) may be linked by peptide bonds. In another embodiment, the subunits may be linked by other bonds (e.g., esters, ethers, etc.). A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may comprise a protein or peptide sequence. As used herein, the term "amino acid" refers to natural and / or unnatural or synthetic amino acids (including glycine and both D and L optical isomers), amino acid analogs, and peptidomimetics.

[0078] As used herein, the terms "F protein" or "F glycoprotein" are used interchangeably and refer to the surface fusion protein responsible for the fusion of the RSV virus and host cell membranes and the formation of syncytia between viral particles. In further embodiments, F protein or its equivalent as used herein also refers to F protein mutants (e.g., mutant F proteins disclosed herein), F protein fragments (such as immunogenic fragments), or any combination thereof (such as naturally occurring variants engineered with additional mutation(s), or fragments thereof).

[0079] The F protein has a highly conserved sequence among strains. The F protein exists in multiple conformational forms. In the native conformation in the prefusion state (PreF), the protein exists in a trimeric form. After binding to a target on the host cell surface, PreF undergoes a conformational change to an elongated, stable form that allows the protein to insert itself into the host cell membrane.

[0080] The surface protein G (glycoprotein) is responsible for the attachment of the virus to the host cell and is highly variable between strains. The G protein can exist in both membrane-bound and secreted forms.

[0081] Together with the G protein, the F protein binds to and activates toll-like receptor 4 (TLR4), initiating innate immune responses and signal transduction.

[0082] As used herein, an amino acid (aa) or nucleotide (nt) residue position in a sequence of interest that "corresponds" to an identified position in a reference sequence refers to the residue position aligned to said identified position in the sequence alignment between the sequence of interest and the reference sequence. Various programs are available for performing such sequence alignments (such as Clustal Omega and BLAST). In one embodiment, equivalent polynucleotides, proteins, and corresponding sequences can be determined using BLAST (available at blast.ncbi.nlm.nih.gov / Blast.cgi, as of last access date August 1, 2021).

[0083] As used herein, an amino acid mutation is referred to herein as two letters separated by an integer (such as T19R). The first letter provides the one-letter designation of the original amino acid residue to be mutated; while the last letter provides the mutation (such as Δ indicating a deletion or the one-letter designation of the amino acid residue after the mutation). In some embodiments, the integer is the numbering of the amino acid residue to be mutated in the amino acid sequence without the mutation, counting from the N-terminus to the C-terminus as appropriate. In some embodiments, the integer is the numbering of the mutated amino acid residue in the mutated amino acid sequence, counting from the N-terminus to the C-terminus as appropriate. In some embodiments, the integer is the numbering of the amino acid residue in (e.g., aligned) SEQ ID NO: 53 that corresponds to the residue to be mutated or the mutated residue or both.

[0084] Unless expressly stated and intended otherwise, when this disclosure relates to polypeptides, proteins, polynucleotides, it should be presumed that these equivalents or biological equivalents are intended to be within the scope of this disclosure.As used herein, the term "biological equivalent thereof" is intended to be synonymous with "equivalent thereof" when referring to a reference protein, polypeptide, or nucleic acid, and is intended to have minimal homology while still maintaining the desired structure or functionality.Unless specifically recited herein, it is intended that any polynucleotide, polypeptide, or protein referred to herein also includes its equivalent. For example, an equivalent contemplates at least about 70% homology or identity, or at least 80% homology or identity, or at least about 85% homology or identity, or at least about 90% homology or identity, or at least about 95% homology or identity, or at least about 96% homology or identity, or at least about 97% homology or identity, or at least about 98% homology or identity, or at least about 99% homology or identity (as determined in one embodiment using the Clustal Omega alignment program) and exhibits substantially equivalent biological activity to the reference protein, polypeptide, or nucleic acid. Alternatively, when referring to polynucleotides, the equivalent is a polynucleotide that hybridizes to the reference polynucleotide or its complementary sequence under stringent conditions.

[0085] An equivalent of a reference polypeptide comprises, consists essentially of, or consists of a polypeptide having at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least about 96%, or at least 97%, or at least 98%, or at least 99% amino acid identity to the reference polypeptide (as determined in one embodiment using Clustal Omega or a BLAST alignment program), or a polypeptide encoded by a polynucleotide that hybridizes to the complement of a polynucleotide encoding the reference polypeptide under high stringency conditions, optionally wherein the high stringency conditions include an incubation temperature of about 55° C. to about 68° C.; a buffer concentration of about 1×SSC to about 0.1×SSC; a formamide concentration of about 55% to about 75%; and a wash solution of about 1×SSC, 0.1×SSC, or deionized water.

[0086] In some embodiments, a first sequence (nucleic acid sequence or amino acid sequence) can be compared to a second sequence, and the percent identity between the two sequences can be calculated. In further embodiments, the first sequence can be referred to herein as an equivalent, and the second sequence can be referred to herein as a reference sequence. In still further embodiments, the percent identity is calculated based on the full length sequence of the first sequence. In other embodiments, the percent identity is calculated based on the full length sequence of the second sequence.

[0087] The terms "polynucleotide", "nucleic acid", and "oligonucleotide" are used interchangeably and refer to either deoxyribonucleotides or ribonucleotides or analogs thereof that are polymeric forms of nucleotides of any length. Polynucleotides can have any three-dimensional structure and can perform any function, known or unknown. The following are non-limiting examples of polynucleotides: genes or gene fragments (e.g., probes, primers, EST tags, or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. Polynucleotides can contain modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polynucleotide. The sequence of nucleotides can be interrupted with non-nucleotide components. Polynucleotides can be further modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double-stranded and single-stranded molecules. Unless otherwise specified or required, any embodiment of the present disclosure that is a polynucleotide encompasses both the double-stranded form and each of the two complementary single-stranded forms that are known or predicted to be in double-stranded form.

[0088] A polynucleotide is composed of a specific sequence of the four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil (U) in place of thymine when the polynucleotide is RNA. Thus, the term "polynucleotide sequence" is the alphabetical representation of a polynucleotide molecule. This alphabetical representation can be entered into a database in a computer having a central processing unit and used for bioinformatics applications, such as functional genomics and homology searching.

[0089] The term "RNA" as used herein refers to its generally accepted meaning in the art. In general, the term RNA refers to a polynucleotide that contains at least one ribofuranoside moiety. This term can include double-stranded RNA, single-stranded RNA, isolated RNA (such as partially purified RNA), essentially pure RNA, synthetic RNA, recombinantly produced RNA, and altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution, and / or modification of one or more nucleotides. Such alterations can include, for example, the addition of non-nucleotide material at one or more nucleotides of the RNA. Nucleotides in the nucleic acid molecule can also include non-standard nucleotides (such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides). These altered RNAs can be referred to as analogs or analogs of naturally occurring RNA. In some embodiments, the RNA is messenger RNA (mRNA).

[0090] "Messenger RNA" (mRNA) refers to any polynucleotide that encodes (at least one) polypeptide (a polymer of naturally occurring, non-naturally occurring, or modified amino acids) and can be translated in vitro, in vivo, in situ, or ex vivo to produce the encoded polypeptide. In some embodiments, an mRNA disclosed herein comprises, consists essentially of, or even consists of at least one coding region, a 5' untranslated region (UTR), a 3'UTR, a 5' cap, and a poly-A tail.

[0091] Vaccination is the most successful medical approach in disease prevention and management. The successful development and use of vaccines has saved thousands of lives and saved large budgets. An important advantage of RNA vaccines is that RNA can be produced from DNA templates using readily available materials in laboratories, making it cheaper and faster than traditional vaccine production, which may require the use of chicken eggs or other mammalian cells. In addition, mRNA vaccines may facilitate rational vaccine discovery and development and rapid response to emerging infectious diseases (see, e.g., Maruggi et al., Mol Ther. 2019; 27(4): 757-772).

[0092] Preclinical and clinical trials have shown that mRNA vaccines provide safe and durable immune responses in animal models and humans. mRNA vaccines against infectious diseases can be developed as prophylactic or therapeutic treatments. mRNA vaccines expressing antigens of infectious pathogens have been shown to induce strong T cell and humoral immune responses. See, for example, Pardi et al., Nat Rev Drug Discov. 2018; 17: 261-279. The production techniques for generating mRNA vaccines are acellular, simple, and rapid compared to the production of whole microorganisms, live attenuated vaccines, and subunit vaccines. This rapid and simple manufacturing process makes mRNA a promising biological product that can potentially bridge the gap between emerging infectious diseases and the desperate need for effective vaccines.

[0093] The term "isolated" as used herein with respect to nucleic acids such as DNA or RNA refers to a molecule that is separated from other DNA or RNA, respectively, present in the natural source of the macromolecule. The term "isolated nucleic acid" is meant to include nucleic acid fragments that are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides, proteins, and / or host cells that are isolated from other cellular proteins, and is meant to include both purified and recombinant polypeptides. In other embodiments, the term "isolated" refers to being separated from constituents, cells, and other (cells, tissues, polynucleotides, peptides, polypeptides, or proteins with which it is normally associated in nature). For example, an isolated cell is one that is separated from tissues or cells of dissimilar phenotypes or genotypes. As will be apparent to one of skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, or protein does not require "isolation" to be distinguished from its naturally occurring counterpart.

[0094] In some embodiments, the term "engineered" or "recombinant" refers to having at least one modification not normally found in a naturally occurring protein, polypeptide, polynucleotide, strain, wild-type strain, or parent host strain of a reference species. In some embodiments, the term "engineered" or "recombinant" refers to being synthesized by human intervention. As used herein, the term "recombinant protein" refers to a polypeptide produced by recombinant DNA technology, where typically the DNA encoding the polypeptide is inserted into a suitable expression vector, which is then used to transform a host cell to produce the heterologous protein.

[0095] As used herein, "complementary" sequences refer to two nucleotide sequences that contain multiple individual nucleotide bases that pair with each other when the two nucleotide sequences are aligned in an antiparallel manner to each other. When the nucleotide bases pair, they form hydrogen bonds, thus stabilizing the double-stranded structure formed by the complementary sequences. It is not necessary for every nucleotide base in two sequences to pair with each other in order for the sequences to be considered "complementary". For example, sequences can be considered complementary if at least 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the nucleotide bases in the two sequences pair with each other. In some embodiments, the term complementary refers to 100% of the nucleotide bases in the two sequences pair with each other. Furthermore, even if the total length of two sequences is significantly different from each other, the sequences can still be considered "complementary". For example, a 15-nucleotide primer can be considered "complementary" to a longer polynucleotide containing several hundred nucleotides if the primer is aligned in antiparallel with a specific region of the longer polynucleotide, and multiple individual nucleotide bases of the primer are paired with nucleotide bases in the longer polynucleotide. Nucleotide base pairing, such as in DNA, is known in the art, and purine adenine (A) pairs with pyrimidine thymine (T), and pyrimidine cytosine (C) always pairs with purine guanine (G); whereas, in RNA, adenine (A) pairs with uracil (U), and guanine (G) pairs with cytosine (C). Furthermore, nucleotide bases that are aligned in antiparallel with each other in two complementary sequences but do not pair are referred to herein as mismatches.

[0096] A "gene" refers to a polynucleotide containing at least one open reading frame (ORF) that is capable of encoding a particular polypeptide or protein after transcription and translation.

[0097] The term "express" refers to the production of a gene product (such as an mRNA, a peptide, a polypeptide, or a protein). As used herein, "expression" refers to the process by which a polynucleotide is transcribed into an mRNA or the transcribed mRNA is subsequently translated into a peptide, a polypeptide, or a protein. If the polynucleotide is derived from genomic DNA, expression may include mRNA splicing in eukaryotic cells.

[0098] "Gene product" or "gene expression product" refers to the amino acids (e.g., peptides or polypeptides) produced when a gene is transcribed and translated. In some embodiments, gene product may refer to the mRNA or other RNA (such as interfering RNA) produced when a gene is transcribed.

[0099] The term "encode" as applied to a polynucleotide refers to a polynucleotide that is said to "encode" a polypeptide when, in its native state or when manipulated by methods well known to those of skill in the art, the polynucleotide can be transcribed to produce an mRNA for the polypeptide or a fragment thereof, and optionally translated to produce the polypeptide or a fragment thereof. The antisense strand is the complement of such a nucleic acid, from which a coding sequence can be deduced. Additionally, as used herein, an amino acid sequence coding sequence refers to a nucleotide sequence that codes for an amino acid sequence.

[0100] The terms "chemical modification" and "chemically modified" refer to at least one of the position, pattern, percentage, or population of modifications to adenosine (A), guanosine (G), uridine (U), thymidine (T), or cytidine (C) ribonucleosides or deoxyribonucleosides. In some embodiments, the terms refer to ribonucleotide modifications in the naturally occurring 5'-terminal mRNA cap portion. In further embodiments, the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, or 2'-O-methyluridine. In some embodiments, the extent of incorporation of chemically modified nucleotides is optimized to improve the immune response of the vaccine formulation. In another embodiment, the term excludes ribonucleotide modifications in the naturally occurring 5'-terminal mRNA cap portion.

[0101] Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) in some embodiments contain non-naturally occurring modified nucleotides that are introduced during or after synthesis of the polynucleotide to achieve a desired function or property. Modifications can be in the internucleotide linkage, the purine or pyrimidine base, or the sugar. Modifications can be introduced at the end of the chain or elsewhere in the chain, using chemical synthesis or polymerase enzymes. Any region of the polynucleotide can be chemically modified.

[0102] In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or a higher percentage of the residues of the RNA are chemically modified with one or more of the modifications as disclosed herein. In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or higher percentage of the uridine residues of the RNA are chemically modified with one or more of the modifications as disclosed herein.

[0103] In some embodiments, the RNA disclosed herein is optimized. Optimization can be used in some embodiments to match the codon frequency in target and host organisms to ensure proper folding; to bias GC content to increase mRNA stability or reduce secondary structure; to minimize tandem repeat codons or base runs that may impair gene assembly and expression; to customize transcriptional and translational regulatory regions; to insert or remove protein transport sequences; to remove / add post-translational modification sites (e.g., glycosylation sites) in encoded proteins; to add, remove, or shuffle protein domains; to insert or delete restriction sites; to modify ribosome binding sites and mRNA degradation sites; to adjust translation rates to allow various protein domains to fold properly; or to reduce or eliminate problematic secondary structures in polynucleotides.

[0104] "3' untranslated region" (3'UTR) refers to the region of an mRNA immediately downstream (i.e., 3') from a stop codon (i.e., a codon in an mRNA transcript that signals the end of translation) that does not encode a polypeptide. In some embodiments, a 3'UTR as used herein comprises, consists essentially of, or even consists of one or more of SEQ ID NOs: 18, 22, or 24.

[0105] "5' untranslated region" (5'UTR) refers to the region of an RNA immediately upstream (i.e., 5') from the start codon (i.e., the first codon of an mRNA transcript that is translated by a ribosome) that does not encode a polypeptide. In some embodiments, a 5'UTR as used herein comprises, consists essentially of, or even consists of one or both of SEQ ID NO:20 or 26.

[0106] A "poly-A tail" is a region of an mRNA downstream, e.g., immediately downstream (i.e., 3'), from the 3'UTR that contains multiple consecutive adenosine monophosphates. A poly-A tail can contain 10-300 adenosine monophosphates. Additionally or alternatively, in relevant biological contexts (e.g., in cells, in vivo), the poly-A tail functions to protect the mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus, and translation. In some embodiments, a poly-A tail as used herein comprises, consists essentially of, or even further consists of one or more of SEQ ID NOs: 27, 28, or 16.

[0107] In vitro transcription (IVT) method can synthesize RNA molecules of almost any sequence in a template-directed manner. The size of RNA molecules that can be synthesized using IVT method ranges from short oligonucleotides to long nucleic acid polymers of several thousand bases. IVT method can synthesize large amounts of RNA transcripts (e.g., microgram to milligram amounts) (Beckert et al., Methods Mol Biol. 703: 29-41 (2011); Rio et al. RNA: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2011, 205-220; and Cooper, Geoffery M. The Cell: A Molecular Approach. 4th ed. Washington DC: ASM Press, 2007, 262-299). In general, IVT utilizes a DNA template that features a promoter sequence upstream of the sequence of interest. The promoter sequence is most commonly of bacteriophage origin (e.g., T7, T3, or SP6 promoter sequences), but many other promoter sequences (including de novo designed promoters) can be tolerated. Transcription of the DNA template is typically best performed by using an RNA polymerase that corresponds to a specific bacteriophage promoter sequence. Exemplary RNA polymerases include, but are not limited to, T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase, etc. IVT generally initiates with dsDNA, but can proceed on a single strand.

[0108] It will be appreciated that any suitable synthesis method can be used to generate the RNA disclosed herein. For example, in some embodiments, RNA is generated using IVT from a single bottom-strand DNA as a template and a complementary oligonucleotide that serves as a promoter. The single bottom-strand DNA can serve as a DNA template for in vitro transcription of RNA, and can be obtained, for example, from a plasmid, a PCR product, or chemical synthesis. In some embodiments, the single bottom-strand DNA is linearized from a circular template. The single bottom-strand DNA template generally includes a promoter sequence (e.g., a bacteriophage promoter sequence) to facilitate IVT. Methods for generating RNA using single bottom-strand DNA and top-strand promoter-complementary oligonucleotides are known in the art. Exemplary methods include, but are not limited to, annealing the top strand of a DNA bottom strand template with a promoter complementary oligonucleotide (e.g., a T7 promoter complementary oligonucleotide, a T3 promoter complementary oligonucleotide, or a SP6 promoter complementary oligonucleotide), followed by IVT using an RNA polymerase corresponding to the promoter sequence (e.g., T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase).

[0109] The IVT method can also be performed using a double-stranded DNA template. For example, in some embodiments, a double-stranded DNA template is generated by extending a complementary oligonucleotide using strand extension techniques available in the art to generate a complementary DNA strand. In some embodiments, a single bottom-stranded DNA template comprising a promoter sequence and a sequence encoding one or more epitopes of interest is annealed to a top-stranded promoter-complementary oligonucleotide and subjected to a PCR-like process to extend the top strand, thereby generating a double-stranded DNA template. Alternatively or additionally, a top-stranded DNA comprising a sequence complementary to the bottom-stranded promoter sequence and complementary to a sequence encoding one or more epitopes of interest is annealed to a bottom-stranded promoter oligonucleotide and subjected to a PCR-like process to extend the bottom strand, thereby generating a double-stranded DNA template. In some embodiments, the number of PCR-like cycles ranges from 1 to 20 cycles, e.g., 3 to 10 cycles. In some embodiments, the double-stranded DNA template is synthesized in whole or in part by chemical synthesis. A double-stranded DNA template can be subjected to in vitro transcription as described herein.

[0110] "Under transcriptional control," as used herein also as "directing the expression of" or any grammatical variation thereof, is a term well understood in the art and indicates that transcription, and optionally translation, of a polynucleotide sequence (usually a DNA sequence) is dependent upon being operably linked to elements that contribute to the initiation of transcription or that promote transcription.

[0111] By "operably linked" is intended that the polynucleotides are positioned in a manner such that they can function within the cell.

[0112] As used herein, the term "control sequence," "expression control element," or "promoter" refers to a polynucleotide that is operably linked to a target polynucleotide to be transcribed or replicated and facilitates the expression or replication of the target polynucleotide.

[0113] Promoter is an example of an expression control element or control sequence. Promoter can be located 5' or upstream of gene or other polynucleotide, thereby providing a control point for gene transcription control. In some embodiments, promoter used herein corresponds to RNA polymerase. In further embodiments, promoter used herein comprises, consists essentially of, or even further consists of T7 promoter, or SP6 promoter, or T3 promoter. Non-limiting examples of suitable promoters are provided in WO2001009377A1.

[0114] "RNA polymerase" refers to an enzyme that produces a polyribonucleotide sequence that is complementary to an existing template polynucleotide (DNA or RNA). In some embodiments, the RNA polymerase is a bacteriophage RNA polymerase, optionally T7 RNA polymerase, or SP6 RNA polymerase, or T3 RNA polymerase. Non-limiting examples of suitable polymerases are further detailed in US10526629B2.

[0115] In some embodiments, the term "vector" refers to a recombinant vector that retains the ability to infect and transduce non-dividing and / or slowly dividing cells and, optionally, integrate into the genome of a target cell. Non-limiting examples of vectors include plasmids, nanoparticles, liposomes, viruses, cosmids, phages, BACs, YACs, and the like. In some embodiments, a plasmid vector can be prepared from a commercially available vector. In other embodiments, a viral vector can be produced from a baculovirus, retrovirus, adenovirus, AAV, and the like, according to techniques known in the art. In one embodiment, the viral vector is a lentiviral vector. In one embodiment, the viral vector is a retroviral vector. In one embodiment, the vector is a plasmid. In one embodiment, the vector is a nanoparticle, optionally a polymeric nanoparticle or a lipid nanoparticle.

[0116] Vectors that contain both a promoter and a cloning site to which a polynucleotide can be operably linked are well known in the art. Such vectors can transcribe RNA in vitro or in vivo and are commercially available from sources such as Stratagene (La Jolla, Calif.) and Promega Biotech (Madison, Wis.). To optimize expression and / or in vitro transcription, it may be necessary to remove, add, or change the 5' and / or 3' untranslated portions of the clone to eliminate redundant potentially inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression at either the transcription or translation level. Alternatively, a consensus ribosome binding site can be inserted immediately 5' to the initiation codon to enhance expression.

[0117] A "plasmid" is an extrachromosomal DNA molecule separate from chromosomal DNA that can replicate independently of chromosomal DNA. Often, plasmids are circular and double-stranded. Plasmids provide a mechanism for horizontal gene transfer within a microbial population, typically providing a selective advantage under a given environmental condition. A plasmid may carry a gene that provides resistance to an antibiotic that occurs naturally in a competitive environmental niche, or the protein produced may act as a toxin under similar circumstances. A large number of plasmids for such uses are commercially available. The gene to be replicated is inserted into a copy of a plasmid that contains a gene that confers resistance to a particular antibiotic to the cell, and a multiple cloning site (MCS, or polylinker), a short region that contains several commonly used restriction sites and at which a DNA fragment can be easily inserted. Another major use of plasmids is to make large amounts of proteins. In this case, researchers grow bacteria that contain a plasmid carrying the gene of interest. They can induce the bacteria to produce large amounts of protein from the inserted gene, just as the bacteria produces a protein to confer its antibiotic resistance. This is a cheap and easy way to produce large amounts of a gene or the protein it subsequently encodes.

[0118] A "viral vector" is defined as a virus or virus particle produced by recombinantly either in vivo, ex vivo, or in vitro that contains a polynucleotide to be delivered to a host cell. As known to those skilled in the art, there are six classes of viruses. DNA viruses are composed of classes I and II. RNA viruses and retroviruses make up the remaining classes. Class III viruses have a double-stranded RNA genome. Class IV viruses have a positive single-stranded RNA genome, and the genome itself acting as an mRNA class V viruses has a negative single-stranded RNA genome that is used as a template for mRNA synthesis. Class VI viruses have a positive single-stranded RNA genome, but form a DNA intermediate not only in replication but also in mRNA synthesis. Retroviruses carry their genetic information in the form of RNA; however, at the time the virus infects a cell, the RNA is reverse transcribed into the form of DNA and integrated into the genomic DNA of the infected cell. The integrated DNA form is called a provirus. Examples of viral vectors include retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, and alphaviral vectors. Alphavirus vectors (such as Semliki Forest virus-based vectors and Sindbis virus-based vectors) have also been developed for use in gene therapy and immunotherapy. See Schlesinger and Dubensky (1999) Curr. Opin. Biotechnol. 5:434-439 and Ying, et al. (1999) Nat. Med. 5(7):823-827. As used herein, multiplicity of infection (MOI) refers to the number of viral particles added per cell during infection.

[0119] Vectors that contain both a promoter and a cloning site to which a polynucleotide can be operably linked are well known in the art. Such vectors can transcribe RNA in vitro or in vivo and are commercially available from sources such as Stratagene (La Jolla, Calif.) and Promega Biotech (Madison, Wis.). To optimize expression and / or in vitro transcription, it may be necessary to remove, add, or change the 5' and / or 3' untranslated portions of the clone to eliminate redundant potentially inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression at either the transcription or translation level. Alternatively, a consensus ribosome binding site can be inserted immediately 5' to the initiation codon to enhance expression.

[0120] Retroviruses, such as gammaretroviruses and / or lentiviruses, comprise (a) an envelope containing lipids and glycoproteins, (b) a vector genome, which is an RNA (usually a dimeric RNA containing a cap at the 5' end and a polyA tail at the 3' end flanked by LTRs) directed to the target cell, (c) a capsid, and (d) proteins (such as proteases). U.S. Pat. No. 6,924,123 discloses that certain retroviral sequences facilitate integration into the target cell genome. The patent teaches that each retroviral genome contains genes called gag, pol, and env, which code for virion proteins and enzymes. These genes are flanked at both ends by regions called long terminal repeats (LTRs). LTRs are responsible for proviral integration and transcription. LTRs also function as enhancer-promoter sequences. In other words, LTRs can regulate the expression of viral genes. Encapsidation of retroviral RNA occurs due to the psi sequence present at the 5' end of the viral genome. The sequences of the LTRs themselves are identical and can be divided into three elements, designated U3, R, and U5. U3 is derived from a sequence unique to the 3' end of the RNA. R is derived from a sequence repeated at both ends of the RNA, and U5 is derived from a sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably in different retroviruses. For the viral genome, the poly(A) addition (termination) site is located at the border of R and U5 on the right side of the LTR. U3 contains most of the transcriptional regulatory elements of the provirus, including the promoter sequence and multiple enhancer sequences that respond to cellular and, in some cases, viral transcriptional activator proteins.

[0121] Regarding the structural genes gag, pol, and env themselves, gag codes for the internal structural protein of the virus. The gag protein is hydrolytically processed into the mature proteins MA (matrix), CA (capsid), and NC (nucleocapsid). The pol gene codes for the reverse transcriptase (RT) containing DNA polymerase, the associated RNase H, and integrase (IN), which mediate genome replication.

[0122] For the production of viral vector particles, the vector RNA genome is expressed in a host cell from a DNA construct encoding said genome. The components of the particle that are not encoded by the vector genome are provided in trans by additional nucleic acid sequences expressed in the host cell (usually a "packaging system" including either or both of the gag / pol and env genes). The set of sequences required for the production of viral vector particles can be introduced into the host cell by transient transfection, or the sequences can be integrated into the host cell genome, or the sequences can be provided in a mixture. The techniques involved are known to those skilled in the art.

[0123] The term "adeno-associated virus" or "AAV" as used herein refers to a member of the class of viruses related to this name, belonging to the genus Dependoparvovirus, family Parvoviridae. Multiple serotypes of this virus are known to be suitable for gene delivery; all known serotypes can infect cells from various tissue types. At least eleven consecutively numbered AAV serotypes are known in the art. Non-limiting examples of serotypes useful in the methods disclosed herein include any of the eleven serotypes (e.g., AAV2, AAV8, AAV9), or variants or synthetic serotypes (e.g., AAV-DJ and AAV PHP.B). AAV particles comprise or consist essentially of, or even further consist of, three major viral proteins: VP1, VP2, and VP3. In one embodiment, AAV refers to serotypes AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV PHP.B, or AAV rh74. These vectors are commercially available or described in the patent or technical literature.

[0124] Gene delivery vehicles also include DNA / liposome complexes, micelles, and targeted viral protein-DNA complexes. Liposomes that also contain targeting antibodies or fragments thereof can be used in the methods of the present disclosure. In addition to the delivery of polynucleotides to cells or cell populations, direct introduction of the proteins described herein into cells or cell populations can be performed by protein transfection techniques (not limited to), or culture conditions that can enhance the expression and / or promote the activity of the proteins disclosed herein are other non-limiting techniques.

[0125] The term "control sequence", "expression control element" or "promoter" as used herein refers to a polynucleotide that is operably linked to a target polynucleotide to be transcribed and / or replicated and facilitates the expression and / or replication of the target polynucleotide. A promoter is an example of an expression control element or control sequence. A promoter can be located 5' or upstream of a gene or other polynucleotide, thereby providing a control point for gene transcription control. Polymerase II and III are examples of promoters.

[0126] Polymerase II or "pol II" promoters catalyze the transcription of DNA to synthesize precursors of mRNA, as well as most shRNAs and microRNAs. Examples of pol II promoters are known in the art and include, but are not limited to, phosphoglycerate kinase ("PGK") promoter; EF1-alpha; CMV (minimal cytomegalovirus promoter); and LTRs from retroviral and lentiviral vectors.

[0127] Enhancers are control elements that increase the expression of a target sequence. A "promoter / enhancer" is a polynucleotide that contains a sequence that can provide both promoter and enhancer functions. For example, the long terminal repeats of retroviruses contain both promoter and enhancer functions. Enhancers / promoters can be "endogenous" or "exogenous" or "heterologous." An "endogenous" enhancer / promoter is one that is naturally linked to a given gene in the genome. An "exogenous" or "heterologous" enhancer / promoter is one that is juxtaposed to said gene by genetic engineering (i.e., molecular biology techniques) such that transcription of the gene is directed by the linked enhancer / promoter.

[0128] "Hybridization" refers to the reaction of one or more polynucleotides to form a complex stabilized by hydrogen bonds between the bases of the nucleotide residues. The hydrogen bonds may occur by Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner. The complex may include two strands forming a duplex structure, three or more strands forming a multistranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction or the enzymatic cleavage of a polynucleotide by a ribozyme.

[0129] Hybridization reactions can be carried out under conditions of different "stringency". Generally, low stringency hybridization reactions are carried out in 10xSSC at about 40°C, or in solutions of equivalent ionic strength / temperature. Medium stringency hybridizations are typically carried out in 6xSSC at about 50°C, and high stringency hybridization reactions are generally carried out in 1xSSC at about 60°C. Hybridization reactions can also be carried out under "physiological conditions", as known to those of skill in the art. Non-limiting examples of physiological conditions include temperature, ionic strength, pH, and Mg concentration normally found in cells. 2+ Concentration.

[0130] Examples of stringent hybridization conditions include: an incubation temperature of about 25°C to about 37°C; a hybridization buffer concentration of about 6xSSC to about 10xSSC; a formamide concentration of about 0% to about 25%; and a wash solution of about 4xSSC to about 8xSSC. Examples of medium hybridization conditions include: an incubation temperature of about 40°C to about 50°C; a buffer concentration of about 9xSSC to about 2xSSC; a formamide concentration of about 30% to about 50%; and a wash solution of about 5xSSC to about 2xSSC. Examples of high stringency conditions include: an incubation temperature of about 55°C to about 68°C; a buffer concentration of about 1xSSC to about 0.1xSSC; a formamide concentration of about 55% to about 75%; and a wash solution of about 1xSSC, 0.1xSSC, or deionized water. Generally, hybridization incubation times are 5 minutes to 24 hours, including one, two or more washing steps, with wash incubation times of about 1, 2, or 15 minutes. SSC is 0.15M NaCl and 15 mM citrate buffer. It is understood that equivalents of SSC using other buffer systems can be used.

[0131] When hybridization occurs between two single-stranded polynucleotides in an antiparallel configuration, the reaction is called "annealing" and these polynucleotides are described as "complementary". A double-stranded polynucleotide can be "complementary" or "homologous" to another polynucleotide if hybridization can occur between one of the first and second polynucleotide strands. "Complementarity" or "homology" (the degree to which one polynucleotide is complementary to another) can be quantified in terms of the ratio of bases in opposite strands that are expected to form hydrogen bonds with each other according to commonly accepted base pairing rules.

[0132] "Homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing positions in each sequence that can be aligned for comparison. If a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the aforementioned sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, or less than 25% identity, with one of the sequences of the present disclosure. In some embodiments, identity is calculated between two peptides or polynucleotides over their entire length, or over two shorter sequences, or over two longer sequences.

[0133] A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) having a certain percentage (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) of "sequence identity" to another sequence means that, when aligned, the aforementioned percentage of bases (or amino acids) in the two sequences being compared are the same. This alignment and the percentage of homology or sequence identity can be determined using software programs known in the art, such as those described in Ausubel et al. eds. (2007) Current Protocols in Molecular Biology. It is preferred to use default parameters for alignment. One alignment program is BLAST, using default parameters. In particular, the programs are BLASTN and BLASTP using the following default parameters: genetic code=standard; filter=none; strand=both; cutoff=60; expectation=10; matrix=BLOSUM62; display=50 sequences; sorting method=HIGH SCORE; database=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translation+SwissProtein+SPupdate+PIR. Details of these programs can be found at the following internet address: blast.ncbi.nlm.nih.gov / Blast.cgi, last accessed on August 1, 2021.

[0134] In some embodiments, the polynucleotides disclosed herein are RNA or analogs thereof. In some embodiments, the polynucleotides disclosed herein are DNA or analogs thereof. In some embodiments, the polynucleotides disclosed herein are DNA and RNA hybrids or analogs thereof.

[0135] In some embodiments, a reference nucleic acid, polynucleotide, or oligonucleotide equivalent encodes a sequence identical to that encoded by said reference. In some embodiments, a reference nucleic acid, polynucleotide, or oligonucleotide equivalent hybridizes to said reference, complementary reference, reverse reference, or reverse-complementary reference, optionally under high stringency conditions.

[0136] Additionally or alternatively, an equivalent nucleic acid, polynucleotide, or oligonucleotide has at least 70% sequence identity, or at least 75% sequence identity, or at least 80% sequence identity, or at least 85% sequence identity, or at least 90% sequence identity, or at least 92% sequence identity, or at least 95% sequence identity, or at least 97% sequence identity, or at least 98% sequence identity, or at least 99% sequence identity to a reference nucleic acid, polynucleotide, or oligonucleotide, or an equivalent nucleic acid hybridizes to a reference polynucleotide or its complement under high stringency conditions. In one embodiment, the equivalent must encode the same protein or a functional equivalent of a protein, which can be identified as needed by one or more assays described herein. Additionally or alternatively, a polynucleotide equivalent will encode a protein or polypeptide of the same or similar function as the reference or parent polynucleotide.

[0137] The term "transduce" or "transduction" refers to the process of introducing an exogenous nucleotide sequence into a cell. In some embodiments, the transduction is by a vector, viral, or non-viral.

[0138] "Detectable label," "label," "detectable marker," or "marker" are used interchangeably and include, but are not limited to, radioisotopes, fluorescent dyes, chemiluminescent compounds, dyes, and proteins, including enzymes. Detectable labels can also be attached to polynucleotides, polypeptides, proteins, or compositions described herein.

[0139] As used herein, the term "label" or detectable label refers to a directly or indirectly detectable compound or composition (e.g., an N-terminal histidine tag (N-His), a magnetically active isotope (e.g., 115 Sn, 117 Sn, and 119 Sn), non-radioactive isotopes ( 13 C and 15N), polynucleotides or proteins (such as antibodies to generate "labeled" compositions). The term also includes sequences conjugated to a polynucleotide that will emit a signal upon expression of the inserted sequence (such as green fluorescent protein (GFP)). The label may be detectable itself (e.g., radioisotope or fluorescent label) or, in the case of an enzymatic label, may catalyze a chemical change in a substrate compound or composition that is detectable. The label may be suitable for small-scale detection or may be more suitable for high-throughput screening. As such, suitable labels include, but are not limited to, magnetically active isotopes, non-radioactive isotopes, radioisotopes, fluorescent dyes, chemiluminescent compounds, dyes, and proteins (including enzymes). The label may be easily detected or quantified. An easily detected response generally includes a response whose presence alone is confirmed, whereas a quantified response generally includes a response that has a quantifiable (e.g., numerically reportable) value (such as intensity, polarization, and / or other property). In luminescent or fluorescent assays, detectable response can be generated directly using a luminophore or fluorophore associated with the assay component that actually participates in binding, or indirectly using a luminophore or fluorophore associated with another (e.g., reporter or indicator) component. Examples of luminescent labels that generate signals include, but are not limited to, bioluminescence and chemiluminescence. Detectable luminescent response generally includes a change or appearance of a luminescent signal. Methods and luminophores suitable for luminescent label assay components are known in the art and are described, for example, in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6th ed). Examples of fluorescent probes include, but are not limited to, aequorin and luciferase.

[0140] As used herein, the term "immunoconjugate" includes an antibody or antibody derivative associated or linked to a second agent, such as a cytotoxic agent, a detectable agent, a radioactive agent, a targeting agent, a human antibody, a humanized antibody, a chimeric antibody, a synthetic antibody, a semi-synthetic antibody, or a multispecific antibody.

[0141] Examples of suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methyl-coumarin, pyrene, malachite green, stilbene, Lucifer Yellow, Cascade Blue™, and Texas Red. Other suitable optical dyes are described in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6th ed.).

[0142] In some embodiments, the fluorescent label is functionalized to facilitate covalent attachment to cellular components (such as cell surface markers) present in or on the surface of cells or tissues. Suitable functional groups include, but are not limited to, isothiocyanate groups, amino groups, haloacetyl groups, maleimides, succinimidyl esters, and sulfonyl halides, all of which can be used to attach the fluorescent label to a second molecule. The choice of functional group of the fluorescent label will depend on the site of attachment to either the linker, agent, marker, or second labeling agent.

[0143] As used herein, a purification label or marker refers to a label that can be used in the purification of a molecule or component, where the label is conjugated to an epitope tag (including, but not limited to, Myc tag, human influenza hemagglutinin (HA) tag, FLAG tag), affinity tag (including, but not limited to, glutathione-S-transferase (GST), poly-histidine (His) tag, calmodulin-binding protein (CBP), or maltose-binding protein (MBP)), fluorescent tag, or the like.

[0144] "Selection marker" refers to a protein or gene encoding said protein required for survival or growth of cells grown in a selective culture regimen. Typical selection markers include sequences encoding proteins that confer resistance to selection agents (such as antibiotics, herbicides, or other toxins). Examples of selection markers include genes that confer resistance to antibiotics (such as spectinomycin, streptomycin, tetracycline, ampicillin, kanamycin, G418, neomycin, bleomycin, hygromycin, methotrexate, dicamba, glufosinate, or glyphosate).

[0145] The term "culture" refers to the in vitro or ex vivo propagation of cells or organisms on or in various types of media. It is understood that the progeny of a cell grown in culture may not be completely identical (i.e., morphologically, genetically, or phenotypically) to the parent cell.

[0146] In some embodiments, the cell disclosed herein is a eukaryotic cell or a prokaryotic cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is a cell line, such as human embryonic kidney 293 cell (HEK293 cell or 293 cell), 293T cell, or a549 cell.

[0147] "Host cell" refers not only to a particular subject cell, but also to the progeny or potential progeny of such a cell. Since certain modifications may occur in later generations, either due to mutation or environmental influences, such progeny may not actually be identical to the parent cell, but still fall within the scope of the term as used herein. Host cells can be prokaryotic or eukaryotic. In some embodiments, host cells are cell lines, such as human embryonic kidney 293 cells (HEK293 cells or 293 cells), 293T cells, or a549 cells.

[0148] "Eukaryotic cell" includes all kingdoms except the kingdom Monera. Eukaryotic cells can be easily distinguished by their membrane-bound nuclei. Animals, plants, fungi, and protists are organisms in which the eukaryotes or cells are organized into complex structures by internal membranes and cytoskeleton. The most characteristic membrane-bound structure is the nucleus. Unless specifically recited, the term "host" includes eukaryotic hosts (including, for example, yeast, higher plants, insects, and mammalian cells). Non-limiting examples of eukaryotic cells or hosts include monkeys, dogs, cows, pigs, mice, rats, birds, reptiles, and humans.

[0149] "Prokaryotic cells" usually lack a nucleus or any other membrane-bound organelles and are classified into two domains, bacteria and archaea. Furthermore, instead of having chromosomal DNA, the genetic information of these cells resides in circular loops called plasmids. Bacterial cells are very small, roughly the size of an animal mitochondrion (approximately 1-2 μm in diameter and 10 μm in length). Prokaryotic cells are characterized by three main shapes: rod-shaped, spherical, and spiral. Instead of undergoing an elaborate replication process like eukaryotes, bacterial cells divide by binary fission. Examples include, but are not limited to, bacteria of the genus Bacillus, Escherichia coli, and bacteria of the genus Salmonella.

[0150] A "composition" means a combination of an active agent with another compound or composition, inert (e.g., a detectable agent or label) or active (such as an adjuvant, diluent, binder, stabilizer, buffer, salt, lipophilic solvent, preservative, or adjuvant), and is intended to include a pharma- ceutically acceptable carrier.

[0151] Carriers also include pharmaceutical excipients and additives proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars including monosaccharides, di-, tri-, tetra-oligosaccharides, and oligosaccharides; sugar derivatives (such as alditols, aldonic acids, and esterified sugars); and polysaccharides or sugar polymers), which may be present alone or in combination and comprise 1-99.99% by weight or volume, alone or in combination. Exemplary protein excipients include serum albumins (such as human serum albumin (HSA)), recombinant human albumin (rHA), gelatin, and casein, and the like. Representative amino acid components that can also function as buffering agents include alanine, arginine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, and aspartame, and the like. Carbohydrate excipients are also contemplated to be within the scope of the present technology, examples of which include, but are not limited to, monosaccharides (such as fructose, maltose, galactose, glucose, D-mannose, and sorbose); disaccharides (such as lactose, sucrose, trehalose, and cellobiose); polysaccharides (such as raffinose, melezitose, maltodextrin, dextran, and starch); and alditols (such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), and myo-inositol).

[0152] The compositions disclosed herein may be pharmaceutical compositions. A "pharmaceutical composition" is intended to include a combination of an active agent with a carrier (inert or active) that makes the composition suitable for in vitro, in vivo, or ex vivo diagnostic or therapeutic use.

[0153] "Pharmaceutically acceptable carrier" refers to any diluent, excipient, or carrier that can be used in the compositions disclosed herein. Pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field. The aforementioned carriers may be selected with respect to the intended form of administration, ie, oral tablets, capsules, elixirs, syrups, and the like, and in accordance with conventional pharmaceutical practice.

[0154] As used herein, the term "excipient" refers to a natural or synthetic substance that is formulated with an active pharmaceutical ingredient and is included for the purposes of long-term stabilization, adding bulk to a solid formulation, or enhancing the therapeutic effect of the active ingredient in the final dosage form (such as enhancing drug absorption, reducing viscosity, or increasing solubility).

[0155] The compositions used according to the present disclosure can be packaged in dosage unit form for ease of administration and uniformity of dosage. The term "unit dose" or "dosage" refers to a physically discrete unit suitable for use by a subject, each unit containing a predetermined amount of the composition calculated to obtain the desired response by its administration (i.e., appropriate route and regimen). The amount to be administered, both according to number of treatments and unit dose, depends on the desired outcome and / or protection. The precise amount of the composition also depends on the judgment of the practitioner and is peculiar to each individual. Factors influencing the dosage include the subject's physical and clinical condition, the route of administration, the intended purpose of the treatment (alleviation of symptoms versus cure), and the efficacy, stability, and toxicity of the particular composition. Upon formulation, the solution is administered in a manner compatible with the dosage formulation and in an amount that is therapeutically or prophylactically effective. The formulation is easily administered in a variety of dosage forms, such as the types of injection solutions described herein.

[0156] As used herein, combination contemplates that the individual active ingredients of the composition for use in combination can be formulated separately and packaged separately, with or without specified dosages. The active ingredients of the combination can be administered simultaneously or sequentially.

[0157] The four-antennary histidine-lysine (HK) peptide polymer H2K4b has been shown to be a good carrier of high molecular weight DNA plasmids (Leng et al. Nucleic Acids Res 2005;33:e40.) but a poor carrier of relatively low molecular weight siRNAs (Leng et al. J Gene Med 2005;7:977-986.) Two histidine-rich peptide analogs of H2K4b, namely H3K4b and H3K(+H)4b, have been shown to be effective carriers of siRNAs (Leng et al. J Gene Med 2005;7:977-986. Chou et al. Biomaterials 2014;35:846-855.), although H3K(+H)4b appears to be slightly more effective (Leng et al. Mol Ther 2012;20:2282-2290.). Moreover, H3K4b carriers of siRNA induced cytokines in vitro and in vivo to a significantly higher extent than H3K(+H)4b siRNA polyplexes (Leng et al.Mol Ther 2012;20:2282-2290.). Suitable HK polypeptides are described in WO / 2001 / 047496, WO / 2003 / 090719, and WO / 2006 / 060182, the contents of each of which are incorporated herein in their entirety. These polypeptides have a lysine backbone (three lysine residues) with lysine side chain ε-amino groups and N-terminus coupled to various HK sequences. HK polypeptide carriers can be synthesized by methods well known in the art, including, for example, solid phase synthesis.

[0158] It has been found that such histidine-lysine peptide polymers ("HK polymers" or "HKPs") are surprisingly effective as mRNA carriers, and that they can be used alone or in combination with liposomes to effectively deliver mRNA to target cells. As with PEI and other carriers, initial results suggested that HK polymers differ in their ability to retain and release nucleic acids. However, because HK polymers can be reproduced in a peptide synthesizer, their amino acid sequence can be easily altered, thereby allowing fine-tuning of RNA binding and release, as well as the stability of polyplexes containing HK polymers and RNA (Chou et al. Biomaterials 2014;35:846-855. Midoux et al. Bioconjug Chem 1999;10:406-411. Henig et al. Journal of American Chemical Society 1999;121:5123-5126.). When mRNA molecules are mixed with one or more HKP carriers, the components self-assemble into nanoparticles.

[0159] As described herein, it is advantageous for the HK polymer to contain four short peptide branches linked to a three-lysine amino acid core. The peptide branches consist of different arrangements of histidine and lysine amino acids. The general structure of these histidine-lysine peptide polymers (HK polymers) is shown in formula I, where R represents the peptide branch and K is the amino acid L-lysine. [ka]

[0160] In Formula I, K is L-lysine, and each of R1, R2, R3, and R4 is independently a histidine-lysine peptide. 1~4 A branch may be the same or different in an HK polymer of the invention. When an R branch is "different", the amino acid sequence of that branch is different from each of the other R branches in the polymer. Suitable R branches for use in the HK polymers of the invention shown in Formula I include the following R branches RA ~R -J Including, but not limited to: R A =KHKHHKHHKHHKHHKHK- (SEQ ID NO: 31) R B =KHHHKHHHKHHHKHHHK- (SEQ ID NO: 32) R C =KHHHKHHHKHHHHKHHHK- (SEQ ID NO: 33) R D = kHHHkHHHkHHHHkHHHk- (SEQ ID NO: 34) R E =HKHHHKHHHKHHHKHHHK- (SEQ ID NO: 35) R F =HHKHHHKHHHKHHHKHHHK- (SEQ ID NO: 36) R G= KHHHHKHHHHKHHHHKHHHHK-(SEQ ID NO:37) R H =KHHHKHHHKHHHKHHHK- (SEQ ID NO: 38) R I =KHHHKHHHHKHHHKHHHK- (SEQ ID NO: 39) R J =KHHHKHHHHKHHHKHHHK-(SEQ ID NO:40)

[0161] A specific HK polymer that can be used in the mRNA composition is one in which each of R1, R2, R3, and R4 is the same and R A ~R J The HK polymers include, but are not limited to, HK polymers selected from (Table 1). These HK polymers are named H2K4b, H3K4b, H3K(+H)4b, H3k(+H)4b, H-H3K(+H)4b, HH-H3K(+H)4b, H4K4b, H3K(1+H)4b, H3K(3+H)4b, and H3K(1,3+H)4b, respectively. In each of these ten examples, the capital "K" represents L-lysine and the lower case "k" represents D-lysine. The extra histidine residues in the branched sequence compared to H3K4b are underlined. The nomenclature of the HK polymers is as follows: 1) For H3K4b, the dominant repeat sequence in the branch is -HHHK- (SEQ ID NO: 45), therefore "H3K" is part of the name; "4b" refers to the branch number; 2) there are four -HHHK- (SEQ ID NO: 45) motifs in the branch of H3K4b and analogs; the first -HHHK- motif (SEQ ID NO: 45) ("1") is closest to the lysine core; 3) H3K(+H)4b is an analog of H3K4b in which one extra histidine is inserted into the second -HHHK- motif (SEQ ID NO: 45) (motif 2) of H3K4b; 4) for H3K(1+H)4b and H3K(3+H)4b peptides, there are extra histidines in the first (motif 1) and third (motif 3) motifs, respectively; 5) For H3K(1,3+H)4b, there are two extra histidines in both the first and third motifs of the branch.

[0162] [Table 1]

[0163] Methods well known in the art (including gel retardation assay, heparin displacement assay, and flow cytometry) can be carried out to assess the ability of different formulations, including HK polymer + liposome, to successfully deliver mRNA.Suitable methods are described, for example, in Gujrati et al., Mol.Pharmaceutics 11:2734-2744 (2014) and Parnaste et al., Mol Ther Nucleic Acids.7:1-10 (2017).

[0164] Detection of mRNA uptake into cells can also be performed using SMARTFLARE® technology (Millipore Sigma). These SmartFLAREs are beads with sequences attached that increase in fluorescence when they recognize an RNA sequence in a cell, and this fluorescence can be analyzed using a fluorescent microscope.

[0165] Other methods include measuring protein expression from mRNA, for example, luciferase-encoding mRNA can be used to measure transfection efficiency. See, for example, He et al. (J Gene Med. 2021 Feb;23(2):e3295), who demonstrate the efficacy of mRNA delivery using HKP and liposomal formulations.

[0166] The combination of H3K(+H)4b and DOTAP (cationic lipid) surprisingly showed synergistic effects in the ability to deliver mRNA into MDA-MB-231 cells (H3K(+H)4b / liposome vs. liposome, P<0.0001). The aforementioned combination was approximately 3-fold and 8-fold more effective as a carrier of mRNA than the polymer alone and the cationic lipid carrier, respectively. Not all HK peptides demonstrated synergistic activity with DOTAP lipids. For example, the combination of H3K4b and DOTAP was less effective as a carrier of luciferase mRNA than DOTAP liposomes. In addition to DOTAP, other cationic lipids that can be used with HK peptides include Lipofectin (ThermoFisher), Lipofectamine (ThermoFisher), and DOSPER.

[0167] The D-isomer of H3k(+H)4b, in which the L-lysine in the branch is replaced by a D-lysine, was the most effective polymeric carrier (H3k(+H)4b vs. H3K(+H)4b, P<0.05). The D-isomer of mRNA / liposome carrier was approximately 4-fold and 10-fold more effective than H3k(+H)4b alone and liposome carrier, respectively. The D-H3k(+H)4b / lipid combination was slightly more effective than the L-H3K(+H)4b / lipid combination, but this comparison was not statistically different.

[0168] Both H3K4b and H3K(+H)4b can be used as carriers of nucleic acids in vitro (see, e.g., Leng et al. J Gene Med 2005;7:977-986; and Chou et al., Cancer Gene Ther 2011;18:707-716). Despite these previous findings, H3K(+H)4b was significantly better as a carrier of mRNA compared to other similar analogs (Table 2).

[0169] [Table 2-1] [Table 2-2] [Table 2-3]

[0170] Notably, H3K(+H)4b has higher mRNA transfection efficiency than H3K4b at various weight:weight (HK:mRNA) ratios. At a 4:1 ratio, luciferase expression in MDA-MB-231 cells was 10-fold higher with H3K(+H)4b than with H3K4b, without significant cytotoxicity. Furthermore, since the percentage of histidine (by weight) in H3K4b and H3K(+H)4b is 68.9 and 70.6%, respectively, buffering capacity does not appear to be an essential factor in the transfection difference.

[0171] Gel retardation assays show that the electrophoretic mobility of mRNA was retarded by HK polymers. This retardation effect increased with increasing weight ratio of peptide to mRNA. However, mRNA was fully retarded with H3K(+H)4b at a 2:1 ratio, whereas it was not fully retarded by H3K4b. This suggested that H3K(+H)4b could form more stable polyplexes, and its ability is advantageous for it to be a suitable carrier for mRNA delivery.

[0172] The tighter binding of H3K(+H)4b peptide to mRNA was further confirmed using a heparin displacement assay. Various concentrations of heparin were added to polyplexes formed with mRNA and HK, and it was observed that mRNA was more easily released by H3K4b polymers than by H3K(+H)4b polymers, especially at lower concentrations of heparin. These data suggest that H3K(+H)4b can bind to mRNA and form more stable polyplexes than H3K4b.

[0173] Using cyanine-5-labeled mRNA, the uptake of H3K4b and H3K(+H)4b polyplexes into MDA-MB-231 cells was compared using flow cytometry. At different time points (1, 2, and 4 h), H3K(+H)4b polyplexes were more efficiently transported into cells than H3K4b polyplexes. Similar to these results, fluorescence microscopy showed that H3K(+H)4b polyplexes were significantly more localized within acidic endosomal vesicles than H3K4b polyplexes (H3K4b vs. H3K(+H)4b, P<0.001). Interestingly, the irregularly shaped H3K4b polyplexes that did not overlap with endocytic vesicles were likely extracellular and were not observed with H3K(+H)4b polyplexes.

[0174] Both HK polymers and cationic lipids (i.e., DOTAP) are known to significantly and independently increase transfection with plasmids. See, for example, Chen et al. Gene Ther 2000;7:1698-1705. Therefore, we investigated whether these lipids would enhance mRNA transfection along with HK polymers. Notably, H3K(+H)4b and H3k(+H)4b carriers were significantly better carriers of mRNA than DOTAP liposomes. The combination of H3K(+H)4b and DOTAP lipids had a synergistic effect on the ability to transport mRNA into MDA-MB-231 cells. The aforementioned combination was approximately 3-fold and 8-fold more effective as a carrier of mRNA than polymer alone and liposomal carriers, respectively (H3K(+H)4b / lipid vs. liposomes or H3K(+H)4b). Notably, not all HK peptides demonstrated improved activity with DOTAP lipids. The combination of H3K4b and DOTAP was less effective than DOTAP liposomes as a carrier for luciferase mRNA. The combination of DOTAP and H3K(+H)4b was found to have a synergistic effect in their ability to deliver mRNA into cells. See, for example, He et al. J Gene Med. 2020 Nov 10:e3295.

[0175] In some embodiments, the carrier such as NKP nanoparticles further comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid. In some embodiments, the cationic lipid is an ionic cationic lipid, the non-cationic lipid is a neutral lipid, and the sterol is cholesterol. In some embodiments, the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA, or MC3), and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

[0176] In some embodiments, the carrier is a lipid nanoparticle (LNP). In some embodiments, the average diameter of the LNP is about 50 nm to about 200 nm. In some embodiments, the lipid nanoparticle carrier / formulation typically comprises, consists essentially of, or even further consists of a lipid, particularly an ionic cationic lipid, such as SM-102, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319) as disclosed herein. In some embodiments, the LNP carrier / formulation further comprises neutral lipids, sterols (such as cholesterol), and molecules that can reduce particle aggregation, such as PEG or PEG-modified lipids (also referred to herein as PEGylated lipids).Further exemplary lipid nanoparticle compositions and methods for making them are described, for example, in Semple et al. (2010) Nat.Biotechnol.28:172-176; Jayarama et al. (2012), Angew.Chem.Int.Ed.,51:8529-8533; and Maier et al. (2013) Molecular Therapy 21:1570-1578, the entire contents of each of which are incorporated herein by reference.

[0177] In one embodiment, the term "disease" or "disorder" as used herein refers to a RSV infection, a condition diagnosed with a RSV infection, a condition suspected of having a RSV infection, or a condition at high risk of having a RSV infection. In one embodiment, the term "disease" or "disorder" as used herein refers to a symptomatic RSV infection, a condition diagnosed with a symptomatic RSV infection, a condition suspected of having a symptomatic RSV infection, or a condition at high risk of having a symptomatic RSV infection.

[0178] As used herein, the term "animal" refers to living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term "mammal" includes both human and non-human mammals, such as non-human primates, such as apes, gibbons, chimpanzees, orangutans, monkeys, and macaques, pet animals, such as dogs and cats, farm animals, such as horses, cows, goats, sheep, pigs, and laboratory animals, such as mice, bats, rats, rabbits, and guinea pigs.

[0179] The terms "subject," "host," "individual," and "patient" are used interchangeably herein to refer to animals, typically mammals. Any suitable mammal can be treated by the methods described herein. Non-limiting examples of mammals include humans, non-human primates (e.g., apes, gibbons, chimpanzees, orangutans, monkeys, and macaques, etc.), pet animals (e.g., dogs and cats), farm animals (e.g., horses, cows, goats, sheep, pigs), and laboratory animals (e.g., mice, rats, bats, rabbits, guinea pigs). In some embodiments, the mammal is a human. The mammal can be of any age or at any stage of development (e.g., adult, teen, child, infant, or mammal in utero). The mammal can be male or female. In some embodiments, the subject is a human. In some embodiments, the subject has a disease, has been diagnosed with a disease, or is suspected of having a disease.

[0180] As used herein, "treating" or "treatment" of a disease in a subject refers to (1) preventing the onset of symptoms or disease in a subject who is susceptible or does not yet show symptoms of the disease; (2) suppressing or arresting the development of the disease; or (3) improving or remitigating the disease or symptoms of the disease. As understood in the art, "treatment" is an approach to obtain beneficial or desired results, including clinical results. The beneficial or desired results of the present technology may include, but are not limited to, one or more of the following: alleviation or amelioration of one or more symptoms, reduction in the extent of symptoms (including disease), a state in which symptoms (including disease) are stabilized (i.e., not worsening), slowing or retardation of the progression of symptoms (including disease), improvement or palliative relief of symptoms (including disease), conditions, and remission (either partial or total) (irrespective of whether detectable or undetectable). In one embodiment, treatment excludes prevention.

[0181] In some embodiments, the terms "treating" and "treatment" as used herein refer to the amelioration of a disease to reduce, improve, or eliminate one or more of its causes, its progression, its severity, or its symptoms, or otherwise favorably alter the disease in a subject. Reference to "treating" or "treatment" of a patient is intended to include prevention. Treatment may also be preventative in nature (i.e., may include prevention of disease in a subject exposed to or at risk for the disease). Prevention of a disease may include complete protection from the disease (such as in the case of prevention of pathogen infection) or may include prevention of disease progression. For example, prevention of a disease may not mean complete containment of any effect associated with the disease at any level, but instead may mean prevention of disease manifestations to a clinically significant or detectable level. Prevention of a disease may also mean prevention of progression of a disease to a subsequent stage.

[0182] "Immune response" broadly refers to an antigen-specific response of lymphocytes to a foreign substance. The terms "immunogen" and "immunogenic" refer to a molecule that has the ability to induce an immune response. All immunogens are antigens, however, not all antigens are immunogenic. The immune response disclosed herein can be humoral (through antibody activity) or cellular (through T cell activation). The response can occur in vivo or in vitro. Those skilled in the art will understand that a variety of macromolecules, including proteins, nucleic acids, fatty acids, lipids, lipopolysaccharides, and polysaccharides, can be immunogenic. Those skilled in the art will further understand that a nucleic acid that encodes a molecule capable of eliciting an immune response necessarily encodes an immunogen. Those skilled in the art will further understand that an immunogen is not limited to a full-length molecule, but can include a partial molecule.

[0183] As used herein, "viral load," also known as "viral load," "viral titer," "viral level," or "viral expression," is in some embodiments a measure of the severity of a viral infection and can be calculated by assessing the amount of virus in an infected organism, associated body fluid, or biological sample.

[0184] As used herein, a biological sample, ie, a sample, is obtained from a subject. Exemplary samples include, but are not limited to, cell samples, tissue samples, biopsies, liquid samples such as blood, and other liquid samples of biological origin (including, but not limited to, anterior nasal swabs, ocular fluid (aqueous humor and vitreous humor), peripheral blood, serum, plasma, peritoneal fluid, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, earwax, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, Cowper's or pre-ejaculatory fluid, vaginal fluid, sweat, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, peritoneal fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions / vaginal washings, synovial fluid, mucosal secretions, watery stool, pancreatic juice, lavage fluid from the sinuses, bronchopulmonary aspirate, blastocyl cavity fluid, or umbilical cord blood).

[0185] In some embodiments, the sample may be an upper respiratory tract specimen, such as a nasopharyngeal (NP) specimen, an oropharyngeal (OP) specimen, a middle turbinate swab, an anterior nares (nasal swab) specimen, or a nasopharyngeal wash / aspirate, or a nasal wash / aspirate (NW) specimen.

[0186] In some embodiments, the sample comprises a fluid from a subject, including, but not limited to, blood or blood products (such as, for example, serum or plasma), umbilical cord blood, amniotic fluid, cerebrospinal fluid, spinal fluid, lavage fluid (such as, for example, bronchoalveolar lavage fluid, gastric lavage fluid, peritoneal lavage fluid, glandular lavage fluid, ear lavage fluid, arthroscopic fluid), washings of the female genital tract, urine, stool, sputum, saliva, nasal mucus, prostatic fluid, lavage fluid, semen, lymph, bile, tears, sweat, breast milk, milk, etc., or combinations thereof. In some embodiments, the liquid biological sample is a blood plasma or serum sample. The term "blood" as used herein refers to a sample or preparation of blood from a subject. The foregoing terms include whole blood, blood products, or any fraction of blood (such as serum, plasma, or buffy coat) as conventionally defined. In some embodiments, the term "blood" refers to peripheral blood. Blood plasma refers to the fraction of whole blood obtained from centrifugation of blood treated with an anticoagulant. Serum in blood refers to the watery portion of the fluid remaining after a blood sample has clotted. Fluid samples are often collected according to standard protocols typically followed by a hospital or clinic. In the case of blood, a suitable amount of peripheral blood (e.g., 3-40 milliliters) is often collected, which can be stored according to standard procedures before or after preparation.

[0187] The term "adjuvant" refers to a substance or mixture that enhances the immune response to an antigen. As a non-limiting example, the adjuvant can include dimethyldioctadecylammonium-bromide, dimethyldioctadecylammonium-chloride, dimethyldioctadecylammonium-phosphate, or dimethyldioctadecylammonium-acetate (DDA), and the non-polar fraction of the total lipid extract of Mycobacterium or a portion of the aforementioned non-polar fraction (see, for example, U.S. Patent No. 8,241,610). In another embodiment, the synthetic nanocarrier can include at least one polynucleotide and an adjuvant. As a non-limiting example, the synthetic nanocarrier including the adjuvant can be formulated by the method described in WO2011150240 and US20110293700 (each of which is incorporated by reference in its entirety herein).

[0188] The term "contact" refers to a direct or indirect binding or interaction between two or more substances. A specific example of a direct interaction is binding. A specific example of an indirect interaction is one entity acting on an intermediate molecule, which then acts on the second mentioned entity. Contacting as used herein includes in solution, in solid phase, in vitro, ex vivo, in cells, and in vivo. Contacting in vivo can be referred to as administering or administration.

[0189] "Administration" or "delivery" of cells or vectors or other agents and compositions comprising them can be performed once, continuously, or intermittently throughout a course of treatment. Methods for determining the most effective means and dosages of administration are known to those skilled in the art and will vary with the composition used for treatment, the therapeutic purpose, the target cells being treated, and the subject being treated. Single or multiple administrations can be performed, with the level and pattern of administration being selected by the attending physician, or in the case of animals, the attending veterinarian. In some embodiments, administering or grammatical variations thereof refers to more than one administration at a certain interval. In some embodiments, the interval is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or more. In some embodiments, one dose is repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. Appropriate dosage formulations and methods of administering drugs are known in the art. The route of administration can also be determined, and methods of determining the most effective route of administration are known to those skilled in the art and will vary depending on the composition used for treatment, the purpose of the treatment, the health condition or disease stage of the subject being treated, and the target cell or tissue. Non-limiting examples of routes of administration include oral administration, intraperitoneal, infusion, intranasal administration, inhalation, injection, and topical application. In some embodiments, administration is infusion (e.g., into the peripheral blood of a subject) for a certain period of time (such as about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 24 hours, or more).

[0190] The term administration is intended to include, but is not limited to, administration orally, parenterally (e.g., intramuscular, intraperitoneal, intravenous, intracerebroventricular (ICV), intrathecal, intracisternal injection or infusion, subcutaneous injection, or implantation), by inhalation spray, or by nasal, vaginal, rectal, sublingual, urethral (e.g., urethral suppository), or topical routes of administration (e.g., gels, ointments, creams, aerosols, etc.), which may be formulated into suitable dosage unit formulations containing conventional non-toxic pharmacologic carriers, adjuvants, excipients, and vehicles appropriate for each route of administration, either alone or in combination. The present disclosure is not limited by route of administration, formulation, or dosing schedule.

[0191] In some embodiments, the RNA, polynucleotide, vector, cell, or composition disclosed herein is administered in an effective amount. An "effective amount" is an amount sufficient to obtain a beneficial or desired result. An effective amount can be administered in one or more administrations, applications, or dosages. Such delivery depends on a number of variables, including the period for which the individual dosage units are used, the bioavailability of the therapeutic agent, the route of administration, and the like. However, it is understood that the specific dosage level of the therapeutic agent disclosed herein for any particular subject will depend on a variety of factors, including the activity of the particular agent used, the bioavailability of said agent, the route of administration, the age of the animal and its weight, general health, sex, diet of the animal, the duration of administration, the excretion rate, the drug combination, and the severity of the particular disorder being treated, and the form of administration. In general, one will wish to administer an amount of agent effective to achieve serum levels equivalent to the concentrations found to be effective in vivo. These considerations, as well as effective formulations and administration techniques, are well known in the art and are described in standard textbooks.

[0192] MODE FOR CARRYING OUT THE DISCLOSURE Prophylactic and therapeutic agents for vaccination, prevention, and treatment of respiratory syncytial virus (RSV) disease are provided.

[0193] Fusion glycoproteins, DNA, and RNA Provided herein is a fusion glycoprotein or immunogenic fragment thereof of respiratory syncytial virus (RSV), or a polynucleotide encoding RSV (DNA or RNA, such as, for example, an mRNA encoding the fusion glycoprotein (F) protein or an immunogenic fragment thereof), or an equivalent of each of these. In one embodiment, the F protein or immunogenic fragment thereof or an equivalent of each of these comprises, consists essentially of, or even further consists of at least one non-naturally occurring amino acid mutation, e.g., compared to amino acids 138-574 of SEQ ID NO:1, 87, or SEQ ID NO:53, or SEQ ID NO:53, or a polynucleotide encoding the same.

[0194] In some embodiments, at least one non-naturally occurring amino acid mutation of the glycoprotein, fragment thereof, or equivalent thereof comprises, consists essentially of, or even consists of one or more, two or more, three or more, or all four of: cysteine ​​(C) as the amino acid corresponding to S155 in SEQ ID NO:53 or 87 (S155C), phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO:53 or 87 (S190F), leucine (L) as the amino acid corresponding to V207 in SEQ ID NO:53 or 87 (V207L), or C as the amino acid corresponding to S290 in SEQ ID NO:53 or 87 (S290C). In one embodiment, the glycoprotein, fragment, or equivalent thereof comprises, consists essentially of, or even further consists of: cysteine ​​(C) as the amino acid corresponding to S155 in SEQ ID NO:53 or 87 (S155C); phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO:53 or 87 (S190F); leucine (L) as the amino acid corresponding to V207 in SEQ ID NO:53 or 87 (V207L); and C as the amino acid corresponding to S290 in SEQ ID NO:53 or 87 (S290C) (see, e.g., Optimized Vaccine F4 (without transmembrane and cytoplasmic domains) and Optimized Vaccine F3 (with transmembrane and cytoplasmic domains)). Further provided are polynucleotides, DNA or RNA, that encode the fusion glycoprotein, immunogenic fragment, or equivalent thereof. An exemplary DNA sequence of the A2 F protein is provided in SEQ ID NO:54 without these specific mutations. An exemplary DNA sequence of the framework or backbone of the optimized F protein is provided in SEQ ID NO:88.

[0195] In another aspect, provided herein is a fusion glycoprotein, fragment thereof, or equivalent thereof comprising one or more non-naturally occurring amino acid mutations in the fusion glycoprotein, fragment thereof, or equivalent thereof, including, consisting essentially of, or even consisting of one or more, two or more, three or more, or all four of: histidine (H) as the amino acid corresponding to D486 in SEQ ID NO:53 or 87 (D486H), glutamine (Q) as the amino acid corresponding to E487 in SEQ ID NO:53 or 87 (E487Q), tryptophan (W) as the amino acid corresponding to F484 in SEQ ID NO:53 or 87 (F484W), and / or H as the amino acid corresponding to D489 in SEQ ID NO:53 or 87 (D489H). In another aspect, provided herein is a fusion glycoprotein, fragment thereof, or equivalent thereof comprising one or more non-naturally occurring amino acid mutations in the fusion glycoprotein, fragment thereof, or equivalent thereof, comprising, or consisting essentially of, or even further consisting of all four of: histidine (H) as the amino acid corresponding to D486 in SEQ ID NO:53 or 87 (D486H), glutamine (Q) as the amino acid corresponding to E487 in SEQ ID NO:53 or 87 (E487Q), tryptophan (W) as the amino acid corresponding to F484 in SEQ ID NO:53 or 87 (F484W), and H as the amino acid corresponding to D489 in SEQ ID NO:53 or 87 (D489H).

[0196] In some embodiments, the at least one non-naturally occurring amino acid mutation of the glycoprotein, fragment thereof, or equivalent thereof is selected from the group consisting of cysteine ​​(C) as the amino acid corresponding to S155 in SEQ ID NO:53 or 87 (S155C), phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO:53 or 87 (S190F), leucine (L) as the amino acid corresponding to V207 in SEQ ID NO:53 or 87 (V207L), C as the amino acid corresponding to S290 in SEQ ID NO:53 or 87 (S290C), , D486 (D486H) of SEQ ID NO: 53 or 87, glutamine (Q) (E487Q) as the amino acid corresponding to E487 of SEQ ID NO: 53 or 87, tryptophan (W) (F484W) as the amino acid corresponding to F484 of SEQ ID NO: 53 or 87, or H (D489H) as the amino acid corresponding to D489 of SEQ ID NO: 53 or 87. Optimized vaccine F6 contains all eight mutations and does not have a transmembrane domain and a cytoplasmic domain, but does contain a trimerization domain, and optimized vaccine F5 contains all eight mutations and has a transmembrane domain and a cytoplasmic domain. See FIG. 5 for maps of optimized vaccines F2 to F6 and vaccines A-2 to A-6. In another embodiment, the glycoprotein, fragment thereof, or equivalent thereof comprises all eight mutations, identified herein as optimized vaccine F5 or F6.

[0197] Further provided is a polynucleotide encoding the fusion glycoprotein, immunogenic fragment, or equivalent thereof, which is DNA or RNA. An exemplary DNA sequence of the F protein is provided in SEQ ID NO: 54, which does not have these specific mutations.

[0198] Further provided are polynucleotides, DNA or RNA, that encode the fusion glycoprotein, immunogenic fragment, or equivalents thereof. An exemplary DNA sequence for the A2 F protein is provided in SEQ ID NO:54, which does not contain these specific mutations.

[0199] In some embodiments, the amino acid sequence of the protein, fragment, or equivalent does not include SEQ ID NO:54.

[0200] The present disclosure also provides a ribonucleic acid (RNA) encoding a fusion (F) protein or a fragment thereof (such as an immunogenic fragment) of a respiratory syncytial virus (RSV). The F protein or fragment, in one embodiment, comprises, consists essentially of, or even consists of at least one non-naturally occurring amino acid mutation disclosed herein.

[0201] In some embodiments, the fragment or immunogenic fragment comprises, consists essentially of, or even consists of the heptad repeat B (HRB) domain of the F protein or its equivalent (such as a fragment corresponding to (e.g., aligning with) aa476 to aa524 of SEQ ID NO:53). In some embodiments, the fragment or immunogenic fragment is at least about 5 amino acids in length, or at least about 8 amino acids in length, or at least about 10 amino acids in length, or at least about 15 amino acids in length, or at least about 20 amino acids in length, or at least about 25 amino acids in length, or at least about 30 amino acids in length, or at least about 40 amino acids in length, or at least about 50 amino acids in length, or at least about 60 amino acids in length, or at least about 70 amino acids in length, or at least about 80 amino acids in length, or at least about 100 amino acids in length, or at least about 125 amino acids in length, or at least about 150 amino acids in length, or at least about 160 amino acids in length, or at least about 170 amino acids in length, or at least about 180 amino acids in length, or at least about 190 amino acids in length, or at least about 200 amino acids in length, or at least about 250 amino acids in length, or at least about 300 or more in length. Immunogenic fragments are useful for inducing an immune response against RSV, or for reducing or inhibiting the binding of RSV to its receptor, or both, and non-immunogenic fragments are useful as controls in the assays provided herein. Immunogenic fragments and glycoproteins can be used in in vitro cell assays to analyze the effectiveness against new virus serotypes and to assay combination therapies, to reduce or inhibit the binding of RSV to its receptor, or both.

[0202] In some embodiments, the at least one non-naturally occurring amino acid mutation comprises, or consists essentially of, or even further consists of, one or more of: cysteine ​​(C) as the amino acid corresponding to S155 in SEQ ID NO: 53 or 87 (S155C), phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO: 53 or 87 (S190F), leucine (L) as the amino acid corresponding to V207 in SEQ ID NO: 53 or 87 (V207L), C as the amino acid corresponding to S290 in SEQ ID NO: 53 or 87 (S290C).

[0203] In some embodiments, the at least one non-naturally occurring amino acid mutation comprises, consists essentially of, or even further consists of one or more of histidine (H) as the amino acid corresponding to D486 in SEQ ID NO:53 or 87 (D486H), glutamine (Q) as the amino acid corresponding to E487 in SEQ ID NO:53 or 87 (E487Q), tryptophan (W) as the amino acid corresponding to F484 in SEQ ID NO:53 or 87 (F484W), or H as the amino acid corresponding to D489 in SEQ ID NO:53 or 87 (D489H).

[0204] In some embodiments, the at least one non-naturally occurring amino acid mutation comprises, consists essentially of, or even further consists of, a cysteine ​​(C) as the amino acid corresponding to S155 in SEQ ID NO:53 or 87 (S155C), a phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO:53 or 87 (S190F), a leucine (L) as the amino acid corresponding to V207 in SEQ ID NO:53 or 87 (V207L), and a C as the amino acid corresponding to S290 in SEQ ID NO:53 or 87 (S290C). In some embodiments, the at least one non-naturally occurring amino acid mutation comprises, consists essentially of, or even further consists of: histidine (H) as the amino acid corresponding to D486 in SEQ ID NO:53 or 87 (D486H); glutamine (Q) as the amino acid corresponding to E487 in SEQ ID NO:53 or 87 (E487Q); tryptophan (W) as the amino acid corresponding to F484 in SEQ ID NO:53 or 87 (F484W); and H (D489H) as the amino acid corresponding to D489 in SEQ ID NO:53 or 87.

[0205] In some embodiments, the polynucleotide, either RNA or mRNA, encodes an F protein comprising a polypeptide of SEQ ID NO:5, 7, or 95, or an equivalent thereof, wherein the equivalent of SEQ ID NO:5, 7, or 95 comprises the mutations S155C, S190F, V207L, and S290C. In some embodiments, the RNA encodes an F protein comprising a polypeptide of SEQ ID NO:11 or 104, or an equivalent thereof, wherein the equivalent of SEQ ID NO:11 or 104 retains the mutations S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H, respectively, compared to SEQ ID NO:53.

[0206] In some embodiments, the fusion glycoprotein, its respective fragment, or its respective equivalent, further comprises a RSV transmembrane domain or a RSV transmembrane domain and a cytoplasmic domain, as well as DNA, RNA (e.g., mRNA) encoding the fusion glycoprotein, its fragment, or its equivalent, and the transmembrane domain.

[0207] In some embodiments, the polynucleotide is an RNA encoding a RSV transmembrane domain. An exemplary RSV transmembrane domain comprises the sequence IMITTIIIVIIVILLSLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN. In further embodiments, the RNA encodes a RSV transmembrane comprising SEQ ID NO: 14 or 90.

[0208] In some embodiments, the RNA encodes an F protein comprising a polypeptide of SEQ ID NO:5 or an equivalent thereof, wherein said equivalent of SEQ ID NO:5 comprises the mutations S155C, S190F, V207L, and S290C. In some embodiments, the RNA encodes an F protein comprising a polypeptide of SEQ ID NO:9 or an equivalent thereof, wherein said equivalent of SEQ ID NO:9 retains the mutations S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H compared to SEQ ID NO:53.

[0209] In some embodiments, the RNA further comprises RNA encoding a p27 peptide. In some embodiments, the p27 peptide comprises SEQ ID NO: 77. In some embodiments, the RNA further comprises RNA encoding a heptad repeat. In some embodiments, the heptad repeat comprises SEQ ID NO: 74. In some embodiments, the RNA further comprises RNA encoding a signal peptide. In some embodiments, the signal peptide comprises SEQ ID NO: 71.

[0210] In some embodiments, equivalents are at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or more identical to a full-length reference sequence as determined by Clustal Omega or BLAST.

[0211] In some embodiments, the RNA further comprises a 3'UTR. In further embodiments, the 3'UTR comprises, consists essentially of, or consists of any one of SEQ ID NOs: 18, 22, or 24.

[0212] In some embodiments, the RNA further comprises a 5'UTR. In further embodiments, the 5'UTR comprises, consists essentially of, or consists of SEQ ID NO: 20 or 26.

[0213] In some embodiments, the RNA further comprises a polyA tail. In further embodiments, the polyA tail comprises any one of SEQ ID NOs: 27, 28, or 16.

[0214] In some embodiments, the RNA further comprises a 5' cap. In further embodiments, the 5' cap comprises, consists of, or even further consists of a 5'CleanCap. This structure uses an initial capped trimer to obtain a naturally occurring 5' cap structure.

[0215] In some embodiments, the RNA optionally comprises, or consists essentially of, in the 5' to 3' direction, a 5' UTR, a coding sequence encoding an F protein or fragment thereof disclosed herein, a 3' UTR, and a poly A. In further embodiments, the RNA comprises, or consists essentially of, or consists of SEQ ID NO: 16.

[0216] In some embodiments, the RNA encodes SEQ ID NO:5 and comprises a 3'UTR selected from SEQ ID NO:18, 22, or 24, a 5'UTR selected from SEQ ID NO:20 or 26, and a polyA tail selected from SEQ ID NO:27, 28, or 16.

[0217] In some embodiments, the RNA is messenger RNA (mRNA).

[0218] DNA encoding the RNA disclosed herein is also provided.

[0219] In some embodiments, the RNA is chemically modified. In further embodiments, the modification comprises, consists essentially of, or consists of modification of uridine (U) residues to N1-methyl-pseudouridine residues. Additionally or alternatively, the modification comprises, consists essentially of, or consists of modification of U residues to pseudouridine residues.

[0220] In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more of the residues of the RNA are chemically modified.

[0221] In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or a higher percentage of the uridine residues in the RNA are optionally chemically modified to N1-methylpseudouridine or pseudouridine. In further embodiments, at least about 50%, or at least about 70%, or about 100% of the uridine residues in the RNA are N1-methylpseudouridine or pseudouridine.

[0222] In some embodiments, all or some uridine residues are replaced with pseudouridine during in vitro transcription. This modification stabilizes mRNA against enzymatic degradation in cells, thereby improving the translation efficiency of mRNA. The pseudouridine used can be N1-methyl-pseudouridine, or other modifications well known in the art, such as N6m-ethyladenosine (m6A), inosine, pseudouridine, 5-methylcytidine (m5C), 5-hydroxymethylcytidine (hm5C), and N1-methyladenosine (m1A). The modification is carried throughout the mRNA as needed. Those skilled in the art will recognize that other modified RNA residues can be used to stabilize the three-dimensional structure of proteins and increase protein translation.

[0223] Without wishing to be bound by theory, RNA encoding a naturally occurring F protein activates endosomal RNA sensing pathways (such as TLR3, TLR7, and TLR8 (Toll-like receptors)), thereby inducing innate immunity and thereby inhibiting translation of fusion proteins. Furthermore, secreted IFN-β induces tumor cell death when bound to cognate receptors expressed on the cell surface by activating downstream apoptotic pathways. However, optimized RNA expressing mutant F proteins as disclosed herein avoids this disadvantage, thus improving translation efficiency (innate immunity) inhibiting translation of fusion proteins. In some embodiments, optimized RNA can be administered to a subject in need thereof to express mutant F proteins in vivo. In further embodiments, the expressed F protein can induce an immune response in the subject, thereby preventing or treating RSV infection as disclosed herein. Additionally or alternatively, optimized RNA can express mutant F proteins in vitro, and, if necessary, such expressed F proteins can activate immune cells in vitro. The activated immune cells can then be used to treat a subject in need thereof.

[0224] In another aspect, a method for producing a fusion (F) protein or an immunogenic fragment thereof of RSV is provided. In some embodiments, the method is an in vitro method. The method comprises, or consists essentially of, or even further comprises culturing a cell disclosed herein under conditions suitable for expression of the F protein or an immunogenic fragment thereof. In further embodiments, the method herein further comprises isolating the F protein or an immunogenic fragment thereof. In some embodiments, the cell is a host cell disclosed herein.

[0225] The mechanism of action of mRNA vaccines can be found, for example, in Wadhwa et al.Pharmaceutics.2020 Jan 28;12(2):102. Briefly, in some embodiments, mRNA is in vitro transcribed (IVT) from a DNA template in a cell-free system. The IVT mRNA is then transfected into dendritic cells (DCs) via endocytosis. The captured mRNA undergoes endosomal escape and is released into the cytoplasm. Using the host cell's translation machinery (ribosomes), the mRNA is translated into an antigenic protein. The translated antigenic protein undergoes post-translational modifications and can act in the cell in which said protein was produced. Alternatively, the protein is secreted from the host cell. The antigenic protein is degraded by proteasomes in the cytoplasm. The generated antigenic peptide epitopes are transported to the endoplasmic reticulum and loaded onto major histocompatibility complex (MHC) class I molecules (MHC I). The loaded MHC I-peptide epitope complex is presented on the cell surface, which ultimately leads to the induction of antigen-specific CD8+ T cell responses after T cell receptor recognition and appropriate co-stimulation. Exogenous proteins are taken up by DCs. The aforementioned proteins are degraded in endosomes and presented via the MHC II pathway. Furthermore, to obtain cognate T cells that assist antigen-presenting cells, the proteins must go through the MHC II pathway. The generated antigen peptide epitopes are then loaded onto MHC II molecules. The loaded MHC II-peptide epitope complex is presented on the cell surface, which leads to the induction of antigen-specific CD4+ T cell responses. Exogenous antigens can also be processed and loaded onto MHC class I molecules via a mechanism known as cross-presentation.

[0226] Without wishing to be bound by theory, the expression of neoantigens on the cell surface is more desirable in terms of inducing an immune response against neoantigens compared to secretion of neoantigens outside the cell or expression of neoantigens inside the cell (such as on an organelle membrane inside the cell). Signal peptides are used to direct the transport and localization of proteins expressed by cells. Thus, combinations with signal peptides have been investigated, and the use of human immunoglobulin heavy chain signal peptide H7 results in unexpectedly high expression of the polypeptide of interest (the RSV-derived peptide disclosed herein) on the cell surface. See Examples.

[0227] In some embodiments, the fragment or immunogenic fragment comprises, consists essentially of, or even further consists of the heptad repeat B (HRB) domain of the F protein or its equivalent (such as a fragment corresponding to (e.g., aligning with) aa476 to aa524 of SEQ ID NO:53). In other embodiments, the fragment or immunogenic fragment comprises, consists essentially of, or even further consists of the F2 cleavage product corresponding to aa137 to 574 of SEQ ID NO:53.

[0228] In some embodiments, the fragment or immunogenic fragment is at least about 5 amino acids in length, or at least about 8 amino acids in length, or at least about 10 amino acids in length, or at least about 15 amino acids in length, or at least about 20 amino acids in length, or at least about 25 amino acids in length, or at least about 30 amino acids in length, or at least about 40 amino acids in length, or at least about 50 amino acids in length, or at least about 60 amino acids in length, or at least about 70 amino acids in length, or at least about 80 amino acids in length, or at least about 100 amino acids in length, or at least about 125 amino acids in length, or at least about 150 amino acids in length, or at least about 160 amino acids in length, or at least about 170 amino acids in length, or at least about 180 amino acids in length, or at least about 190 amino acids in length, or at least about 200 amino acids in length, or at least about 250 amino acids in length, or at least about 300 or more in length. Immunogenic fragments are useful for inducing an immune response to RSV, or for reducing or inhibiting binding of RSV, or both, and non-immunogenic fragments are useful as controls in the assays provided herein.

[0229] In some embodiments, the RNA is chemically modified. In some embodiments, the chemical modification comprises, consists essentially of, or even consists of one or both of the incorporation of N1-methyl-pseudouridine residues or pseudouridine residues. In some embodiments, at least about 50% to about 100% of the uridine residues in the RNA are N1-methylpseudouridine or pseudouridine. In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or a higher percentage of the residues of the RNA are chemically modified with one or more of the modifications as disclosed herein. In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or higher percentage of the uridine residues of the RNA are chemically modified with one or more of the modifications as disclosed herein.In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more of the uridine residues in the RNA are N1-methylpseudouridine or pseudouridine.

[0230] In some embodiments, all or some uridine residues are replaced with pseudouridine during in vitro transcription. This modification stabilizes mRNA against enzymatic degradation in cells, thereby improving the translation efficiency of mRNA. The pseudouridine used can be N1-methyl-pseudouridine, or other modifications well known in the art, such as N6m-ethyladenosine (m6A), inosine, pseudouridine, 5-methylcytidine (m5C), 5-hydroxymethylcytidine (hm5C), and N1-methyladenosine (m1A). The modification is carried throughout the mRNA as needed. Those skilled in the art will recognize that other modified RNA residues can be used to stabilize the three-dimensional structure of proteins and increase protein translation.

[0231] Polynucleotides, Vectors, Cells, and Related Methods Further provided herein is a polynucleotide that encodes the RNA disclosed herein, or a polynucleotide complement thereto, or both. In some embodiments, the polynucleotide is selected from the group of deoxyribonucleic acid (DNA), RNA, a hybrid of DNA and RNA, or an analog of each of these. In further embodiments, the analog comprises, consists essentially of, or even further consists of a peptide nucleic acid or a locked nucleic acid, or both of these.

[0232] In some embodiments, the polynucleotide comprises SEQ ID NO:8 or an equivalent thereof, wherein said equivalent of SEQ ID NO:8 encodes SEQ ID NO:7 or an equivalent thereof. In some embodiments, the polynucleotide comprises SEQ ID NO:12 or an equivalent thereof, wherein said equivalent of SEQ ID NO:12 encodes SEQ ID NO:11 or an equivalent thereof. In some embodiments, the polynucleotide comprises SEQ ID NO:6 or an equivalent thereof, wherein said equivalent of SEQ ID NO:6 encodes SEQ ID NO:5 or an equivalent thereof. In some embodiments, the polynucleotide comprises SEQ ID NO:10 or an equivalent thereof, wherein said equivalent of SEQ ID NO:10 encodes SEQ ID NO:9 or an equivalent thereof.

[0233] In still further embodiments, the polynucleotide may encode a fusion peptide. In some embodiments, the fusion peptide comprises SEQ ID NO:81. In some embodiments, the polynucleotide may encode a p27 peptide. In some embodiments, the p27 peptide comprises SEQ ID NO:78. In some embodiments, the polynucleotide may encode a heptad repeat. In some embodiments, the heptad repeat comprises SEQ ID NO:75. In some embodiments, the polynucleotide may encode a signal peptide. In some embodiments, the signal peptide comprises SEQ ID NO:72.

[0234] In a further aspect, there is provided a vector comprising, consisting essentially of, or consisting of a polynucleotide disclosed herein.

[0235] In some embodiments, the vector further comprises a control sequence operably linked to the polynucleotide to direct its transcription. In some embodiments, the control sequence is suitable for use in an in vitro transcription system. In further embodiments, the control sequence comprises, or consists essentially of, or consists of a promoter. In still further embodiments, the promoter is an RNA polymerase promoter, optionally a bacteriophage RNA polymerase promoter. In some embodiments, the promoter comprises, or consists essentially of, or even further comprises a T7 promoter, or an SP6 promoter, or a T3 promoter. In some embodiments, the T7 promoter comprises, or consists essentially of, or even further comprises TAATACGACTCACTATAA (SEQ ID NO: 86). In some embodiments, the control sequence is suitable for use in a cell to express an RNA disclosed herein. In further embodiments, the control sequence comprises, or consists essentially of, or even further comprises a promoter, or an enhancer, or both.

[0236] In some embodiments, the vector further comprises a control sequence operably linked to the polynucleotide to direct its replication, hi further embodiments, the control sequence comprises, consists essentially of, or even further consists of one or more of an origin of replication or a primer annealing site, a promoter, or an enhancer.

[0237] In some embodiments, the RNA, or polynucleotide, or vector further comprises a marker selected from a detectable marker, a purification marker, or a selection marker.

[0238] In some embodiments, the vector is a non-viral vector, optionally a plasmid, or a liposome, or a micelle.In some embodiments, the plasmid comprises, or consists essentially of, or consists of SEQ ID NO:29 or its equivalent.In some embodiments, the vector is a viral vector, optionally an adenoviral vector, or an adeno-associated viral vector, or a retroviral vector, or a lentiviral vector, or a plant viral vector.

[0239] In some embodiments, the polynucleotide or vector disclosed herein is suitable for producing (such as transcribing or expressing or replicating) the RNA disclosed herein. Such production can be in vivo or in vitro. For example, the polynucleotide or vector can be used to produce or replicate the RNA in vitro. Such RNA is then administered to a subject in need, optionally with a suitable pharmaceutically acceptable carrier. Alternatively, the polynucleotide or vector can be used as gene therapy and directly administered to a subject in need, optionally with a suitable pharmaceutically acceptable carrier. In further embodiments, gene therapy can further deliver other prophylactic or therapeutic agents to the subject.

[0240] In another aspect, the cell comprises one or more of the RNA disclosed herein, the polynucleotide disclosed herein, or the vector disclosed herein. In some embodiments, the cell is a prokaryotic cell, optionally an E. coli cell. In some embodiments, the cell is a eukaryotic cell, optionally a mammalian cell, an insect cell, or a yeast cell. In some embodiments, the cell is a human embryonic kidney 293 cell (HEK293 cell or 293 cell) or a 293T cell.

[0241] In some embodiments, the cells disclosed herein are suitable for producing (such as transcribing or expressing) the RNA disclosed herein. Such production can be in vivo or in vitro. For example, the cells can be used to produce RNA in vitro. Such RNA is then administered to a subject in need, optionally with a suitable pharma- ceutically acceptable carrier. Alternatively, the cells can be used as cell therapy and administered directly to a subject in need, optionally with a suitable pharma- ceutically acceptable carrier. In further embodiments, the cell therapy can further deliver other prophylactic or therapeutic agents to the subject.

[0242] In yet another aspect, there is provided a composition comprising, consisting essentially of, or even further consisting of a carrier, optionally a pharma- ceutically acceptable carrier, and one or more of the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, or the cell disclosed herein.

[0243] In some embodiments, the composition further comprises an additional prophylactic or therapeutic agent. In one aspect, the agent comprises an additional viral polynucleotide (e.g., an infectious viral polynucleotide optionally selected from a coronavirus, a COVID-19 virus, an influenza virus, a papilloma virus, hepatitis A, hepatitis B, hepatitis C, a poliovirus, a varicella virus, a measles virus, a mumps, a virus responsible for rubella, or a rotavirus, or a human immunodeficiency virus (HIV)).

[0244] In some embodiments, the additional prophylactic or therapeutic agent is suitable for preventing or treating RSV-related diseases as disclosed herein. In further embodiments, the additional prophylactic or therapeutic agent comprises, or essentially consists of, or even further consists of, an antiviral agent, optionally remdesivir, lopinavir, ritonavir, ivermectin, tamiflu, or favipiravir; an anti-inflammatory agent, optionally dexamethasone, tocilizumab, kevzara, colcrys, hydroxychloroquine, chloroquine, or a kinase inhibitor; convalescent plasma from a subject who has recovered from RSV infection; an antibody that binds to RSV, optionally bamlanivimab, etesevimab, casirivimab, or imdevimab; or an antibiotic agent, optionally azithromycin.

[0245] In some embodiments, the additional prophylactic agent is suitable for the prevention of diseases not related to RSV. For example, the additional prophylactic agent comprises, or essentially consists of, or even further consists of a vaccine for another virus. Additionally or alternatively, the additional prophylactic agent comprises, or essentially consists of, or even further consists of a vaccine for another virus (such as influenza (flu) vaccine, papillomavirus vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, polio vaccine, chickenpox vaccine, measles vaccine, mumps vaccine, rubella vaccine, rotavirus vaccine, etc.). In some embodiments, the additional prophylactic agent comprises, or essentially consists of, or even further consists of a vaccine for bacteria or other pathogens (such as diphtheria vaccine, Haemophilus influenzae type b vaccine, whooping cough vaccine, pneumococcal vaccine, tetanus vaccine, or meningococcal vaccine). In some embodiments, the additional prophylactic agent comprises, or essentially consists of, or even further consists of a vaccine for non-infectious diseases such as cancer.

[0246] In some embodiments, the composition further comprises an adjuvant.

[0247] In one aspect, a method for producing the RNA disclosed herein is provided. In some embodiments, the method comprises, or consists essentially of, or even further consists of culturing the cells disclosed herein under conditions suitable for expression and / or replication of the RNA. In further embodiments, the RNA is produced by a plasmid DNA (pDNA) vector delivery system. In still further embodiments, the plasmid vector can be adapted for mRNA vaccine production. Commonly used plasmids include pSFV1, pcDNA3, and pTK126, all of which are commercially available. One unique mRNA expression system is pEVL (see Grier et al. Mol Ther Nucleic Acids. 19;5:e306 (2016)).

[0248] In some embodiments, the method comprises, or consists essentially of, or even further consists of contacting the polynucleotide disclosed herein or the vector disclosed herein with an RNA polymerase, adenosine triphosphate (ATP), cytidine triphosphate (CTP), guanosine-5'-triphosphate (GTP), and uridine triphosphate (UTP) or chemically modified UTP under conditions suitable for expression of the RNA. In some embodiments, the RNA is produced from a linear DNA template comprising a bacteriophage promoter, a UTR, and a coding sequence by using an RNA polymerase (T7, T3, or SP6) and a mix of different nucleosides in a linear in vitro transcription (IVT) system. In some embodiments, the method further comprises isolating the RNA. In further embodiments, the method further comprises storing the RNA.

[0249] In some embodiments, the polypeptide comprises, consists essentially of, or even further consists of any one or more of the amino acid sequences set forth in Table 2 below. In some embodiments, the polypeptide further comprises a fusion peptide. In some embodiments, the polypeptide further comprises a p27 peptide. In some embodiments, the polypeptide further comprises a heptad repeat. In some embodiments, the polypeptide further comprises a signal peptide.

[0250] In some embodiments, the fusion peptide comprises SEQ ID NO: 80. In some embodiments, the p27 peptide comprises SEQ ID NO: 77. In some embodiments, the heptad repeat comprises SEQ ID NO: 74. In some embodiments, the signal peptide comprises SEQ ID NO: 71.

[0251] Further provided is a respiratory syncytial virus (RSV) ribonucleic acid (RNA) encoding a RSV fusion glycoprotein (F) protein or an immunogenic fragment thereof, wherein said RNA encodes a peptide comprising one or more non-naturally occurring amino acid mutations selected from cysteine ​​(C) as the amino acid corresponding to S155 in SEQ ID NO:87 or 53 (S155C), phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO:87 or 53 (S190F), leucine (L) as the amino acid corresponding to V207 in SEQ ID NO:87 or 53 (V207L), and cysteine ​​(C) as the amino acid corresponding to S290 in SEQ ID NO:87 or 53 (S290C).

[0252] In another embodiment, the RNA RSV encodes an immunogenic fragment comprising a fusion peptide, a heptad repeat A (HRA), an F protein, and a heptad repeat B, and optionally, said immunogenic fragment further comprises an N-terminal signal peptide, said immunogenic fragment further comprises an N-terminal HRC peptide, said immunogenic fragment further comprises an N-terminal p27 peptide, said immunogenic fragment further comprises a C-terminal transmembrane domain and a cytoplasmic domain, or said immunogenic fragment further comprises a C-terminal trimerization domain.

[0253] In another embodiment, the RSV RNA encodes an F protein that includes one or more non-naturally occurring amino acid mutations selected from histidine (H) (D486H) as the amino acid corresponding to D486 in SEQ ID NO: 87 or 53, glutamine (Q) (E487Q) as the amino acid corresponding to E487 in SEQ ID NO: 87 or 53, tryptophan (W) (F484W) as the amino acid corresponding to F484 in SEQ ID NO: 87 or 53, or H (D489H) as the amino acid corresponding to D489 in SEQ ID NO: 87 or 53.

[0254] In further embodiments, the RSV RNA encodes an immunogenic fragment comprising a fusion peptide, a heptad repeat A (HRA), an F protein, and a heptad repeat B (HRB), and optionally further comprises an N-terminal signal peptide, an N-terminal HRC peptide, an N-terminal p27 peptide, a C-terminal transmembrane domain and a cytoplasmic domain, or a C-terminal trimerization domain.

[0255] In one embodiment, the RSV RNA encodes an immunogenic fragment that further comprises an N-terminal signal peptide, an N-terminal HRC peptide, and an N-terminal p27 peptide, or the immunogenic fragment further comprises an additional C-terminal transmembrane domain and a cytoplasmic domain, or a C-terminal trimerization domain, or the immunogenic fragment further comprises an N-terminal signal peptide, an N-terminal HRC peptide, and an N-terminal p27 peptide, as well as a C-terminal transmembrane domain and a cytoplasmic domain, or a C-terminal trimerization domain.

[0256] In a further embodiment, the RSV RNA encodes a polypeptide having at least one non-naturally occurring amino acid mutation selected from the group consisting of D486H, E487Q, F484W, and D489H and / or S155C, S190F, V207L, and S290C of SEQ ID NO: 87 or 53.

[0257] In another embodiment, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, and trimerization domain of an optimized F4 vaccine (SEQ ID NO:7) or an equivalent thereof, wherein said equivalent of SEQ ID NO:7 comprises the mutations S155C, S190F, V207L, and S290C; or said F protein comprises the fusion peptide, HRA, F protein, and trimerization domain of an A2-4 vaccine (amino acids 138-556 of SEQ ID NO:62) or an equivalent thereof, wherein said equivalent of SEQ ID NO:62 comprises the mutations S155C, S190F, V207L, and S290C.

[0258] In another embodiment, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, and trimerization domain of an optimized F vaccine (SEQ ID NO: 11) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 11 comprises the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H; or the F protein comprises the fusion peptide, HRA, F protein, and trimerization domain of an A2-6 vaccine (amino acids 138-556 of SEQ ID NO: 68) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 68 comprises the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H. Alternatively, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, transmembrane domain, and cytoplasmic domain of an optimized F vaccine (SEQ ID NO:5) or an equivalent thereof, wherein said equivalent of SEQ ID NO:5 comprises the mutations S155C, S190F, V207L, and S290C; or said F protein comprises the fusion peptide, HRA, F protein, and transmembrane domain and cytoplasmic domain of an A2-3 vaccine (amino acids 138-574 of SEQ ID NO:59) or an equivalent thereof, wherein said equivalent of SEQ ID NO:59 comprises the mutations S155C, S190F, V207L, and S290C. Furthermore, the RSV RNA encodes an F protein comprising the fusion peptide, HRA, F protein, transmembrane domain, and cytoplasmic domain of an optimized F vaccine (SEQ ID NO: 9) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 9 includes the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H; or the F protein comprises the fusion peptide, HRA, F protein, and transmembrane domain and cytoplasmic domain of an A2-5 vaccine (amino acids 138-574 of SEQ ID NO: 65) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 65 includes the following mutations: S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H.

[0259] The RSV RNA of the disclosure can further include RNA encoding a p27 peptide (eg, a p27 peptide including SEQ ID NO:77 or including amino acids 110-137 of SEQ ID NO:53).

[0260] The RSV RNA of the disclosure can further include RNA encoding an HRC (eg, an HRC comprising amino acids 27-109 of SEQ ID NO:74 or SEQ ID NO:53).

[0261] In another embodiment, the RSV RNA of the disclosure can further include RNA encoding a signal peptide (eg, a signal peptide comprising SEQ ID NO: 71 or comprising amino acids 1-26 of SEQ ID NO: 53).

[0262] As used herein, an equivalent is at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or more identical to a full-length reference sequence.

[0263] In yet further embodiments, the RSV RNA further comprises a 3'UTR (e.g., the 3'UTR is selected from SEQ ID NO: 18, 22, or 24) and / or a 5'UTR selected from SEQ ID NO: 20 or 26, and / or a polyA tail (e.g., the polyA tail is selected from SEQ ID NO: 27, 28, or 16).

[0264] In a further aspect, provided herein is an RSV RNA encoding an F protein fragment comprising SEQ ID NO:5, a fusion peptide comprising SEQ ID NO:80, a p27 peptide comprising SEQ ID NO:77, an HRC comprising SEQ ID NO:74, and a signal peptide comprising SEQ ID NO:71 (SEQ ID NO:95), further comprising a 3'UTR selected from SEQ ID NO:18, 22, or 24, a 5'UTR selected from SEQ ID NO:20 or 26, and a polyA tail selected from SEQ ID NO:27, 28, or 16.

[0265] In another embodiment, provided herein is a RSV RNA selected from the RNA of any one of SEQ ID NOs: 61, 64, 67, 70, 97, 100, 103, or 106.

[0266] Provided herein is a polynucleotide comprising SEQ ID NO:8 or an equivalent thereof (wherein the aforementioned equivalent of SEQ ID NO:8 encodes SEQ ID NO:7 or an equivalent thereof), or a polynucleotide comprising SEQ ID NO:12 or an equivalent thereof (wherein the aforementioned equivalent of SEQ ID NO:12 encodes SEQ ID NO:11 or an equivalent thereof), or a polynucleotide comprising SEQ ID NO:6 or an equivalent thereof (wherein the aforementioned equivalent of SEQ ID NO:6 encodes SEQ ID NO:5 or an equivalent thereof), or a polynucleotide comprising SEQ ID NO:10 or an equivalent thereof (wherein the aforementioned equivalent of SEQ ID NO:10 encodes SEQ ID NO:9 or an equivalent thereof).

[0267] 34. The polynucleotide of claim 33, wherein the polynucleotide is selected from any one of SEQ ID NOs: 60, 63, 66, 69, 93, 96, 99, 102, or 105. Alternatively, a polypeptide is provided which is selected from any one of SEQ ID NOs: 59, 62, 65, 68, 88, 95, 98, 101, or 104.

[0268] For purposes of this disclosure, an equivalent is at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or more identical to a full-length reference sequence.

[0269] In embodiments of the disclosure, the RSV RNA is optionally chemically modified to optionally include one or more N1-methyl-pseudouridine residues or pseudouridine residues, and optionally, at least about 50%, or at least about 70%, or about 100% of the uridine residues in the RNA are N1-methylpseudouridine or pseudouridine.

[0270] Also provided are polypeptides or proteins encoded by the RNA disclosed herein, as well as DNA (e.g., mRNA) encoding the aforementioned polypeptides or proteins. Alternatively, the polynucleotides of the present disclosure are hybrids of DNA and RNA, or analogs of each of these.

[0271] Further provided are optimized F protein scaffold peptides comprising SEQ ID NO:87 or SEQ ID NO:92, as well as DNA or RNA (e.g., mRNA) encoding optimized F protein scaffolds comprising SEQ ID NO:89 or SEQ ID NO:94.

[0272] In some embodiments, the polynucleotide further comprises a control sequence that directs its transcription. In some embodiments, the control sequence is suitable for use in an in vitro transcription system. In further embodiments, the control sequence comprises, consists essentially of, or even further comprises a promoter. In still further embodiments, the promoter comprises, consists essentially of, or even further comprises a bacteriophage RNA polymerase promoter (such as a T7 promoter, or an SP6 promoter, or a T3 promoter). In some embodiments, the polynucleotide comprises a marker selected from a detectable marker, a purification marker, or a selection marker.

[0273] In a further aspect, there is provided a vector comprising, consisting essentially of, or even consisting of a polynucleotide disclosed herein.

[0274] In some embodiments, the vector further comprises a control sequence operably linked to the polynucleotide to direct its transcription. In some embodiments, the control sequence is suitable for use in an in vitro transcription system. In further embodiments, the control sequence comprises, consists essentially of, or even further comprises a promoter. In still further embodiments, the promoter comprises, consists essentially of, or even further comprises a bacteriophage RNA polymerase promoter (such as a T7 promoter, or an SP6 promoter, or a T3 promoter). In some embodiments, the vector further comprises a marker selected from a detectable marker, a purification marker, or a selection marker.

[0275] In some embodiments, the vector further comprises a control sequence operably linked to the polynucleotide to direct its replication, hi further embodiments, the control sequence comprises, consists essentially of, or even further consists of one or more of an origin of replication or a primer annealing site, a promoter, or an enhancer.

[0276] In some embodiments, the vector is a non-viral vector. In further embodiments, the non-viral vector is a plasmid, or a liposome, or a micelle. In some embodiments, the vector is pUC57, or pSFV1, or pcDNA3, or pTK126, or another plasmid available at addgene or Standard European Vector Architecture (SEVA). In some embodiments, the vector comprises, consists essentially of, or even further consists of any one of SEQ ID NO:29 or its equivalent. In some embodiments, the equivalent of SEQ ID NO:29 still expresses the same polypeptide.

[0277] In some embodiments, the vector is a viral vector. In further embodiments, the viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a lentiviral vector, or a plant viral vector.

[0278] In yet another aspect, a cell is provided that comprises one or more of the RNA disclosed herein, the polynucleotide disclosed herein, or the vector disclosed herein.In some embodiments, the cell is suitable for replicating any one or more of the RNA, polynucleotide, or vector, thereby producing one or more of the RNA, polynucleotide, or vector.In some embodiments, the cell is suitable for transcribing the polynucleotide or vector into RNA, thereby producing RNA.

[0279] In some embodiments, the cell is a prokaryotic cell. In further embodiments, the prokaryotic cell is an E. coli cell.

[0280] In some embodiments, the cell is a eukaryotic cell. In further embodiments, the eukaryotic cell is any one of a mammalian cell, an insect cell, or a yeast cell. In some embodiments, the cell is a 293T cell. In some embodiments, the cell is a HEp-2 cell.

[0281] In some embodiments, the cells disclosed herein are suitable for producing (such as transcribing or expressing) the RNA disclosed herein. Such production can be in vivo or in vitro. For example, the cells can be used to produce RNA in vitro. Such RNA is then administered to a subject in need, optionally with a suitable pharma- ceutically acceptable carrier. Alternatively, the cells can be used as cell therapy and administered directly to a subject in need, optionally with a suitable pharma- ceutically acceptable carrier. In further embodiments, the cell therapy can further deliver other prophylactic or therapeutic agents to the subject. In some embodiments, the cells used as cell therapy are immune cells (such as T cells, B cells, NK cells, NKT cells, dendritic cells, myeloid cells, monocytes, or macrophages).

[0282] In one aspect, a composition is provided that comprises, consists essentially of, or further consists of a carrier and one or more of the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, or the cell disclosed herein.In some embodiments, the carrier is a pharma- ceutically acceptable carrier.In some embodiments, the composition further comprises an additional antiviral treatment.In addition, or alternatively, the composition further comprises an adjuvant.

[0283] Formulations and Related Methods Thus, in one aspect, compositions (such as immunogenic compositions) are provided that comprise, consist essentially of, or even consist of, for example, an effective amount of an RNA disclosed herein formulated in a pharma- ceutically acceptable carrier. In some embodiments, the compositions comprise, consist essentially of, or even consist of, an RNA and a pharma- ceutically acceptable carrier.

[0284] In some embodiments, the pharma- ceutically acceptable carrier comprises, or consists essentially of, or even further consists of nanoparticles. In some embodiments, the nanoparticles are polymeric nanoparticles or liposomal nanoparticles or both. In some embodiments, the nanoparticles are lipid nanoparticles (LNPs). In some embodiments, the pharma-ceutically acceptable carrier comprises, or consists essentially of, or even further consists of polymeric nanoparticles or liposomal nanoparticles or both.

[0285] In some embodiments, the polymeric nanoparticle carrier comprises, or consists essentially of, or even further consists of histidine-lysine copolymer (HKP). In further embodiments, the HKP comprises, or consists essentially of, or even further consists of H3K(+H)4b. In still further embodiments, the HKP comprises, or consists essentially of, or even further consists of H3k(+H)4b. In some embodiments, the HKP comprises a side chain selected from SEQ ID NOs: 31-44.

[0286] In some embodiments, the mass ratio of HKP to RNA in the composition can be any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5, or any other ... The ratio of HKP to RNA in the composition is about 10:1 to about 1:10, including about 1:1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the ratio of HKP to RNA in the composition is about 2.5:1 by weight. In another embodiment, the ratio of HKP to RNA in the composition is about 4:1 by weight.

[0287] In some embodiments, the polymeric nanoparticle carrier further comprises a lipid. In further embodiments, the lipid is a cationic lipid. In yet further embodiments, the cationic lipid is ionic.

[0288] In some embodiments, the cationic lipid comprises, consists essentially of, or even further consists of Dlin-MC3-DMA (MC3) or dioleoyloxy-3-(trimethylammonio)propane (DOTAP), or both.

[0289] In some embodiments, the lipid further comprises one or more of a helper lipid, cholesterol, or a PEGylated lipid. In some embodiments, the lipid further comprises PLA or PLGA.

[0290] In some embodiments, the HKPs and mRNA self-assemble into nanoparticles upon mixing.

[0291] In some embodiments, the pharma- ceutically acceptable carrier is a lipid nanoparticle (LNP). In some embodiments, the LNP comprises, consists essentially of, or even further consists of one or more of 9-heptadecanyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate (SM-102), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), or equivalents of each of these. In some embodiments, the LNP further comprises one or more of a helper lipid, cholesterol, or a PEGylated lipid. In some embodiments, the lipid is a cationic lipid. In a further embodiment, the cationic lipid is ionic.

[0292] In some embodiments, the mass ratio of LNP to RNA in the composition can be any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5: The mass ratio of the LNP to RNA in the composition is about 10:1 to about 1:10, including about 1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the LNP to RNA in the composition is about 2.5:1. In another embodiment, the mass ratio of the LNP to RNA in the composition is about 4:1.

[0293] In some embodiments, the helper lipid comprises, consists essentially of, or even further consists of one or more of disteroylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), (2R)-3-(hexadecanoyloxy)-2-{[(9Z)-octadec-9-enoyl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate (POPC), or dioleoylphosphatidylethanolamine (DOPE).

[0294] In some embodiments, the cholesterol comprises, consists essentially of, or even further consists of plant cholesterol or animal cholesterol or both.

[0295] In some embodiments, the PEGylated lipid comprises, consists essentially of, or even further consists of one or more of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethylene glycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine), PEG-DSG (1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-dimyristoyl-sn-glycerol), optionally PEG2000-DMG ((1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000)]), or PEG-DPG (1,2-dipalmitoyl-sn-glycerol, methoxypolyethylene glycol).

[0296] In some embodiments, the mass ratio of cationic lipid to helper lipid is any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5, or any other ... In one embodiment, the mass ratio of the cationic lipid to the helper lipid is about 10:1 to about 1:10, including about 1:1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the cationic lipid to the helper lipid is about 1:1.

[0297] In some embodiments, the mass ratio of cationic lipid to cholesterol is any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5, or any other ... about 1:1 to about 1:10, including about 10:1 to about 1:10, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10). In one embodiment, the mass ratio of cationic lipid to cholesterol is about 1:1.

[0298] In some embodiments, the mass ratio of cationic lipid to PEGylated lipid can be any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5, or any other ... In one embodiment, the mass ratio of the cationic lipid to the PEGylated lipid is about 10:1 to about 1:10, including about 1:1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the cationic lipid to the PEGylated lipid is about 1:1.

[0299] The mass ratios of cationic lipid, helper lipid, cholesterol, and PEGylated lipid can be calculated by one of skill in the art based on the ratios of cationic lipid to helper lipid, the ratio of cationic lipid to cholesterol, and the ratio of cationic lipid to PEGylated lipid disclosed herein.

[0300] In some embodiments, the LNP comprises, consists essentially of, or even further consists of SM-102, DSPC, cholesterol, and PEG2000-DMG. In some embodiments, the mass ratio of SM-102, DSPC, cholesterol, and PEG2000-DMG is about 1:1:1:1. In some embodiments, the molar ratio of SM-102, DSPC, cholesterol, and PEG2000-DMG is about 50:10:38.5:1.5.

[0301] In some embodiments, the liposomal nanoparticle carrier comprises, consists essentially of, or even consists of spermine-lipid cholesterol (SLiC), in some embodiments, the SLiC is selected from any one of TM1-TM5 exemplified below. [ka]

[0302] In some embodiments, the mass ratios provided herein can be replaced with other parameters (such as molar ratios, weight percentages relative to total weight, weight of components relative to total volume, percentages of moles relative to total molar amount, etc.) If the components and their molecular weights are known, one of ordinary skill in the art would have no difficulty converting the mass ratios to molar ratios or other equivalent parameters.

[0303] In a further aspect, there is provided a method of producing the compositions disclosed herein, the method comprising, consisting essentially of, or even further consisting of contacting an RNA disclosed herein with an HKP, whereby said RNA and HKP self-assemble into nanoparticles.

[0304] In some embodiments, the mass ratio of HKP to RNA in the contacting step can be any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, about 20:1, about 21:1, about 22:1, about 23:1, about 24:1, about 25:1, about 26:1, about 27:1, about 28:1, about 29:1, about 30:1, about 31:1, about 32:1, about 33:1, about 34:1, about 35:1, about 36:1, about 37:1, about 38:1, about 39:1, about 40:1, about 41:1, about 42:1, about 43:1, about 44:1, about 45:1, about 46:1, about 47:1, about 48:1, about 49:1, about 50:1, about 51:1, about 52:1, about The mass ratio of HKP to RNA in the contacting step is about 10:1 to about 1:10, including about 1:5:1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of HKP to RNA in the contacting step is about 2.5:1. In another embodiment, the mass ratio of HKP to RNA in the contacting step is about 4:1.

[0305] In some embodiments, the method further comprises contacting the HKP and RNA with a cationic lipid. In further embodiments, the cationic lipid comprises, consists essentially of, or even further consists of Dlin-MC3-DMA (MC3) or DOTAP (dioleoyloxy-3-(trimethylammonio)propane) or both. In still further embodiments, the mass ratio of cationic lipid to RNA in the contacting step can be any range or ratio therebetween (e.g., about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5, or any other ... The mass ratio of the HKP to the cationic lipid is about 10:1 to about 1:10, including about 1:1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the RNA to the cationic lipid in the contacting step is about 1:1. Thus, the mass ratio of the HKP to the RNA to the cationic lipid in the contacting step can be calculated based on the ratio between the HKP and the RNA and the ratio between the RNA and the cationic lipid. For example, if the ratio of HKPs to RNA is about 4:1 and the ratio of RNA to cationic lipid is about 1:1, then the ratio of HKPs, RNA, cationic lipid is about 4:1:1.

[0306] In yet a further aspect, a method for producing the compositions disclosed herein is provided.The method comprises, or consists essentially of, or even further consists of contacting the RNA disclosed herein with lipid, whereby said RNA and lipid are self-assembled into lipid nanoparticles (LNPs).

[0307] In some embodiments, the LNPs comprise, consist essentially of, or even further consist of one or more of 9-heptadecanyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate (SM-102), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), or equivalents of each of these.

[0308] In some embodiments, the LNP further comprises one or more of a helper lipid, cholesterol, or a PEGylated lipid: In some embodiments, the helper lipid comprises, consists essentially of, or even further comprises one or more of disteroylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), (2R)-3-(hexadecanoyloxy)-2-{[(9Z)-octadec-9-enoyl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate (POPC), or dioleoylphosphatidylethanolamine (DOPE). In some embodiments, the cholesterol comprises, consists essentially of, or even further comprises plant cholesterol or animal cholesterol or both. In some embodiments, the PEGylated lipid comprises, consists essentially of, or even further consists of one or more of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethylene glycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine), PEG-DSG (1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-dimyristoyl-sn-glycerol), optionally PEG2000-DMG ((1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000)]), or PEG-DPG (1,2-dipalmitoyl-sn-glycerol, methoxypolyethylene glycol).

[0309] In some embodiments, the LNP comprises, consists essentially of, or even further consists of SM-102, DSPC, cholesterol, and PEG2000-DMG. In some embodiments, the mass ratio of SM-102, DSPC, cholesterol, and PEG2000-DMG is about 1:1:1:1. Additionally or alternatively, the molar ratio of SM-102, DSPC, cholesterol, and PEG2000-DMG is about 50:10:38.5:1.5.

[0310] In some embodiments, the contacting step is carried out in a microfluidic mixer. In further embodiments, the microfluidic mixer is a slit-type interdigital micromixer or a staggered herringbone micromixer (SHM).

[0311] In some embodiments, the composition is for use in raising an immune response in a patient.

[0312] Compositions produced by the methods disclosed herein are also provided.

[0313] Treatment In one embodiment, the present invention provides a method for preventing or treating the disease disclosed herein.In addition, or alternatively, the present invention provides one or more of the following: (a) a method for preventing symptomatic RSV infection in a subject; (b) a method for preventing hospitalization after infection with RSV in a subject; (c) a method for eliminating the need for intensive care (such as in an intensive care unit (ICU)) or mechanical ventilation or both after infection with RSV in a subject; (d) a method for inducing an immune response against RSV in a subject in need of induction of an immune response against RSV; (e) a method for reducing the binding of RSV or its F protein to its receptor in a subject in need of reducing the binding of RSV or its F protein to its receptor; (f) a method for treating a subject infected with RSV; or (g) a method for reducing the RSV viral load in a subject in need of reducing the RSV viral load.

[0314] The method optionally comprises, or alternatively consists essentially of, or even further consists of administering to the subject an effective amount of one or more of the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, the cell disclosed herein, or the composition disclosed herein.

[0315] In some embodiments, the methods further comprise the step of treating the subject in need of treatment (eg, administering to the subject) an additional prophylactic or therapeutic agent.

[0316] In some embodiments, the additional prophylactic or therapeutic agent is suitable for preventing or treating RSV-related diseases as disclosed herein. In further embodiments, the additional prophylactic or therapeutic agent comprises, or essentially consists of, or even further consists of, an antiviral agent, optionally remdesivir, lopinavir, ritonavir, ivermectin, tamiflu, or favipiravir; an anti-inflammatory agent, optionally dexamethasone, tocilizumab, kevzara, colcrys, hydroxychloroquine, chloroquine, or a kinase inhibitor; convalescent plasma from a subject who has recovered from RSV infection; an antibody that binds to RSV, optionally bamlanivimab, etesevimab, casirivimab, or imdevimab; or an antibiotic agent, optionally azithromycin.

[0317] In some embodiments, the additional prophylactic agent is suitable for the prevention of diseases not related to RSV. Additionally or alternatively, the additional prophylactic agent comprises, or essentially consists of, or even further comprises a vaccine for another virus (such as coronavirus, influenza (flu) vaccine, papillomavirus vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, polio vaccine, chickenpox vaccine, measles vaccine, mumps vaccine, rubella vaccine, rotavirus vaccine, etc.). In some embodiments, the additional prophylactic agent comprises, or essentially consists of, or even further comprises a vaccine for bacteria or other pathogens (such as diphtheria vaccine, Haemophilus influenzae type b vaccine, whooping cough vaccine, pneumococcal vaccine, tetanus vaccine, or meningococcal vaccine). In some embodiments, the additional prophylactic agent comprises, or essentially consists of, or even further comprises a vaccine for non-infectious diseases such as cancer.

[0318] In some embodiments, the subject is not infected with RSV when the RNA or composition is administered. In some embodiments, RSV infection can be diagnosed using conventional methods, such as nucleic acid amplification tests (NAATs), antigen tests, or antibody tests. NAATs for RSV specifically identify RNA (ribonucleic acid) sequences that contain the genetic material of the virus, and NAATs include, but are not limited to, reverse transcription polymerase chain reaction (RT-PCR), or isothermal amplification (such as nicking endonuclease amplification reaction (NEAR), transcription-mediated amplification (TMA), loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), clustered regularly interspaced short palindromic repeats (CRISPR), or standard displacement amplification (SDA)). Antigen tests are immunoassays that detect the presence of specific viral antigens, which signify current viral infection. Antibody or crystallography tests are commonly used to search for RSV-fighting antibodies in the blood and indicate past infection or successful vaccination.

[0319] In some embodiments, the subject is at risk of having a disease disclosed herein, such as RSV infection. In some embodiments, the subject has not been exposed to RSV. In some embodiments, the subject is at risk of being exposed to RSV.

[0320] In some embodiments, the subject is more likely than others to develop severe disease after infection with RSV. For example, the subject may require hospitalization, intensive care, or mechanical ventilation, or may die after infection. In some embodiments, the subject is over 65 years old. In some embodiments, the subject is over 45 years old. In some embodiments, the subject has one or more of the following conditions: cancer, chronic kidney disease, chronic pulmonary disease (such as chronic obstructive pulmonary disease (COPD), asthma (moderate to severe), interstitial lung disease, cystic fibrosis, or pulmonary hypertension), dementia or other neurological condition, diabetes (type 1 or type 2), Down's syndrome, cardiac condition (such as heart failure, coronary artery disease, cardiomyopathy, or hypertension), HIV infection, immunocompromised (weakened immune system), liver disease, overweight, obesity, pregnancy, sickle cell disease, thalassemia, smoking (current or past), solid organ or blood stem cell transplant, stroke or cerebrovascular disease (where blood flow to the brain is affected), or substance use disorder.

[0321] In some embodiments, administration is by inhalation.In further embodiments, RNA or composition is atomized by nebulizer inhalation system before or during administration.In yet further embodiments, nebulizer system is a portable nebulizer for whole airway drug delivery.

[0322] In some embodiments, administration is by subcutaneous injection. In some embodiments, administration is by intramuscular injection. In some embodiments, administration is by intraperitoneal injection (ip).

[0323] In some embodiments, the compositions disclosed herein can be in the form of an aerosol, dispersion, solution, or suspension and can be formulated for inhalation, intramuscular, oral, sublingual, buccal, parenteral, nasal, subcutaneous, intradermal, or topical administration. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like.

[0324] As used herein, an effective dose of the RNA, or polynucleotide, or vector, or cell, or composition disclosed herein is the dose required to obtain a protective immune response in the subject to which it is administered. A protective immune response in this context is a response that prevents or ameliorates disease in a subject challenged with RSV or its pseudovirus. The RNA, or polynucleotide, or vector, or cell, or composition disclosed herein can be administered one or more times. An initial measurement of the immune response to the vaccine can be measured by measuring antibody production in the subject that has received the RNA, or polynucleotide, or vector, or cell, or composition. Methods for measuring antibody production in this manner are also well known in the art, and the dose is the dose required to prevent, inhibit the onset, or treat (alleviate some range of symptoms, preferably all symptoms) of a disease state. A pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the particular mammal under consideration, the medicines currently in use, and other factors that a person skilled in the medical field would recognize. Generally, an amount between 0.1 mg / kg and 100 mg / kg of body weight / day of the active ingredient is administered depending on the potency of the formulated composition.

[0325] In a further aspect, there is provided an inhalation system comprising, consisting essentially of, or even further consisting of an RNA disclosed herein, a polynucleotide disclosed herein, a vector disclosed herein, or a composition disclosed herein, and a nebulizer. In a further embodiment, the nebulizer is a handheld nebulizer for total airway drug delivery.

[0326] In some embodiments, the RNA compositions can be administered at a dosage level sufficient to deliver 0.0001 mg / kg to 100 mg / kg, 0.001 mg / kg to 0.05 mg / kg, 0.005 mg / kg to 0.05 mg / kg, 0.001 mg / kg to 0.005 mg / kg, 0.05 mg / kg to 0.5 mg / kg, 0.01 mg / kg to 50 mg / kg, 0.1 mg / kg to 40 mg / kg, 0.5 mg / kg to 30 mg / kg, 0.01 mg / kg to 10 mg / kg, 0.1 mg / kg to 10 mg / kg, or 1 mg / kg to 25 mg / kg of subject body weight per day, e.g., once or more times per day, week, month, etc., to obtain the desired therapeutic or prophylactic effect. The desired dosage can be delivered three times a day, twice a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, every four weeks, every two months, every three months, every six months, etc. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more administrations). When multiple administrations are used, a split dosing regimen (such as those described herein) can be used. In some embodiments, the RNA composition can be administered at a dosage level sufficient to deliver 0.0005 mg / kg to 0.01 mg / kg, e.g., about 0.0005 mg / kg to about 0.0075 mg / kg, e.g., about 0.0005 mg / kg, about 0.001 mg / kg, about 0.002 mg / kg, about 0.003 mg / kg, about 0.004 mg / kg, or about 0.005 mg / kg. In some embodiments, the RNA composition can be administered once or twice (or more) at a dosage level sufficient to deliver 0.025 mg / kg to 0.250 mg / kg, 0.025 mg / kg to 0.500 mg / kg, 0.025 mg / kg to 0.750 mg / kg, or 0.025 mg / kg to 1.0 mg / kg.

[0327] In some embodiments, the RNA composition is administered twice (e.g., at days 0 and 7, 0 and 14, 0 and 21, 0 and 28, 0 and 60, 0 and 90, 0 and 120, 0 and 150, 0 and 180, 0 and 3 months, 0 and 6 months, 0 and 9 months, 0 and 12 months, 0 and 18 months, 0 and 2 years, 0 and 5 years, or 0 and 10 years) at 0.0100 mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.100 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.200 mg, The compound can be administered at a total dose of 0.225 mg, 0.250 mg, 0.275 mg, 0.300 mg, 0.325 mg, 0.350 mg, 0.375 mg, 0.400 mg, 0.425 mg, 0.450 mg, 0.475 mg, 0.500 mg, 0.525 mg, 0.550 mg, 0.575 mg, 0.600 mg, 0.625 mg, 0.650 mg, 0.675 mg, 0.700 mg, 0.725 mg, 0.750 mg, 0.775 mg, 0.800 mg, 0.825 mg, 0.850 mg, 0.875 mg, 0.900 mg, 0.925 mg, 0.950 mg, 0.975 mg, or 1.0 mg, or at a dosage level sufficient to deliver the total dose. Higher and lower dosages and frequencies of administration are encompassed by the present disclosure. For example, the RNA composition can be administered three or four times.

[0328] kit In one embodiment, kits are provided for use in the methods disclosed herein.

[0329] In some embodiments, the kit comprises, consists essentially of, or even further consists of instructions and one or more of the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, the composition disclosed herein, or the inhalation system disclosed herein. In further embodiments, the kit is suitable for use in the treatment methods disclosed herein.

[0330] In some embodiments, the kit comprises, or consists essentially of, or even further consists of instructions and one or more of the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, the cell disclosed herein, the composition disclosed herein, the HKP, or the lipid, optionally a cationic lipid. In further embodiments, the kit is suitable for use in a method of producing the RNA or composition disclosed herein.

[0331] In some embodiments, the kit comprises, consists essentially of, or even further consists of instructions for use, a polynucleotide or vector disclosed herein, an RNA polymerase, ATP, CTP, GTP, and UTP or chemically modified UTP. In further embodiments, the kit is suitable for use in a method for in vitro production of an RNA or composition disclosed herein.

[0332] Also provided are kits for use in the methods described herein. In some embodiments, the kits comprise, or consist essentially of, or further consist of instructions for use, and one or more of the DNA disclosed herein, the fusion glycoprotein disclosed herein, fragments thereof, or equivalents thereof, the RNA disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, the cell disclosed herein, the composition disclosed herein, and optionally, the inhalation system disclosed herein.

[0333] The following examples are offered to illustrate, but not to limit the invention of the present disclosure.

[0334] Experimental Method The following examples are illustrative of procedures that can be used in various instances in practicing the present disclosure.

[0335] Example 1: In vitro transcription (IVT) assay In vitro transcription was performed according to RNAimmune's in vitro transcription SOP. Briefly, a plasmid producing RSV mRNA was linearized using BspQI (NEB) for 4 hours at 37°C, and the linearized plasmid was purified using a QIAquick PCR purification kit according to the manufacturer's instructions (Qiagen). After purification, an in vitro transcription reaction was performed. In a 20 μl reaction, all components were added in the following order: 1 μg linearized DNA; 1 μl ATP, CTP, GTP, and N1-methyl-pseudouridine triphosphate; 0.8 μl CleanCap AG (3'Ome); 2 μl 10×IVT reaction buffer; 0.5 μl mouse RNase inhibitor; 0.4 μl E. coli inorganic pyrophosphatase; and 3.2 μl T7 RNA polymerase. The IVT reaction was incubated at 37°C for 4 hours. The components of the 10x transcription buffer include 400 mM Tris-HCL (pH 8), 100 mM DTT, 20 mM spermidine, 0.02% TritonX, 165 mM magnesium acetate, and DNase / RNase free water.

[0336] After the in vitro transcription reaction, the mRNA was purified using the RNeasy Mini Kit according to the manufacturer's instructions (Qiagen). The IVT reaction was adjusted to a volume of 100 μl with RNase-free water. The mRNA was then mixed thoroughly with 350 μl of RLT buffer. 250 μl of 100% ethanol was then added to the mixture, mixed thoroughly by pipetting, and 700 μl of the sample was transferred to an RNeasy Mini spin column and centrifuged at ≥8000×g (≥10,000 rpm) for 15 seconds. After discarding the flow-through, the spin column was washed twice with 500 μl of RPE buffer. The spin column was then transferred to a 1.5 ml collection tube (provided by the kit) and the mRNA was eluted with 30 μl RNase-free water. If the expected yield of RNA is greater than 30 μg, the elution step with another 30 μl RNase-free water was repeated. RNA gel electrophoresis. The quality of the purified mRNA was assessed using a 1% agarose gel in NorthernMax™-Gly Gel Prep (1:20,000) containing Sybr Gold.

[0337] Running buffer was prepared by diluting NorthernMax™-Gly Gel Prep from a 10× stock solution with DEPC-treated ultrapure water. RNA samples were prepared by adding 1 volume of RNA (up to 30 μg total RNA) to 1 volume of NorthernMax®-Gly sample loading buffer and incubated at 65° C. for 30 minutes to prevent secondary structure formation. Gel markers were treated similarly. RNA samples and markers were then run on a 1% agarose gel at 5 V / cm. Electrophoresis was stopped when the bromophenol blue dye front had migrated approximately 3 / 4 of the length of the gel, and mRNA was visualized using blue light.

[0338] Example 2: Lipid nanoparticle formulations To make a 4x stock solution of each component in ethanol, each component was prepared as follows: 100mg SM-102 in 5.63ml 100% ethanol; 39.5mg DSPC in 10ml 100% ethanol; 74.4mg cholesterol in 100% ethanol; and 18.8mg DMG-PEG2000 in 100% ethanol. The final concentrations of the 4x stock are 25mM SM-102, 5mM DSPC, 19.5mM cholesterol, and 0.75mM DMG-PEG2000. Each lipid component was then added to a 5ml tube in a 1:1:1:1 ratio to make a 1x working solution. The final concentrations of the working concentrations are 6.25mM SM-102, 1.25mM DSPC, 4.815mM cholesterol, and 0.1875mM DMG-PEG2000. To make the mRNA working concentration, the mRNA stock solution was diluted to a final concentration of 0.13 mg / ml in 25 mM sodium acetate (pH 5.0). Lipid nanoparticle formulation was performed using NanoAssmblr Ignite (PNI) according to the manufacturer's instructions at a mRNA:lipid ratio of 3:1. After formulation, the formulated LNPs were transferred to a pre-soaked dialysis cassette and dialyzed for at least 18 hours at 4°C in 20 mM Tris-HCl, 8% sucrose dialysis buffer. After dialysis, the LNPs are removed from the dialysis cassette using a 3-5 ml syringe and filter sterilized using an Acrodisc filter (pore size 0.2 μM) to fill the upper compartment of an Amicon® Ultra-15 centrifugal filter tube. The tubes are spun at 2000×g at 4°C until the solution is reconcentrated to the desired volume. The LNPs are transferred to new tubes and characterized by dynamic light scattering using a Zetasizer Ultra (Malven Panalytical) to measure particle size, polydispersity, and zeta potential. Encapsulation efficiency was measured using the Ribogreen assay (Invitrogen). mRNA concentration was measured using the Ribogreen assay and Nanodrop. The final LNPs are stored at -80°C for further use.

[0339] Example 3: Western blot analysis To test the in vitro expression of the optimized vaccine candidates, Western blot analysis was used to examine the expression of the RSV optimized vaccine candidates. 293T cells were transfected with various forms of His-tagged RSV mRNA using Lipofectamin MessengerMax transfection reagent. 48 hours after transfection, cells were harvested, cell lysates were prepared, and protein concentrations were determined using a BCA assay. The expression levels of each construct were compared using Western blot analysis using an anti-His antibody.

[0340] FIG. 8 shows the relative expression levels of optimized vaccine-F3 and optimized vaccine-F6 as determined by anti-His antibody staining.

[0341] Example 4: Flow Cytommetry Flow cytometry was used to test the expression of the native form of RSV pre-fusion F protein. After transfection, Expi293F cells (2 × 10 5 Cells) were pelleted in U-bottom 96-well plates and resuspended in PBS (200 μL). Cells were pelleted, washed twice with cell staining buffer (200 μL / well, Biolegend), resuspended in cell staining buffer with D25-Alexa Fluor 488 or AM14-Alexa Fluor 488, and Palivizumab-Alexa Fluor 647, or isotype control antibodies (5 μg / mL each), and incubated for 1 hour at 4° C. in the dark. Cells were then pelleted, washed twice with cell staining buffer (200 μL / well), and then stained with DAPI (0.25 μg / mL, 100 μL / well) in cell staining buffer for 15 minutes at 4° C. in the dark. After incubation, cells were pelleted, washed twice with PBS (200 μL / well), and resuspended in PBS (200 μL / well). Cells were acquired using a BD Celesta flow cytometer (BD Biosciences) and flow cytometry data were analyzed using FlowJo software.

[0342] The ratio of Alexa488 to Alexa647 indicates the ratio of prefusion and postfusion proteins of the PreFusion form of F protein. In this example, the mRNA was expressed mainly in the prefusion form, which exposes more antigen sites and is advantageous for vaccine design.

[0343] Using the results of the FACS analysis from FIG. 7, RSV A2-F3, RSV A2-F5, RSV-optimized F3, RSV-optimized F4, RSV-optimized F5, and RSV-optimized F6 were determined to be suitable for incorporation into animal studies.

[0344] Example 5: Sandwich ELISA Assay Cell supernatants were harvested and analyzed according to the following standard sandwich ELISA protocol. Briefly, 96-well flat-bottom plates (MaxiSorp ELISA plates, Nunc) were incubated with rabbit anti-human RSV-F monoclonal antibody (2 μg / mL, 100 μL / well) in PBS overnight at 4° C. Plates were washed three times with PBS-T and then incubated with 1× ELISA dilution buffer (Biolegnd) for 1 h at room temperature. After three washes with PBS-T, cell supernatants were added to the wells (100 μL / well) at a dilution of 1:5, 1:25, or 1:125 in 1× ELISA dilution buffer and incubated at room temperature for 2 h. After 2 hours of incubation at room temperature, the plates were washed three times with PBS-T and incubated with rabbit anti-human RSV-F monoclonal antibody conjugated with horseradish peroxidase (HRP) (detection antibody) (0.1 μg / mL in 1× ELISA dilution buffer, 100 μL / well) at room temperature for 1 hour. Color reaction was performed with TMB substrate (Biolgend) for 15 minutes at room temperature and then stopped with 1N HCl. Absorbance was detected at 450 nm.

[0345] The sandwich ELISA results for the secreted candidate A2 and the optimized vaccine in Figures 6A and 6B show the relative antibody levels compared to the A2 strain background. Sandwich ELISA was used to measure the in vitro expression of the secreted forms of the A2 and optimized vaccine candidates. Cell supernatants were diluted in ELISA blocking buffer at 1:5, 1:25, and 1:125 dilutions. The results show that the secreted pre-fusion F protein in both the optimized and A2 sequence backgrounds has similar expression levels.

[0346] Example 6: ELISA Assay Balb / c female mice were immunized with 10 μg of RSV A2 and optimized vaccine candidates at weeks 0 and 3. Serum was collected 2 weeks after immunization. Total IgG was analyzed according to standard ELISA protocols. Briefly, 96-well plates were coated with 1 μg / mL of RSV A2 F (Sino Biological), RSVB F (Sino Biological), and PreF proteins (in-house) per well and incubated overnight at 4°C. For measurement of total IgG, individual sera were diluted 3-fold starting from a 1:200 dilution in 1× ELISA dilution buffer (Biolegnd) to a 1:437400 dilution and incubated for 2 hours at room temperature. Then, 100 μl of a 1:5000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch) was added, followed by incubation at room temperature for 1 hour. The color reaction was developed with TMB substrate (Biolgend) for 15 min at room temperature and then stopped with 1N HCl. The absorbance was detected at 450 nm.

[0347] Figures 10A and 10B show that the optimized RSV candidate-F3 and the optimized RSV candidate-F6 possessed the best properties when measured by this assay. Six vaccine candidates were subjected to the first animal study. Two weeks after the second immunization, serum was collected for measurement of immunogenicity and neutralizing activity. ELISA using RSV A2 F protein as antigen showed that all six vaccine candidates had similar IgG titers when serum was diluted at 1:600. When in-house pre-fusion F protein was used as antigen, all six vaccine candidates showed very similar IgG titers at dilutions as high as 1:5000.

[0348] Figures 13A-13B show the immunogenicity of RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 after the first immunization. Two weeks after the first immunization, serum was collected for measurement of IgG titers. In-house His-tagged pre-fusion F protein was used as the antigen. The results shown here are the IgG titers of individual mice in each group. The results showed that RNAi vaccine F3 induced higher IgG titers after the first immunization.

[0349] Immunogenicity of RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 after the second immunization. Two weeks after the second immunization, serum was collected for IgG titer measurement. In-house His-tagged pre-fusion F protein and RSV A2 F protein were used as antigens. The results showed that the IgG titers of RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 were similar when we used pre-fusion F specific protein as antigen (Figure 14A). When we used RSV A2 F protein as antigen, RNAi-optimized vaccine F3 had a higher IgG titer than RNAi-optimized vaccine F6 (Figure 14B).

[0350] In Figure 15, the IgG titers induced by RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 after the second immunization were measured using RSVB F protein as antigen. Two weeks after the second immunization, serum was collected for IgG titer measurement. The results showed that RNAi-optimized vaccine F3 had a higher IgG titer than RNAi-optimized vaccine F6. This result suggested that the optimized vaccine had broad cross-reactivity between different RSV subtypes.

[0351] Figures 16A-16B and 17A-17B show the endpoint IgG titers induced by RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 after the second immunization. The endpoint IgG titers of RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 were determined based on the ELISA results from Figures 14A-14B and 15. In Figures 16A-16B, the results showed that RNAi-optimized vaccine F3 had a higher IgG titer than RNAi-optimized vaccine F6, regardless of the protein used as the antigen. In Figures 17A-17B, we compared the endpoint IgG titers measured using different antigens within each vaccine group. These results showed that 1) the IgG titer of RNAi-optimized vaccine F3 was higher than that of RNAi-optimized vaccine F6, and 2) the IgG titers were similar when different antigens were used.

[0352] Figure 20 shows a summary of 90% neutralization efficiency (PRNT90). The neutralization titer of the test serum sample was defined as the reciprocal of the highest serum dilution at which viral infectivity was reduced by 90% and above.

[0353] Example 7: ELISpot Assay Eight weeks after the final boost immunization, mouse spleens were harvested, mechanically dissociated into single cell suspensions, passed through a 70-μm cell strainer (Miltenyi Biotec), and lysed with ACK lysis buffer (KD Medical). Cells were then resuspended in RPMI supplemented with 10% FBS, 1× Pen / Strep, and 1× 2-mercaptoethanol, counted, and diluted to 2×10 6 The cells were adjusted to 100 cells / ml. After this, 100 μl of splenocytes were added to wells of an IFN-γ-coated 96-well ELISpot plate (Mabtech). The splenocytes were then incubated for 16 hours in a cell culture incubator with or without (stimulated) stimulation of human RSVB PepMix prepared according to the manufacturer's instructions (JPT peptide). After incubation, biotinylated anti-IFN-γR4-A2-biotin monoclonal antibody was used as detection Ab according to the manufacturer's instructions; the presence of spots was revealed using streptavidin-ALP complex and BCIP / NBT-plus substrate (Mabtech). Spots formed by IFN-γ-secreting cells were counted using Cytation7 (Biotek) and the results were expressed as 2 × 10 5 The results are expressed as spot forming cells per splenocyte.

[0354] Figures 21 and 22 show the results of ELSIpot assay for optimized vaccine F3 and optimized vaccine F6. ELISpot assay measures the T cell response induced by RNAi optimized vaccine F3 and RNAi optimized vaccine F6. In this assay, human RSVB PepMix was used to stimulate splenocytes. IFNr secretion spots were counted. The results showed that RNAi optimized vaccine F3 and RNAi optimized vaccine F6 induced similar T cell response. The cell viability of RSV-F3 was 81.4%, and the cell viability of RSV-F6 was 43.8%.

[0355] Example 8: Intracellular staining (ICS) assay The induction of antigen-specific T cells was determined using ICS. Splenocytes were prepared as described above. 1 × 10 6 Splenocytes were added to 12x75mm plastic tubes in the presence of the protein transport inhibitor Brefeldin A (BioLegend) with or without stimulation of human RSVB PepMix prepared according to the manufacturer's instructions (JPT peptide). After 16 hours of incubation, FACS analysis was performed to determine cytokine splenocytes. Cell surface staining was performed using antibodies against CD3 (FITC), CD4 (BV421), and CD8 (BV650). Intracellular staining was performed using antibodies against IL-4 (APC), and IFN-γ (PE). eFluor450 was used to distinguish live / dead cells (Invitrogen). Cells were acquired using a BD Celesta flow cytometer (BD Biosciences) and flow cytometry data was analyzed using FlowJo software.

[0356] Intracellular staining was used to measure subtype T cell response. Human RSVB PepMix stimulated splenocytes were subjected to FACS analysis. Results showed that IFNr secreting cells were mainly CD8+ T cells, indicating that the T cell response induced by RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 was mediated by CD8+ T cells.

[0357] Figures 23A-23D demonstrate that vaccine F6 induces stronger T cell responses than vaccine F3. However, as shown by the cell viability assay above, vaccine F6 may have higher cytotoxicity. Figures 24A-24I provide an overview of the gating strategy for ICS assay.

[0358] Example 9: RSV plaque reduction neutralization assay Neutralizing activity was determined via plaque assay on HEp-2 cells. Briefly, sera were heat inactivated, diluted, and added in duplicate to 6-well plates using a traditional plaque assay. HEp-2 cells were pre-seeded the day before the assay and incubated at 37°C. On the day of the assay, virus was added to confluent cell monolayers for 1 hour at 37°C, the liquid was aspirated, washed twice with PBS, and 0.4% agarose was added. After 8 days at 37°C, cells were fixed and stained with anti-RSV antibody. Viral plaques were counted and titers were expressed as pfu / ml serum.

[0359] Figure 11 shows that the neutralizing activity of these six vaccine candidates was determined using a plaque assay against RSV A2 isolates. The PRNT (plaque reduction neutralization titer) 50 was determined based on the results of the plaque assay. In this experiment, optimized RNAi vaccine F3 and optimized RNAi vaccine F6 showed higher PRNT50 titers when compared to other vaccine candidates. Based on the results of the ELISA and plaque assay, RNAi vaccine F3 and RNAi vaccine F6 were selected for further study. Figure 20 shows that using this assay, vaccine F3 achieves 90% neutralization at a higher dilution than vaccine F6.

[0360] 18A-18B and 19A-19B show the neutralizing activity of RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 as determined using plaque assay against RSV A2 isolates. Plaque reduction neutralizing titer (PRNT)50 and PRNT90 were determined based on the results of plaque assay. In this experiment, RNAi-optimized vaccine F3 and RNAi-optimized vaccine F6 showed similar PRNT50, while RNAi-optimized vaccine F3 has a higher PRNT90 than RNAi-optimized vaccine F6 at both 14 DPI and 35 DPI.

[0361] Example 10: RSV Cotton Rat Study Groups of five 3-7 week-old female cotton rats (SAGE) were randomly assigned to receive either two doses of 25 μg and 10 μg of RSV-F3 mRNA / LNP vaccine intramuscularly on study days 0 and 21, or 10 μg of RSV-F3 mRNA / LNP vaccine intramuscularly on study days 1 and 21. 5.5 Immunization is with a single intranasal dose of pfu of RSV A2.

[0362] Animals were bled for serology prior to the first immunization and on days 21, 28, 42, and 56. On day 56 (4 weeks after the second immunization), all study animals received 5.9×10 5 The animals are challenged intranasally with pfu of RSV A2 or B 18537 strain delivered in a volume of 0.1 mL. Four days after RSV challenge, the animals are euthanized and lung and nasal tissues are isolated for viral load quantification.

[0363] A vaccine-associated enhanced respiratory disease (VERD) study in cotton rats is conducted. Groups of 10 3-7 week old female cotton rats are immunized with the vaccine candidate RSV-F3 mRNA / LNP (25 μg and 10 μg) or the following controls: empty LNP (or PBS) without mRNA, FI-RSV Lot 100 from the original FI-RSV clinical trial, and two non-vaccinated groups. One of the non-vaccinated groups is challenged to serve as a control for pathological changes associated with natural infection, while the second aforementioned group is left unchallenged to serve as a control for natural cotton rat physiology. Cotton rats are immunized twice intramuscularly, 3 weeks apart, and all groups except one of the non-vaccinated groups, which remains unchallenged as a control for normal cotton rat pathology, are challenged with 10 0.1 mL of 0.1% 10 ... 5.5 Four weeks after the second immunization with pfu of RSV A2, the animals are challenged intranasally. Five days after challenge, the animals are sacrificed. Noses are harvested for virus quantification, and the lungs from each animal are cut into thirds and processed for virus quantification, pathology, and cytokine mRNA analysis.

[0364] Example 11: RSV Human Study Healthy subjects will be recruited to participate in the RSV challenge study through an active screening protocol at appropriate facilities. Interested subjects will include pediatric subjects, adult subjects, pregnant subjects, and subjects over 60 years of age. Subjects who meet the selection criteria will be asked to provide informed consent. Subjects who provide informed consent will be pre-screened for anti-RSV antibodies approximately 2 weeks prior to the study start date.

[0365] The day before inoculation, subjects will have repeat RSV antibody testing. Subjects will also undergo laboratory tests, including complete blood counts, serum chemistry, and liver enzymes.

[0366] On the day of vaccination, a dose of RSV vaccine manufactured and processed under current manufacturing and quality control standards for pharmaceuticals and quasi-pharmaceuticals will be administered according to standard procedures.

[0367] Subjects will be hospitalized in an isolation facility for 48 hours after RSV vaccination and must remain there for 48 hours after vaccination. Blood will be drawn at designated intervals after vaccination for further study.

[0368] To accurately determine the success and timing of RSV vaccination, samples for RSV titers are obtained from each subject daily. 48 hours after vaccination, subjects are released from quarantine and return in the morning for three consecutive days to obtain samples and review symptom scores. One measure of vaccine efficacy is cessation of hospitalization.

[0369] Equivalent Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this technology belongs.

[0370] The technology illustratively described herein may suitably be practiced in the absence of any element or limitation not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like, shall be interpreted broadly and without limitation. Furthermore, the terms and expressions used herein are used as terms of description and not of limitation, and when such terms and expressions are used, it is not intended to exclude any equivalents of the features shown and described or portions thereof, and it is recognized that various modifications may be within the scope of the technology described in the claims.

[0371] Accordingly, it should be understood that the materials, methods, and examples provided herein are representative of preferred embodiments, are illustrative, and are not intended to limit the scope of the technology.

[0372] While the present invention has been specifically disclosed by certain aspects, embodiments, and optional features, it is to be understood that modifications, improvements, and variations of such aspects, embodiments, and optional features may be made by those skilled in the art, and such modifications, improvements, and variations are deemed to be within the scope of the present disclosure.

[0373] The present technology is described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the present technology. This includes generic descriptions of the present technology with any condition or negative limitation that removes any inventive subject matter from the genus, regardless of whether the removed material is specifically recited herein.

[0374] Furthermore, when features or aspects of the technology are described in terms of Markush groups, those of skill in the art will recognize that the technology is also thereby described in terms of any individual members or subgroups of members of the Markush group.

[0375] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety to the same extent as if each was individually incorporated by reference. In the case of conflict, the present specification, including definitions, will control.

[0376] Other aspects are within the scope of the following claims. [Table 3-1] [Table 3-2] [Table 3-3]

[0377] SEQ ID NO:1, amino acid sequence of the optimized F glycoprotein fragment:

[0378] [ka]

[0379] SEQ ID NO:2, DNA nucleotide sequence encoding an optimized F protein:

[0380] [ka] [ka]

[0381] SEQ ID NO:3, an optimized protein fragment without a transmembrane domain:

[0382] [ka]

[0383] SEQ ID NO: 4, DNA sequence of an optimized protein without a transmembrane domain:

[0384] [ka] [ka]

[0385] Optimized vaccine F3 protein fragment having SEQ ID NO:5, S155C, S190F, V207L ​​S290C and having a transmembrane domain:

[0386] [ka]

[0387] SEQ ID NO:6: DNA sequence of mutant F-optimized protein with S155C, S190F, V207L ​​S290C:

[0388] [ka] [ka]

[0389] SEQ ID NO:7, mutant F optimized protein fragment having S155C, S190F, V207L ​​S290C and no transmembrane domain:

[0390] [ka]

[0391] SEQ ID NO: 8: DNA sequence of the mutant F-optimized protein with S155C, S190F, V207L ​​S290C and no transmembrane domain:

[0392] [ka]

[0393] A mutant F-optimized protein fragment having SEQ ID NO:9, 155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H and having a transmembrane domain:

[0394] [ka] [ka]

[0395] SEQ ID NO:10: DNA sequence of mutated F-optimized protein with 155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H, and transmembrane domain:

[0396] [ka]

[0397] An optimized F protein fragment having SEQ ID NO:11, s155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H, and no transmembrane domain:

[0398] [ka]

[0399] The DNA sequence of an optimized F protein having SEQ ID NO:12, s155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H, and no transmembrane domain:

[0400] [ka] [ka]

[0401] SEQ ID NO:13 RNA sequence of optimized F protein fragment with s155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H and the TM domain:

[0402] [ka] [ka]

[0403] SEQ ID NO: 14: RSV transmembrane domain

[0404] [ka]

[0405] SEQ ID NO: 15, DNA sequence of the polyA signal HSV:

[0406] [ka]

[0407] SEQ ID NO: 16, RNA sequence of the polyA signal HSV:

[0408] [ka]

[0409] SEQ ID NO:17, DNA sequence of 3'UTR:

[0410] [ka]

[0411] SEQ ID NO:18, RNA sequence of 3'UTR:

[0412] [ka]

[0413] SEQ ID NO:19, DNA sequence of β-globulin 5'UTR:

[0414] [ka]

[0415] SEQ ID NO:20, RNA sequence of β-globin 5'UTR:

[0416] [ka]

[0417] SEQ ID NO:21, DNA sequence of SYS UTR2.0:

[0418] [ka]

[0419] SEQ ID NO:22, RNA sequence of SYS UTR2.0:

[0420] [ka]

[0421] SEQ ID NO:23, DNA sequence of SYS UTR1.0:

[0422] [ka]

[0423] SEQ ID NO:24, RNA sequence of SYS UTR1.0:

[0424] [ka]

[0425] SEQ ID NO:25, DNA sequence of SYS4 5'UTR:

[0426] [ka]

[0427] SEQ ID NO:26, RNA sequence of SYS4 5'UTR:

[0428] [ka]

[0429] SEQ ID NO:27, DNA and RNA sequence of polyA 40:

[0430] [ka]

[0431] SEQ ID NO:28, DNA and RNA sequence of polyA 60:

[0432] [ka]

[0433] SEQ ID NO:29, plasmid DNA sequence:

[0434] [ka] [ka] [ka] [ka] [ka]

[0435] SEQ ID NO:30, RNA sequence of an exemplary protein having s155C, S190F, V207L, S290C, and TM domain UTR-polyA:

[0436] [ka] [ka]

[0437] SEQ ID NO:31, HKP side chain: [ka]

[0438] SEQ ID NO:32, HKP side chain: [ka]

[0439] SEQ ID NO:33, HKP side chain: [ka]

[0440] SEQ ID NO:34, HKP side chain: [ka]

[0441] SEQ ID NO:35, HKP side chain: [ka]

[0442] SEQ ID NO:36, HKP side chain: [ka]

[0443] SEQ ID NO:37, HKP side chain: [ka]

[0444] SEQ ID NO:38, HKP side chain: [ka] (The first, fifth, nineth, fourteenth and eighteenth amino acids in the sequence are D-amino acids).

[0445] SEQ ID NO:39, HKP side chain: [ka]

[0446] SEQ ID NO:40, HKP side chain: [ka]

[0447] SEQ ID NO:41, HKP side chain: [ka]

[0448] SEQ ID NO:42, HKP side chain: [ka]

[0449] SEQ ID NO:43, HKP side chain: [ka]

[0450] SEQ ID NO:44, HKP side chain: [ka]

[0451] SEQ ID NO:45: [ka]

[0452] SEQ ID NO:46: [ka]

[0453] SEQ ID NO:47: [ka]

[0454] SEQ ID NO:48: RNA sequence of SEQ ID NO:1: [ka]

[0455] SEQ ID NO: 49, RNA sequence of SEQ ID NO: 3:

[0456] [ka]

[0457] SEQ ID NO:50, RNA sequence of SEQ ID NO:5:

[0458] [ka] [ka]

[0459] SEQ ID NO:51, RNA sequence of SEQ ID NO:7:

[0460] [ka] [ka]

[0461] SEQ ID NO:52, RNA sequence of SEQ ID NO:11:

[0462] [ka] [ka]

[0463] SEQ ID NO:53, Amino acid sequence of A2 glycoprotein (A2-1):

[0464] [ka]

[0465] SEQ ID NO:54, DNA sequence of A2 glycoprotein (A2-1):

[0466] [ka] [ka]

[0467] SEQ ID NO:55, RNA sequence of A2 glycoprotein (A2-1):

[0468] [ka] [ka]

[0469] SEQ ID NO:56, Protein sequence of A2 glycoprotein without transmembrane domain (A2-2):

[0470] [ka]

[0471] SEQ ID NO:57, DNA sequence of A2 glycoprotein without transmembrane domain (A2-2):

[0472] [ka] [ka]

[0473] SEQ ID NO: 58 RNA sequence of A2 glycoprotein without transmembrane domain (A2-2):

[0474] [ka] [ka]

[0475] Mutant A2 protein (A2-3) having SEQ ID NO: 59, S155C, S190F, V207L ​​S290C:

[0476] [ka]

[0477] DNA sequence of SEQ ID NO:60, amino acid sequence SEQ ID NO:59 (A2-3):

[0478] [ka] [ka]

[0479] RNA sequence of SEQ ID NO:61, amino acid sequence SEQ ID NO:59 (A2-3):

[0480] [ka] [ka]

[0481] Mutant A2 protein having SEQ ID NO: 62, S155C, S190F, V207L ​​S290C and no transmembrane domain (A2-4):

[0482] [ka]

[0483] DNA sequence of SEQ ID NO:63, amino acid sequence SEQ ID NO:62 (A2-4):

[0484] [ka] [ka]

[0485] SEQ ID NO:64, RNA sequence of amino acid SEQ ID NO:62 (A2-4):

[0486] [ka] [ka]

[0487] Mutated A2 protein (A2-5) having SEQ ID NO: 65, 155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H, and a transmembrane domain:

[0488] [ka] [ka]

[0489] DNA sequence of SEQ ID NO:66, amino acid sequence of SEQ ID NO:65 (A2-5):

[0490] [ka] [ka]

[0491] SEQ ID NO:67, RNA sequence of amino acid SEQ ID NO:65 (A2-5):

[0492] [ka] [ka]

[0493] A mutant A2 protein (A2-6) having SEQ ID NO: 68, S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H and no transmembrane domain:

[0494] [ka]

[0495] DNA sequence of SEQ ID NO:69, amino acid sequence SEQ ID NO:68 (A2-6):

[0496] [ka] [ka]

[0497] DNA sequence of SEQ ID NO:70, amino acid sequence SEQ ID NO:68 (A2-6):

[0498] [ka] [ka]

[0499] SEQ ID NO:71, Optimized signal peptide:

[0500] [ka]

[0501] DNA of SEQ ID NO: 72, SEQ ID NO: 71:

[0502] [ka]

[0503] RNA of SEQ ID NO: 73, SEQ ID NO: 71:

[0504] [ka]

[0505] SEQ ID NO:74, optimized heptad repeat C:

[0506] [ka]

[0507] DNA of SEQ ID NO: 75, SEQ ID NO: 74:

[0508] [ka]

[0509] RNA of SEQ ID NO: 76, SEQ ID NO: 74:

[0510] [ka]

[0511] SEQ ID NO: 77, optimized p27 fragment:

[0512] [ka]

[0513] DNA of SEQ ID NO: 78, SEQ ID NO: 77:

[0514] [ka]

[0515] RNA of SEQ ID NO: 79, SEQ ID NO: 77:

[0516] [ka]

[0517] SEQ ID NO:80, S155 fusion peptide:

[0518] [ka]

[0519] DNA of SEQ ID NO:81, SEQ ID NO:80:

[0520] [ka]

[0521] RNA of SEQ ID NO: 82, SEQ ID NO: 80:

[0522] [ka]

[0523] SEQ ID NO:83, trimerization domain:

[0524] [ka]

[0525] DNA of SEQ ID NO: 84, SEQ ID NO: 83:

[0526] [ka]

[0527] RNA of SEQ ID NO: 85, SEQ ID NO: 83:

[0528] [ka]

[0529] SEQ ID NO: 86, promoter region

[0530] [ka]

[0531] SEQ ID NO: 87. Optimized F protein vaccine F1 sequence lacking any mutations and having a transmembrane domain:

[0532] [ka]

[0533] SEQ ID NO: 88, the DNA sequence of SEQ ID NO: 87;

[0534] [ka] [ka]

[0535] RNA of SEQ ID NO: 89, SEQ ID NO: 87:

[0536] [ka] [ka]

[0537] SEQ ID NO: 90, RSV cytoplasmic domain

[0538] [ka]

[0539] SEQ ID NO: 91, RSV trimerization domain

[0540] [ka]

[0541] SEQ ID NO: 92, Optimized F protein vaccine F2 sequence lacking any mutations and without the transmembrane domain:

[0542] [ka] [ka]

[0543] DNA of SEQ ID NO:93, SEQ ID NO:92:

[0544] [ka] [ka]

[0545] RNA of SEQ ID NO:94, SEQ ID NO:92

[0546] [ka] [ka]

[0547] Optimized vaccine F3 complete construct with SEQ ID NO: 95, S155C, S190F, V207L ​​S290C and with transmembrane domain:

[0548] [ka]

[0549] DNA of SEQ ID NO:96 and SEQ ID NO:95

[0550] [ka] [ka]

[0551] RNA of SEQ ID NO: 97, SEQ ID NO: 95

[0552] [ka] [ka]

[0553] Optimized vaccine F4 complete construct with SEQ ID NO: 98, S155C, S190F, V207L ​​S290C and no transmembrane domain:

[0554] [ka]

[0555] DNA of SEQ ID NO:99 and SEQ ID NO:98

[0556] [ka] [ka]

[0557] RNA of SEQ ID NO: 100, SEQ ID NO: 98:

[0558] [ka] [ka]

[0559] Optimized F5 vaccine with SEQ ID NO:101, mutations 155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H and with a transmembrane domain:

[0560] [ka]

[0561] DNA of SEQ ID NO: 102, SEQ ID NO: 101:

[0562] [ka] [ka]

[0563] RNA of SEQ ID NO: 103, SEQ ID NO: 101

[0564] [ka] [ka]

[0565] Optimized F6 vaccine with SEQ ID NO: 104, mutations 155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H, and no transmembrane domain:

[0566] [ka]

[0567] DNA of SEQ ID NO: 105 and SEQ ID NO: 104

[0568] [ka] [ka]

[0569] RNA of SEQ ID NO: 106, SEQ ID NO: 104:

[0570] [ka] [ka]

[0571] [ka]

[0572]

Claims

1. A respiratory syncytial virus (RSV) ribonucleic acid (RNA) encoding a RSV fusion glycoprotein (F) protein or an immunogenic fragment thereof, said RNA comprising: Cysteine ​​(C) as the amino acid corresponding to S155 of SEQ ID NO: 87 or 53 (S155C); Phenylalanine (F) as the amino acid corresponding to S190 in SEQ ID NO: 87 or 53 (S190F); Leucine (L) as the amino acid corresponding to V207 in SEQ ID NO: 87 or 53 (V207L); or Cysteine ​​(C) as the amino acid corresponding to S290 in SEQ ID NO: 87 or 53 (S290C) A respiratory syncytial virus (RSV) ribonucleic acid (RNA) encoding a peptide comprising one or more non-naturally occurring amino acid mutations selected from:

2. The immunogenic fragment comprises a fusion peptide, a heptad repeat A (HRA), an F protein, and a heptad repeat B, and optionally the immunogenic fragment further comprises an N-terminal signal peptide; the immunogenic fragment further comprises an N-terminal heptad repeat C (HRC) peptide; the immunogenic fragment further comprises an N-terminal p27 peptide; the immunogenic fragment further comprises a C-terminal transmembrane domain and a cytoplasmic domain; The RSV RNA of claim 1 , wherein the immunogenic fragment further comprises a C-terminal trimerization domain.

3. The F protein is Histidine (H) as the amino acid corresponding to D486 in SEQ ID NO: 87 or 53 (D486H); Glutamine (Q) as the amino acid corresponding to E487 in SEQ ID NO: 87 or 53 (E487Q); Tryptophan (W) as the amino acid corresponding to F484 in SEQ ID NO: 87 or 53 (F484W); or H (D489H) as the amino acid corresponding to D489 in SEQ ID NO: 87 or 53 The RNA of claim 1, further comprising one or more non-naturally occurring amino acid mutations selected from:

4. The immunogenic fragment comprises a fusion peptide, a heptad repeat A (HRA), an F protein, and a heptad repeat B, and optionally the immunogenic fragment further comprises an N-terminal signal peptide; the immunogenic fragment further comprises an N-terminal HRC peptide; the immunogenic fragment further comprises an N-terminal p27 peptide; the immunogenic fragment further comprises a C-terminal transmembrane domain and a cytoplasmic domain; The RSV RNA of claim 3 , wherein the immunogenic fragment further comprises a C-terminal trimerization domain.

5. The immunogenic fragment comprises: further comprising the N-terminal signal peptide, the N-terminal HRC peptide, and the N-terminal p27 peptide; the immunogenic fragment further comprises the C-terminal transmembrane and cytoplasmic domains, or the C-terminal trimerization domain; the immunogenic fragment further comprises the N-terminal signal peptide, the N-terminal HRC peptide, and the N-terminal p27 peptide, and the C-terminal, transmembrane and cytoplasmic domains; 5. The RSV RNA of claim 2 or 4, wherein the immunogenic fragment further comprises the N-terminal signal peptide, the N-terminal HRC peptide, the N-terminal p27 peptide, and the C-terminal trimerization domain.

6. The RNA of any one of claims 1 to 5, wherein the at least one non-naturally occurring amino acid mutation comprises D486H, E487Q, F484W, and D489H and / or S155C, S190F, V207L, and S290C of SEQ ID NO: 87 or 53.

7. 7. The RNA of claim 6, wherein the F protein comprises the fusion peptide, the HRA, the F protein, and the trimerization domain of the optimized F4 vaccine (SEQ ID NO: 7) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 7 comprises the mutations S155C, S190F, V207L, and S290C; or wherein the F protein comprises the fusion peptide, the HRA, the F protein, and the trimerization domain of the A2-4 vaccine (amino acids 138-556 of SEQ ID NO: 62) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 62 comprises the mutations S155C, S190F, V207L, and S290C.

8. 7. The RNA of claim 6, wherein the F protein comprises the fusion peptide, the HRA, the F protein, and the trimerization domain of the optimized F-6 vaccine (SEQ ID NO: 11) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 11 comprises the mutations S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H; or the F protein comprises the fusion peptide, the HRA, the F protein, and the trimerization domain of the A2-6 vaccine (amino acids 138-556 of SEQ ID NO: 68) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 68 comprises the mutations S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H.

9. 7. The RNA of claim 6, wherein the F protein comprises the fusion peptide, the HRA, the F protein, the transmembrane domain, and the cytoplasmic domain of the optimized F-3 vaccine (SEQ ID NO:5) or an equivalent thereof, wherein the equivalent of SEQ ID NO:5 comprises the mutations S155C, S190F, V207L, and S290C; or wherein the F protein comprises the fusion peptide, the HRA, the F protein, the transmembrane domain, and the cytoplasmic domain of the A2-3 vaccine (amino acids 138-574 of SEQ ID NO:59) or an equivalent thereof, wherein the equivalent of SEQ ID NO:59 comprises the mutations S155C, S190F, V207L, and S290C.

10. 7. The RNA of claim 6, wherein the F protein comprises the fusion peptide, the HRA, the F protein, the transmembrane domain, and the cytoplasmic domain of the optimized F-5 vaccine (SEQ ID NO: 9) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 9 comprises the mutations S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H; or wherein the F protein comprises the fusion peptide, the HRA, the F protein, and the transmembrane domain and the cytoplasmic domain of the A2-5 vaccine (amino acids 138-574 of SEQ ID NO: 65) or an equivalent thereof, wherein the equivalent of SEQ ID NO: 65 comprises the mutations S155C, S190F, V207L, S290C, D486H, E487Q, F484W, and D489H.

11. The RNA according to any one of claims 1 to 10, further comprising RNA encoding a p27 peptide.

12. The RNA of claim 11, wherein the p27 peptide comprises SEQ ID NO:77 or comprises amino acids 110 to 137 of SEQ ID NO:

53.

13. The RNA of any one of claims 1 to 12, further comprising RNA encoding the HRC.

14. The RNA of claim 13, wherein the HRC comprises SEQ ID NO:74 or amino acids 27-109 of SEQ ID NO:

53.

15. The RNA according to any one of claims 1 to 14, further comprising RNA encoding a signal peptide.

16. The RNA of claim 15, wherein the signal peptide comprises SEQ ID NO:71 or comprises amino acids 1 to 26 of SEQ ID NO:

53.

17. 17. The RNA of any one of claims 1 to 16, wherein the equivalent is at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or more identical to the full-length reference sequence.

18. The RNA of any one of claims 1 to 17, further comprising a 3'UTR.

19. The RNA of claim 18, wherein the 3'UTR is selected from SEQ ID NO: 18, 22, or 24.

20. The RNA of any one of claims 1 to 19, further comprising a 5'UTR.

21. The RNA of claim 20, wherein the 5'UTR comprises SEQ ID NO: 20 or 26.

22. The RNA of any one of claims 1 to 21, further comprising a polyA tail.

23. 25. The RNA of claim 24, wherein the polyA tail is selected from SEQ ID NO: 27, 28, or 16.

24. 2. The RNA of claim 1, wherein the RNA encodes an F protein fragment comprising SEQ ID NO:5, a fusion peptide comprising SEQ ID NO:80, a p27 peptide comprising SEQ ID NO:77, an HRC comprising SEQ ID NO:74, and a signal peptide comprising SEQ ID NO:71 (SEQ ID NO:95), and further comprises a 3'UTR selected from SEQ ID NOs:18, 22, or 24, a 5'UTR selected from SEQ ID NOs:20 or 26, and a poly A tail selected from SEQ ID NOs:27, 28, or 16.

25. 2. The RNA of claim 1, wherein the RNA is selected from the RNA of any one of SEQ ID NOs: 61, 64, 67, 70, 97, 100, 103, or 106.

26. 26. The RNA of any one of claims 1 to 25, wherein the RNA is chemically modified and optionally comprises one or more N1-methyl-pseudouridine residues or pseudouridine residues, and optionally at least about 50%, or at least about 70%, or about 100% of the uridine residues in the RNA are N1-methylpseudouridine or pseudouridine.

27. A polypeptide encoded by the RNA of any one of claims 1 to 26, or an equivalent thereof.

28. 28. The polypeptide of claim 27, wherein the polypeptide is selected from any one of the polypeptides of SEQ ID NOs: 59, 62, 65, 68, 95, 98, 101, or 104.

29. A polynucleotide comprising SEQ ID NO:8 or an equivalent thereof, wherein said equivalent of SEQ ID NO:8 encodes SEQ ID NO:7 or an equivalent thereof.

30. A polynucleotide comprising SEQ ID NO:12 or an equivalent thereof, wherein said equivalent of SEQ ID NO:12 encodes SEQ ID NO:11 or an equivalent thereof.

31. A polynucleotide comprising SEQ ID NO:6 or an equivalent thereof, wherein said equivalent of SEQ ID NO:6 encodes SEQ ID NO:5 or an equivalent thereof.

32. A polynucleotide comprising SEQ ID NO:10 or an equivalent thereof, wherein said equivalent of SEQ ID NO:10 encodes SEQ ID NO:9 or an equivalent thereof.

33. A polynucleotide encoding the RNA according to any one of claims 1 to 26, or its equivalent.

34. 34. The polynucleotide of claim 33, wherein the polynucleotide is selected from any one of the polynucleotides set forth in SEQ ID NOs: 60, 63, 66, 69, 96, 99, 102, or 105.

35. 35. The polynucleotide of any one of claims 29 to 34, wherein the equivalent is at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or more identical to the full-length reference sequence.

36. Optionally, the polynucleotide encodes the RNA of any one of claims 1 to 26, or encodes the polypeptide of claim 27 or 28, or a polynucleotide complement thereto, wherein the polynucleotide is selected from the group of deoxyribonucleic acid (DNA), RNA, a hybrid of DNA and RNA, or an analog of each of these.

37. Optimized F protein scaffold peptide comprising SEQ ID NO:87 or SEQ ID NO:

92.

38. 36. An RNA encoding the peptide of claim 35 comprising SEQ ID NO:89 or SEQ ID NO:

94.

39. A polynucleotide encoding the RNA of claim 36 comprising SEQ ID NO:88 or SEQ ID NO:

93.

40. A vector comprising the polynucleotide according to any one of claims 29 to 36.

41. 41. The vector of claim 40, further comprising a control sequence operably linked to the polynucleotide to direct its transcription.

42. The vector of claim 41 , wherein the control sequence comprises a promoter.

43. 43. The vector of claim 42, wherein the promoter comprises a bacteriophage RNA polymerase promoter, optionally a T7 promoter, or an SP6 promoter, or a T3 promoter.

44. The vector of any one of claims 40 to 43, further comprising a marker selected from a detectable marker, a purification marker, or a selection marker.

45. The vector according to any one of claims 40 to 44, wherein the vector is a non-viral vector, optionally a plasmid, or a liposome or a micelle.

46. 46. ​​The vector of claim 45, wherein the plasmid comprises SEQ ID NO:29 or an equivalent thereof.

47. 45. The vector according to any one of claims 40 to 44, wherein the vector is a viral vector, optionally an adenoviral vector, or an adeno-associated viral vector, or a retroviral vector, or a lentiviral vector, or a plant viral vector.

48. A cell comprising one or more of the RNA of any one of claims 1 to 26, the polypeptide of any one of claims 27 to 28, the polynucleotide of any one of claims 29 to 36, or the vector of any one of claims 40 to 47.

49. 49. The cell of claim 48, wherein the cell is a prokaryotic cell, optionally an E. coli cell.

50. 49. The cell of claim 48, wherein the cell is a eukaryotic cell, optionally a mammalian cell, an insect cell, or a yeast cell.

51. A composition comprising a carrier and one or more of the RNA of any one of claims 1 to 26, the polypeptide of any one of claims 27 to 28, the polynucleotide of any one of claims 29 to 36, the vector of any one of claims 40 to 47, or the cell of any one of claims 48 to 50.

52. 52. The composition of claim 51, wherein the carrier is a pharma- ceutically acceptable carrier.

53. 51. A method for producing an RNA according to any one of claims 1 to 26, comprising culturing a cell according to any one of claims 48 to 50 under conditions suitable for expression of said RNA.

54. A method for producing an RNA according to any one of claims 1 to 26, comprising contacting a polynucleotide according to any one of claims 29 to 36 or a vector according to any one of claims 40 to 47 with an RNA polymerase, adenosine triphosphate (ATP), cytidine triphosphate (CTP), guanosine-5'-triphosphate (GTP), and uridine triphosphate (UTP) or chemically modified UTP under conditions suitable for expression of the RNA.

55. 55. The method of claim 53 or 54, further comprising isolating the RNA.

56. A composition comprising the RNA of any one of claims 1 to 26 and a pharma- ceutically acceptable carrier.

57. 57. The composition of claim 56, wherein the pharma- ceutically acceptable carrier comprises a polymeric nanoparticle comprising histidine-lysine copolymer (HKP).

58. 58. The composition of claim 57, wherein the HKP comprises a side chain selected from SEQ ID NOs: 31-44.

59. 58. The composition of claim 57, wherein the pharma- ceutically acceptable carrier further comprises a lipid.

60. 60. The composition of claim 59, wherein the lipid comprises a cationic lipid.

61. 61. The composition of claim 60, wherein the cationic lipid is ionic.

62. 61. The composition of claim 59 or 60, wherein the cationic lipid comprises Dlin-MC3-DMA (MC3) or dioleoyloxy-3-(trimethylammonio)propane (DOTAP) or both.

63. 63. The composition of any one of claims 60 to 62, wherein the lipid further comprises one or more of a helper lipid, cholesterol, or a PEGylated lipid.

64. 57. The composition of claim 56, wherein the pharma- ceutically acceptable carrier comprises a lipid nanoparticle (LNP).

65. 65. The composition of claim 64, wherein the LNPs comprise one or more of 9-heptadecanyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate (SM-102), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), or equivalents of each of these.

66. 66. The composition of claim 65, wherein the LNP further comprises one or more of a helper lipid, cholesterol, or a PEGylated lipid.

67. 67. The composition of claim 63 or 66, wherein the helper lipid comprises one or more of disteroylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), (2R)-3-(hexadecanoyloxy)-2-{[(9Z)-octadec-9-enoyl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate (POPC), or dioleoylphosphatidylethanolamine (DOPE).

68. 68. The composition of any one of claims 52, 66, or 67, wherein the cholesterol comprises plant cholesterol or animal cholesterol or both.

69. 69. The composition of any one of claims 63 or 66-68, wherein the PEGylated lipid comprises one or more of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethylene glycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine), PEG-DSG (1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-dimyristoyl-sn-glycerol), optionally PEG2000-DMG ((1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000)], or PEG-DPG (1,2-dipalmitoyl-sn-glycerol, methoxypolyethylene glycol).

70. The composition of any one of claims 63 or 66-69, wherein the LNP comprises SM-102, DSPC, cholesterol, and PEG2000-DMG.

71. 71. The composition of claim 70, wherein the mass ratio of SM-102, DSPC, cholesterol, and PEG200-DMG is about 1:1:1:1 and / or the molar ratio of SM-102, DSPC, cholesterol, and PEG2000-DMG is about 50:10:38.5:1.

5.

72. 72. A composition according to any one of claims 51, 52 or 56-71 for use in raising an immune response in a patient.

73. 11. A method of producing the composition of any one of claims 51, 52, or 56-71, comprising contacting an RNA of any one of claims 1-26 with HKPs, whereby the RNA and the HKPs self-assemble into nanoparticles.

74. 74. The method of claim 73, wherein the mass ratio of HKPs and RNA in the contacting step is from about 10:1 to about 1:10, optionally 2.5:

1.

75. 75. The method of claim 73 or 74, further comprising contacting said HKPs and RNA with cationic lipids.

76. 76. The method of claim 75, wherein the cationic lipid comprises Dlin-MC3-DMA (MC3) or DOTAP (dioleoyloxy-3-(trimethylammonio)propane) or both.

77. 77. The method of claim 75 or 76, wherein the mass ratio of said cationic lipid and said RNA in said contacting step is from about 10:1 to about 1:10, optionally 1:

1.

78. 78. The method of any one of claims 73 to 77, wherein the mass ratio of the HKP, the mRNA, and the cationic lipid in the contacting step is about 4:1:

1.

79. 11. A method of producing a composition according to any one of claims 56 or 64-72, comprising contacting an RNA according to any one of claims 1-26 with a lipid, whereby the RNA and lipid self-assemble into a lipid nanoparticle (LNP).

80. 80. The method of claim 79, wherein the LNPs comprise one or more of 9-heptadecanyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate (SM-102), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), or equivalents of each of these.

81. 81. The method of claim 80, wherein the LNP further comprises one or more of a helper lipid, cholesterol, or a PEGylated lipid.

82. 82. The method of claim 81, wherein the helper lipid comprises one or more of disteroylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), (2R)-3-(hexadecanoyloxy)-2-{[(9Z)-octadec-9-enoyl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate (POPC), or dioleoylphosphatidylethanolamine (DOPE).

83. 83. The method of claim 81 or 82, wherein the cholesterol comprises plant cholesterol or animal cholesterol or both.

84. 83. The method of any one of claims 81-82, wherein the PEGylated lipid comprises one or more of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethylene glycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine), PEG-DSG (1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-dimyristoyl-sn-glycerol), optionally PEG2000-DMG ((1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000)], or PEG-DPG (1,2-dipalmitoyl-sn-glycerol, methoxypolyethylene glycol).

85. The method of any one of claims 79 to 84, wherein the LNP comprises SM-102, DSPC, cholesterol, and PEG2000-DMG.

86. 86. The method of claim 85, wherein the mass ratio of SM-102, DSPC, cholesterol, and PEG200-DMG is about 1:1:1:1 and / or the molar ratio of SM-102, DSPC, cholesterol, and PEG2000-DMG is about 50:10:38.5:1.

5.

87. 87. The method of any one of claims 79 to 86, wherein the contacting step is carried out in a microfluidic mixer selected from a slit-type interdigital micromixer or a staggered herringbone micromixer (SHM), as appropriate.

88. In a subject in need thereof, (a) a method for preventing symptomatic RSV infection; (b) a method of inducing an immune response against RSV; (c) a method of treating a subject infected with RSV; or (d) Methods for reducing RSV viral load one or more of the methods 13. A method comprising administering to said subject one or more of the RNAs of any one of claims 1-26 or one or more of the compositions of any one of claims 51, 52, or 56-74, optionally wherein said subject is a human patient selected from an infant, a pediatric patient, or a pregnant woman, or an adult aged 60 or over.

89. 90. The method of claim 88, further comprising optionally treating the subject with an additional therapeutic or prophylactic agent selected from one or more of influenza virus, coronavirus, Ebola virus, human immunodeficiency virus (HIV), or COVID-19.

90. 90. The method of claim 89, wherein the additional therapeutic agent optionally comprises an RNA polynucleotide derived from another infectious virus selected from one or more of an influenza virus vaccine, a coronavirus vaccine, an Ebola virus vaccine, a human immunodeficiency virus (HIV) vaccine, or a COVID-19 vaccine.

91. 91. The method of any one of claims 88-90, wherein the subject does not have or show signs of RSV infection at the time the RNA or composition is administered.

92. 92. The method of any one of claims 88 to 91, wherein the RNA or composition is nebulized by a nebulizer inhalation system before or during administration.

93. 93. The method of claim 92, wherein the nebulizer system is a portable nebulizer for total airway drug delivery.

94. The method of any one of claims 88 to 91, wherein the RNA or composition is administered by subcutaneous injection.

95. The method of any one of claims 88 to 91, wherein the RNA or composition is administered by intramuscular injection.

96. The method of any one of claims 88 to 91, wherein the RNA or composition is administered by intraperitoneal injection (i.p.).

97. An inhalation system comprising an RNA according to any one of claims 1 to 26, or a composition according to any one of claims 56 to 71, and a nebulizer.

98. 98. The inhalation system of claim 97, wherein the nebulizer is a portable nebulizer for total airway drug delivery.

99. A kit for use in the method of any one of claims 88 to 96 comprising instructions for use and one or more of the RNA of any one of claims 1 to 26, the composition of any one of claims 56 to 71, or the inhalation system of claim 97 or 98.

100. A kit for use in the method of any one of claims 51 and 71 to 87 comprising instructions for use and one or more of the RNA of any one of claims 1 to 26, the polypeptide of any one of claims 27 to 28, the polynucleotide of any one of claims 29 to 36, the vector of any one of claims 40 to 47, or the cell of any one of claims 48 to 50, the composition of claim 51 or 52, a HKP, a lipid, and optionally a cationic lipid.

101. A kit for use in claim 54 or 55, comprising instructions for use, the polynucleotide of claim 54 or the vector of any one of claims 55 to 62, an RNA polymerase, ATP, CTP, GTP, and UTP or chemically modified UTP.